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RÉSUMÉ 
La vitamine D3 25-hydroxylase CYP27 A est exprimé principalement dans le foie. 
Cependant, son expression est également détecté dans les tissus extra-hépatiques tel 
l'intestin. Le but de notre étude est de vérifier l'effet du statut nutritionnel en vitamine D3 
(D3) et de la supplémentation en D3 chez le rat et chez l'humain sur l'expression génique du 
CYP27A hépatique et intestinal, et en corollaire sur l'expression des cytochromes CYP24 
(vitamine D3 24-hydroxylase) et CYP27Bl (vitamine D3 lcx-hydroxylase). Nos études chez 
l'humain ont révélées par analyse de Northem la présence du CYP27 A non seulement dans 
le foie adulte, mais également dans le rein adulte ainsi que le foie et le rein fétal. Les niveaux 
des ARNm du CYP27A sont augmentés dans des specimens d'hépatocarcinome et de 
métastases intrahépatiques d'origine du colon. Chez le rat, les niveaux des ARNm du 
CYP27A hépatique ne sont pas influencés par le statut nutritionnel en D3 mais sont regulés 
par la 1,25 dihydroxyvitamine D3 (1,25(OHhD3) au niveau de la transcription. Par ailleurs, 
les ARNm du CYP27 A intestinal sont hautement régulés in vivo par tous les métabolites de 
la D3, soient la D3, la 25-dihydroxyvitamin D3 (25(OH)D3) et la 1,25(OHhD3 chez le rat. 
Chez l'humain, les trois hydroxylases ainsi que le récepteur nucléaire de la D3 (VDRn) sont 
exprimés tout au long de l'intestin et du colon humain fétal. Une comparaison entre les 
niveaux d'expression des ARNm du CYP27Bl entre le jejunum et le colon indique une 
expression génique du CYP27Bl significativement plus grande dans le colon. Finalement, 
par culture organo-typique, nous avons observé que la 1,25(OH)2D3 affecte les trois 
hydroxylases, en abaissant les ARNm des CYP27A et CYP27Bl, et en augmentant les 
niveaux des CYP24 et CYP3A4. En conclusion, nos études montrent clairement qu'une 
carence en D3, l'administration de D3, de 25(OH)D3, de 1,25(OHhD3, ainsi que certaines 
pathologies peuvent influencer l'expression du CYP 27 A hépatique et intestinal, à la fois chez 
l'humain ainsi que chez le rat. Les résultats de ces études représentent un ajout important à 
la compréhension des effets de la carence en D3, un phénomène encore largement répandu 
à travers le monde. De plus, dans l'optique d'une utilisation croissante de certains analogues 
de la D3 dans le traitement de différentes pathologies, ces résultats permettront de mieux 
comprendre les effets de l'administration de ces produits sur l'homéostasie en D3, ainsi que 
sur certains autres cytochromes impliquées dans le rnétabolisme des médicaments. 
IV 
Mots clés: vitamine D3, CYP27 A (vitamine D3 25-hydroxylase), CYP24 (vitamine D3 24-
hydroxylase), CYP27Bl(vitamine D31cx-hydroxylase), CYP3A4 (cytochrome P450 3A4). 
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SUMMARY 
The vitamin D3 25 hydroxylase CYP27 A is predominantly located in the liver. However, 
its expression is also detected in extrahepatic tissues such as the intestine. The aim of our 
studies was to investigate the effect of the vitamin D3 (D3) status and of D3 repletion both in 
the rat (in vivo) and in hum an (ex vivo) on CYP 27 A in the liver and the intestine. In paraIlel, 
studies with CYP24(vitamin D3 24-hydroxylase) and CYP27Bl (vitamin D3 la-hydroxylase) 
were also carried out. The human studies reveal through Northem blot analyses the presence 
of CYP27A rnRNA not only in adult liver, but also in the adult kidney and in the fetalliver 
and the kidney. The studies also illustrate that CYP27A can be significantly upregulated in 
certain pathological situations such as hepatic carcinoma and intrahepatic colon metastasis. 
In the rat, hepatic CYP27 A rnRNA levels are not influenced by the D3 nutritional status but 
are transcriptionaUy regulated by 1,25 dihydroxyvitamin D3 (1,25(OHhD3). Furthermore, 
intestinal CYP27A is highly regulated in vivo by all three D3 metabolites, namely D3, 25-
hydroxyvitamin D3 (25(OH)D3) and 1,25(OHhD3. The human fetal intestine expresses aU 
three D3 hydroxylases, CYP3A4, and the nuclear vitamin D3 receptor (VDR) aIl along the 
small intestine and colon, with only CYP27Bl rnRNA levels significantly higher in the colon 
compared to the levels observed in the jejunum. Moreover, when human fetal intestine was 
harvested and subjected to organotypic culture conditions, aIl three D3 hydroxylases and 
CYP3A4 were found to be sensitive to 1,25(OH)2D3 administration. lndeed, CYP27A and 
CYP27Bl rnRNA levels were significantly downregulated by the hormone, whereas CYP24 
and CYP3A4 were upregulated. Our studies indicate that D3 deficiency, D3, 25(OH)D3, 
1,25(OH)2D3 administration as weIl as malignant transformation can modulate hepatic and 
intestinal CYP27A rnRNA expression in the rat and human. These findings are of important 
relevance for our further understanding the effects of D3 deficiency, an ever-present 
widespread problem in today's societies. Furthermore, the increased use of certain D3 
analogues in the treatment of various pathologies will benefit in the better understanding of 
the effect of D3 metabolites on the D3 endocrine system and overall D3 homeostasis, as well 
as on other cytochromes such as those involved in drug metabolism. 
VI 
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CHAPTERl: GENERAL INTRODUCTION 
1.1 CYTOCHROME P450s 
The cytochromes P450s (P450s) are monooxygenase enzymes which are members of a 
superfamily of hemoproteins that play a pivotaI role in the metabolism of a wide variety of 
xenobiotic and endogenous compounds. There is considerable interest in the function of 
these enzymes due to their involvement in the detoxification of foreign compounds and 
bioactivation of drugs and carcmogens. Moreover, P450s catalyze key steps ln 
steroidogenesis, as weU as in the metabolism of endogenous compounds such as 
prostaglandins, biogenenic amines, leukotrienes, bile acids as weU as cholecalciferol (vitamin 
D3) and ergocalciferol (vitam in D2). P450s are widely distributed in nature with different 
isoforms present in plants, insects, sorne bacteria, yeast and mammals (1). 
1.1.1 BIOCHEMICAL PROPERTIES 
Reactions catalyzed by the rnonooxygenase system include hydroxylations, epoxidations, 
0-, S- and N-dealkylations, and N-oxidations (2). P450s contain approximately 500 amino 
acids. A cysteine residue molecule located near the carboxyl-terminus of the protein 
provides the essential thiol-ligand for the herne iron. The amino-terminus of the prote in is 
rich in hydrophobic arnino acids and is believed to act as a domain for binding the prote in 
to cell membranes. The P450s isoforms catalyze the nicotinamide dinucleotide phosphate 
(NAD PH) and oxygen dependent oxidative transformation of a large number of different 
chemical compounds. In general, a specific P450 isoform will catalyze the metabolism of 
a limited number of chernical structures (such as steroids and fatty acids) while other P450s 
have a broad substrate specificity suggesting a role for a unique "active site geometry" for 
sorne but not aU P450s. In tissues such as liver, intestine and the cortex of the adrenal gland, 
the concentration ofP450s greatly exceeds the concentration of other hemeproteins (such as 
the mitochondrial cytochrornes). Indeed, in the rat liver the concentration ofP450s can be 
as high as 50 nmol per gram wet weight of tissue, thereby representing more than one percent 
of hepatic proteins. 
2 
P450s are distributed in almost every organ of the human body, although the type of 
P450s in a tissue or organ appears to be specific. Moreover, the cellular expression ofmany 
P450s is regulated by transcription factors which become activated during exposure to 
various chemicals. 
In general, P450s undergo a cyclic series of reactions (Figure 1.1) where a ferric form of 
the hemeprotein initially reacts with a molecule to form a complex. This ferric P450-
substrate complex is reduced by an electron transported from NADPH. The ferrous substrate 
complex reacts with molecular oxygen to form a ternary complex offerrous P450-substrate-
oxygen. Carbon monoxide can compete with molecular oxygen resulting in the formation 
of a carbon monoxide complex of ferrous P450. The carbon monoxide reacts with reduced 
P450 producing an absorbance band with a maximum at 450 nm in the optical spectrum. 
The ternary complex of ferrous P450, organic chemical substrate and molecular oxygen is 
further reduced by a second electron transferred from NADPH. This generates a two electron 
reduced intermediate (that has not been fully identified) that yields a molecular 
rearrangement. The chemistry of oxygen incorporation into the substrate results in the 
complex of ferric P450, which can participate in the metabolism of another substrate. 
Central to the operations of the P450s is the need to provide electrons from NADPH 
(Figure 1.2). Marnmalian tissues have two types of electron transport systems operative for . 
different P450s. One type is located in the mitochondria of sorne cells and consists of a 
flavin adenosine diphosphate (FAD)-containing reductase and an iron-sulfur prote in (called 
ferredoxin or adrenodoxin). This mini-electron transport system is similar to that found in 
bacteria where a P450 may be functioning to break down chemicals as an energy source for 
growth. The second type is associated with the endoplasmic reticulum of many cell types 
where a unique flavoprotein containing both FAD and FMN (flavin mononuc1eotide) 
function as cofactors. The latter type is frequently referred to as the microsomal type ofP450 
system. 
Figure 1.1: Cyclic mechanism for the oxygenation of a substrate by a cytochrome 
P450 enzyme. After the initial binding of the substrate to the cytochrome P450 (P450) 
enzyme (upper right), the iron atom (Fe) in the enzyme is reduced (from the ferric [Fe3+] to 
the ferrous [Fe2+] form) by the addition of an electron (e-) from another donor molecule (a 
flavin-containing enzyme called NADPH-P450- reductase). The reduction of the iron atom 
allows it to bind to molecular oxygen (02). The addition of another electron and a proton 
(H+) to the iron atom forms a FeOOH complex. The loss of a molecule ofwater produces 
an (FeO)3+ complex, which transfers its oxygen atom to the substrate. The oxidized substrate 
is released freeing the P450 enzyme to repeat the cycle. 
4 
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Figure 1.2: Molecular constituents of the cell's cytochrome P450 system lie within 
the membrane of the endoplasmic reticulum, or the inner mitochondrial membrane. 
Before the cytochrome P450 (P450) enzyme can oxidize a substrate, the iron atom in the 
enzyme's heme group must accept two electrons from either one of two molecules: NADPH, 
located in the cytoplasm, or cytochrome bs, which is embedded in the membrane. P450 
reductase, which contains two subcomponents, F AD and FMN, acts as an intermediary 
molecule in the transfer of electrons from NADPH. The F AD containing reductase 
equivalent in mitochondria is termed ferredoxin (or adrenodoxin). 
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1.1.2 CLASSIFICATION 
P450 enzymes are ubiquitous in living organisms, and more than 400 individual isoforms 
have been thus far identified and sequenced from plants, animaIs, bacteria and yeast (3). 
Based on their sequence, P450s are classified into gene families and subfamilies. Members 
of the same family exhibit at least 40% amino acid sequence identity, while within a 
subfamily the identity is greater or equal to 55% (3). 
Furthermore, based on their requirements for the redox partner, P450 enzymes can be 
divided into 2 main groups: class 1 enzymes, found in mitochondria and class II enzymes, 
more abundant in endoplasmic reticulum. Class 1 enzymes require both an iron-sulfur 
protein (ferredoxin) and an FAD-containing NAD(P)H-ferredoxin reductase for catalysis, 
whereas class II P450s require an F ADIFMN-containing NADPH-P450 reductase, although 
they may utilize an additional electron donor, namely cytochrome b5• Finally, there are class 
III enzymes that do not require any exogenous source of electrons, the latter being obtained 
from a peroxide substrate (i.e. prostacyclene synthase). In mammals, the main xenobiotic 
metabolizing enzymes belong to class II and comprise families 1-4 (3). In contrast, P450s 
involved in steroidogenesis are split between class 1 and class Il, with for example CYP70', 
CYPII and CYP27A being class 1 families and CYPI7, 19 and 21 being class II families. 
Over half the families (ni ne) of human P450s are associated with cholesterol and steroid 
hormone metabolism. Four families ofP450s are located within mitochondria and therefore 
use the mini-electron transport chain containing an iron sulfur protein. As mentioned above, 
many forms ofP450s display broad substrate specificities, yet they often exhibit strict regio-
and stereospecificity toward a particular compound. 
1.1.3 INHIBITIONTION AND INDUCTION OF P450 CYTOCHROMES 
Impairment of any of the steps of the P450 catalytic cycle can lead to inhibition. The 
binding of the substrate to the ferric form of the enzyme, binding of molecular oxygen and 
substrate oxygenation are particularly vulnerable to inhibition (4). The mechanisms ofP450 
inhibition can be grossly divided into 3 categories: reversible inhibition, quasi-irreversible 
inhibition and irreversible inhibition (5). Among these, reversible inhibition is probably the 
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most common mechanism responsible for documented drug interactions. Ketoconazole, a 
broad spectrum imidazole antimycotic agent, is an example of a non-specific competitive 
inhibitor ofP450-catalysed reactions. In mechanistic terms, reversible interactions arise as 
a result of competition at the P450 active site and probably involve only the first step of the 
P450 catalytic cycle. On the other hand, agents that act during or subsequently to the oxygen 
transfer step are generally irreversible or quasi-irreversible inhibitors. Both irreversible and 
quasi-irreversible inhibition are caused by the formation of reactive metabolites. Thus, the 
irreversible and quasi-irreversible inhibition require at least one cycle of the catalytic process. 
One of the intriguing aspects of the P450s is that only sorne of these enzymes are 
inducible. Unlike inhibition, which is an almost immediate response, induction is a slow 
regulatory process that can reduce drug concentrations in plasma, and may compromise the 
efficacy of the drug in a time-dependent manner. From a biological point ofview, induction 
is an adaptive response that protects the cells from toxic xenobiotics by increasing the 
detoxification activity. 
Induction ofP450 enzymes occurs predominantly at the level of transcription (6-8). A 
notable exception is the well-studied a1cohol inducible CYP2EI gene, the induction ofwhich 
involves a post-transcriptional mechanism (7;9). Induction generally occurs at sites of 
exposure or excretion of xenobiotics, such as in the liver, lung, skin and other tissues. 
Depending on the chemical nature of the xenobiotic, P450 isozymes belonging to a particular 
sub-family are predominantly induced. For example, the major isozymes induced by 
polycyclic aromatic hydrocarbon, such as co al tar constituents (benzopyrenes and anthrenes) 
and by-products of paper bleaching (dibenzodioxins) are those of the CYP 1 A sub-family 
(10). In contrast, chlorinated hydrocarbon pesticides (such as DDT, chlordane, dieldrin) and 
therapeutics (such as the sedative phenobarbital) predominantly induce isozymes of the 
CYP2B sub-family (11). Members of the CYP4A sub-family are chiefly induced by the 
plasticizing agent 2-ethylhexyl phthalate and by other peroxisomal proliferators, such as the 
antilipidaemic drug clofibrate (12; 13). The glucocorticoid dexamethasone (7) and 
metyrapone (14) predominantly induce isozymes of the CYP3A sub-family. It should be 
noted that there are often species-specific P450 isozymes and that sorne P450 isozymes can 
be differentially induced in different species. The molecular mechanisms by which various 
hydrophobic foreign chemicals increase the transcriptional activation of species specific 
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P450 genes constitute a fascinating problem of gene regulation. Most of the information on 
P450 gene regulation has been obtained from animal studies. Important interspecies 
differences also exist in the response of other inducible subfamilies ofP450s. Specifically, 
phenobarbital induces predominantly members ofthe CYP2B subfamily in rats, whereas in 
humans it appears that the major form induced belongs to the CYP3A subfamily (15). 
Furthermore, members of the CYP3A subfamily in rats are inducible by the steroidal agent, 
pregnenolone-16ex-carbonitrile, but not by the antibiotic rifampicin. The opposite is true in 
rabbits and humans (16). Thus, drugs that induce P450 enzymes in animaIs should not be 
assumed necessarily to have enzyme-inducing capacity in humans and vice-versa. 
1.1.4 CYTOCHROME P450s IN VITAMIN D3 METABOLlSM 
Vitamin D3 (D3) is a natural secosteroid that has, in its native form, virtually no 
biological activity. Once in circulation, D3 is taken up by the liver and hydroxylated at C-25 
by a P450-dependent mixed function oxidase systems (Figure 1.3). At physiological 
concentrations, 25-hydroxyvitamin D3 (25(OH)D3) has no biological activity and must be 
hydroxylated at position C-l ex (principally in the kidney) into 1 ex,25 dihydroxyvitamin D3 
(calcitriol, 1,25(OH)2D3) in order for the vitamin to achieve hormonal status and thus its full 
biological potentialThere are four P450s required for the activation and inactivation of D3 
(cholecalciferol). 7 -dehydrocholesterol, a late intermediate in the cholesterol biosynthetic 
pathway is photolyzed by UV light producing D3' The vitamin is first hydroxylated at 
position C-25 by a mitochondrial and/or microsomal enzyme. The mitochondrial D3 25-
hydroxylase, CYP27 A, has been identified, whereas the status and role of the D3 microsomal 
entity remains questionable. The product of this reaction, 25(OH)D3 is then converted to 
lex,25(OHhD3 by a mitochondrial P450, the vitamin D3 lex-hydroxylase, CYP27Bl. This 
enzyme has been known to exist in kidney mitochondria for decades but because of its very 
low level of expression and presumed instability, it had been virtually impossible to purify. 
Only within the past four years has it been c10ned and found to be a member of the CYP27 A 
family (17-20). The C-l ex hydroxylation generates the active and hormonal form of D3, 
lex,25(OH)2D3. A third mitochondrial P450, vitamin D3-24 hydroxylase (CYP24), 
inactivates calcitriol by hydroxylation on the side chain at position C-24 which greatly 
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reduces binding to the nuclear vitamin D3 receptor (VDR). 
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Figure 1.3: Key vitamin D sterol structures. Top row: vitamin D3 (D3) is structurally 
related to cholesterol (the numbering of the carbon atoms is identical). D3 is produced (in 
the skin) from 7-dehydrocholeserol by a UV-mediated photochemical reaction. The 
immediate photo che mi cal product, preD3 then thermally equilibrates (over time) into D3. 
Middle row: conformational representation of D3. Structure presented is an extended 
version derived from X-ray crystallographic analysis; Bottom row: structures of the three 
principal metabolites ofD3. 
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1.2 VITAMIN D METABOLISM 
1.2.1 VITAMIN D3 25-HYDROXYLASES 
1.2.1.1. Evidencefor microsomal and mitochondrial D3 25-hydroxylase activity 
As previously mentioned 25-hydroxylation of D3 is catalyzed by P450 dependent 
enzyme systems in both mitochondrial (21 ;22) and microsomal fractions (23 ;24). The 
relative importance of the two 25-hydroxylase systems in vivo is not known, but it is 
generally believed that the microsomal 25-hydroxylation of D3 is more important than the 
mitochondrial 25-hydroxylation in the bioactivation process under normal conditions 
(25;26). In humans, the mitochondrial D3 25-hydroxylase was believed to be the 
predominant and only form expressed (27), although a microsomal form is also active (28). 
There is abundant evidence that the 25-hydroxyvitamin D3 1cx-hydroxylase, as weIl as 
the degradation system 25-hydroxyvitamin D3 24-hydroxylase, are highly regulated (29-31). 
However the question of whether the 25-hydroxylase is regulated remains undetermined. 
Interestingly, the D3 25-hydroxylase that has been described to date, in terms of gene 
regulation, is the enzyme CYP27 A of mitochondrial origin. The porcine microsomal D3 25-
hydroxylase has been cloned (32), although its presence remains to be characterized in other 
species (33). This microsomal25-hydroxylase identified can catalyse 25-hydroxylation of 
both D3 and D2(34). A cDNA encoding the pig liver microsomal D3 25-hydroxylase, as 
deduced by both DNA sequence analysis, showed 70-80% identity with members of the 
CYP2D subfamily and has been assigned the name CYP2D25 (35). However, the only 
CYP2D enzyme known to be expressed in man is CYP2D6. This enzyme is polymorphically 
expressed and is lacking in 5-10% of the caucasian population. It is not known whether D3 
25-hydroxylation in man could be catalysed by CYP2D6. 
1.2.1.2 Biochemical and Molecular aspects ofmitochondrial and microsomal D metabolism 
The microsomal 25-hydroxylase fraction of rat liver and was influenced by the D 
status (36-38) and required the presence of a cytosolic factor for optimum activity. 25-
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hydroxylation of the synthetic compound dihydrotachysterol (DHT3)was not regulated 
compared to that of the natural substrate D3(38). The presence of the enzyme was confrrmed 
to be a rat liver microsomal P-450 (24;39), requiring a soluble cytosolic factor (for full 
reconstitution of enzyme activity) (39). In 1983, a rat microsomal cytochrome P450 active 
in C-25 hydroxylation ofbile acid intermediates 5 [3-cholestane-3ex,7ex,12ex-triol, cholestane-
3ex,7ex-diol as weIl as D3 and lex (OH)D3 but not D2 (40). A purified and partially sequenced 
P450 active in 25-hydrxylation ofD3 with an inhibitor removed from the microsomes during 
the purification steps (41), and did not require the presence of a cytoplasmic factor. 
In 1980, Bjorkhem and Holmberg studied the activities of a P450 preparation 
solubilized from rat liver mitochondria obtained from rats which had been treated with 
phenobarbital or subjected to a rachitogenic diet (22). They observed that both phenobarbital 
and the rachitogenic diet increased C-25hydroxylation ofD3 but had little effect on the C-27 
hydroxylation of the C-triol. These observations led the investigators to conclude that 2 
distinct P450 species existed, each responsible for the hydroxylation of cholestanetriol and 
D3. At the same time, Masumoto et al purified to homogeneity the D3 25-hydroxylase from 
rat liver mitochondria and characterised it as a P450 catalysing the C-25 hydroxylation of 
both D3 and lex (OH)D3 (42). These researchers proposed that a single enzyme was involved 
in the C-27 hydroxylation of 5 [3-cholestane-3ex,7ex,l2ex-triol and in the C-25 hydroxylation 
of D3, although the preparation exhibited much lower activity toward D3 compounds than 
toward the C-27 hydroxylation ofbile acid intermediates. D3 competitively inhibited the 27-
hydroxylation ofC-triol, whereas C-triol inhibited D3 25..;hydroxylation (42), concluding that 
both substrates were catalysed at a common active site on a single protein. D3 25-
hydroxylation and C27 sterol hydroxylation activities were located , probably exclusively, 
in the inner mitochondrial membrane matrix (27;43). 
Heterologous cell systems confirmed the identity of sterol 27-hydroxylase and D3 25-
hydroxylase as weIl as the requirement for adrenodoxin and adrenodoxin reductase but not 
NADPH P450 reductase (44). 
J.2.1.3. CYP27A (MITOCHONDRIAL VITAMIN D3 25-HYDROYLASE) 
1.2.J.3.1 The CYP27A gene 
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CYP27A, the mitochondrial D3 25-hydroxylase, has been cloned in several species 
including the rabbit (44), rat (45;46), and human (47;48). The gene has been shown to be 
located on chromosome 2q33-qter (49). Northern analyses demonstrate two mRNA sizes 
of 1.9 and 2.3kb for CYP27A in liver and fibroblasts (46;48). Characterization of the 2.3kb 
mRNA indicated a sequence identical to the 1.9kb mRNA in its protein-coding region, 
except for ~ 400-nucleotides in an extended sequence at its S'end (50). The rat CYP27A 
gene contains Il exons of 80-415 nucleotides that are separated by 10 introns of 83 bases to 
~ IOkb (51). The protein sequence of the human enzyme has been reported to be 72% 
identical to the rat and 81 % identical to the rabbit CYP27A (45;48). The mature protein 
contains 444 to 501 amino acids depending on the species involved and the rat enzyme 
molecular weight has been estimated to be 51 kDa (45). 
1.2.1.3.2 CYP27Apromoter and regulation studies 
Functional assays showed that the -217/-10 nucleotide region for the translation start 
site (minimal promoter), devoid of TATA and CAAT boxes, contains aU the elements for 
basal transcription (52). Possible positive transcription regulation sites are located at 
position -187 to -320 and -857 to 1087bp (53). A negative transcription regulator site is 
located in position -320 to -413bp. An enhancer sequence is located upstream to position 
-1087 (53). A putative bile acid response element (BARE) is also located between -110 and 
-86bp ofthe CYP27 promo ter ,on which HNFIcx and CIEBP bound (54) . 
. Footprinting analysis of the minimal promoter showed four protected region. Three 
of the regions contained and SpI binding site, and one an HNF4 site. Electrophoretic 
mobility shi ft assays demonstrated that SPI, Sp3, and HNF4 transcription factors bind these 
sites (52). Mutagenesis ofany ofthese sites resulted in the loss ofpromoter activity. SpI, 
Sp3 and HNF4 were found to cooperate in the expression of the human CYP27 A gene in 
HepG2 ceUs (52). A dexamethasone responsive element was found to be located between 
1087 and 678bp upstream to the putative ATG. The cyclosporin A-responsive element is 
mapped to between 1087 and 4000 bp upstream of the ATG (53). Cholic acid represses 
sterol 27-hydroxylase mRNA level by affecting the stability of its mRNA (53). 
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1.2.1.3.3. CYP27A regulation not related to vitamin D metabolism 
CYP27A is a high-capacity enzyme involved primarily in the hydroxylation ofbile acid 
intermediates, but its substrate specificity is broad and exceeds the field of bile acid 
biosynthesis. The purified enzyme has been shawn ta be active on both the C-25 and C-27 
hydroxylation of cholesterol as well as on other bile acid intermediates (55;56). Rat hepatic 
CYP27 A is highly sensitive to the prevailing concentrations of bile acids with increases in 
enzyme activity, steady state mRNA level and the rate of gene transcription being observed 
after interruption of the enterohepatic circulation (57;58). Physiological concentrations of 
insulin also down-regulate CYP27A gene transcription through a direct effect of the hormone 
on the transcription rate in hepatocytes (59). 
CYP27A is also sensitive to pituitary-regulated steroids, growth hormone and the diurnal 
rhythm, with a two fold increase in enzyme activity observed in the mid-dark compared to 
the mid-light period (57). Both the 1.9 and 2.3kb mRNA species appear to be modulated by 
the physiological state of the animal and regulated by growth hormone in paraUel to the 
serine protease inhibitor mRNAs (50). 
1.2.1.3.4. CYP27A regulation related to vitamin D metabolism 
Most regulation studies on CYP27A have been linked to the metabolism of cholesterol 
and bile acids. Few studies, until recently, have addressed the effect ofthese compounds on 
the handling ofD3.CYP27A also catalyzes the C-24, 25 and 27 hydroxylation ofD3, D2 and 
related compounds (47). While D3 substrates were found to be preferably hydroxylated at 
C-25, Guo et al., (47) observed that when the substrates exhibited the ergocalciferol side 
chain, such as that found in D2 or 1 cx(OH)D2, a predominance of 24-hydroxy metabolites 
occurred (metabolites which have also been found in vivo in rat, cow and chicken) (60-62). 
In addition, sorne production ofC-27 hydroxylated products also occured (63). Surprisingly, 
D2 was not, while lcx(OH)D2 was only poorly hydroxylated at position C-25 (47). 
In addition, several laboratories have now shown that the enzyme prefers 1 cx-
hydroxylated analogs of D3 or D2 over their non-hydroxylated counterparts. This includes 
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the natural substrate D3, which is hydroxylated at C-25 several times less efficiently than 
lcx(OH)D3 (22;35;47). 
Of the studies examining regulation of CYP27 A by the D3 status, Axén et ai. (64) 
reported that renal and hepatic CYP27A was affected by 1,25(OH)2 D3 administration but that 
kidney CYP27A rnRNA was decreased to a larger extent than that of the liver. Furthermore, 
CYP27A mRNA has been shown to be inducible by D3 in keratinocytes (65). 
1.2.1.3.5 Vitamin D and minerai metabolism in CTX humans and in the CYP27-/- mouse 
Mutations affecting the expression of CYP27A or its primary sequence leads to 
cerebrotendinous xanthomatosis (CTX) (66;67), which is an inherited disorder of sterol 
metabolism and storage characterized by atherosc1erosis and progressive neurological 
dysfunction. CTX is a rare autosomal recessive neurometabolic disease involving lipid 
metabolism. The c1assical phenotype, due to mutations in the CYP27 gene, is characterized 
by neurologie dysfunction, tendon xanthomas and juvenile cataracts. 
Bone fractures occurred frequently in patients with CTX (68). Serum 25(OH)D levels 
were in the low to normal range whereas 24,25(OHhD levels were markedly decreased. 
Serum concentration of 1,25(OH)2D, Ca, inorganic phosphorus, alkaline phosphatase, 
parathyroid hormone and calcitonin were normal (69).Interestingly, both normal (70) and 
abnormal (67;69;71) D3 and/or calcium metabolism have been reported which suggests the 
presence of more than one enzyme active in the 25-hydroxylation of D3. However, sorne 
CTX patients have been shown to retain residual C-27 hydroxylase activity (72). The 
creation ofa CYP27A-/- mouse has not provided any further insight into the role ofCYP27A 
in relation to D3 homeostasis. Indeed, the CYP27A-/- mouse surprinsingly displays elevated 
levels of 25(OH)D, and no CTX abnormalities (73). The latter observations suggest 
alternative C-25 hydroxylation pathway(s) in the CYP27A ablated mouse possibly through 
the microsomal D3 25-hydroxylase. 
The circulating concentrations of 25(OH)D was however somewhat higher in the 
CYP27-/- than in the CYP27 +/+ mice whereas the corresponding concentrations of 
1,25(OHhD were similar in the two groups (73). Thus it seems less likely that sterol 27-
hydroxylase is of importance in formation of 25(OH)D and 1,25(OH)2D in this species. 
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1.2.2 VITAMIN D3 24-HYDROXYLASE (CYP24) 
1.2.2.1 The vitarnin D3 24-hydroxylase gene 
The purification of the rat kidney mitochondrial D3 24-hydroxylase enzyme and the 
raising of a rabbit polyclonal antibody (74;75) were milestone achievements that led to the 
isolation of a cDNA clone for the rat 24-hydroxylase by immunological screening (76). The 
mRNA contains an open reading frame of 514 amino acid residues that includes the 
mitochondrial signal sequence. Full-Iength cDNA clones were subsequentIy isolated for the 
hum an (77) and mouse (78) D3 24-hydroxylase proteins. The human D3 24-hydroxylase 
showed about 80% amino acid sequence identity with both the rat and mouse homologs, 
whereas the latter two where 95% identical. DJ 24-hydroxylase was not more than 30% 
identical with any other P450s sequence reported to date. The highest homology (30% 
identity) was found to be with CYP27 A (45). 
Genomic clones for rat (79) and human (77) D3 24-hydroxylase have been isolated. The 
rat gene is a single copy gene that spans about 15kb and contains 12 exons (79). The intron-
ex on arrangement of the gene most closely resembles that of the CYP22 family (79). The 
transcription start site for the rat CYP24 and a likely TATA box have been located and 
several possible control elements have been identified in the promoter including vitamin D 
response elements (VDREs), CCAAT, GC, and TATA binding sites (79;80). Similar 
binding sites for the transcription factors are aiso present in the promoter for human CYP 24 
(81). 
Aithough three VDREs have been identified in the rat CYP24 promoter (82), only two 
functionai elements have been identified on the antisense strand (30;80;83). Initial studies 
established the binding ofVDR as an retinoid-X-receptor (RXR) complex at VDRE-l, which 
was verified and extended to include VDRE-2 through supershift analysis with a specifie 
monoclonal RXR antibody (82). When analyzed separately, VDRE-2 showed about 4- to 
5- fold higher affinity for the VDR-RXR complex than VDRE-l. There is transcriptional 
synergism between the VDREs, as the wild type induction (18 fold) is greater than the sum 
of the individual contributions ofVDRE-1 (6 fold) and VDRE-2 (3 fold). Two VDREs for 
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the human promoter have been identified by Chen and DeLuca (81). 
1.2.2.2 Catabolism of 1,25 dihydroxyvitaminDj 
CYP24 directs the synthesis of 24,25 (OH)2D3 and l,24,25(OH)3D3 (84). The two D3 
metabolites express less biologie al activity than 1,25(OH)2D3, although 24,25(OH)2D3 is 
suggested to have foeused actions in bone and cartilage. Both metabolites also represent 
initial reactants in the C-24 oxidation pathway that leads to metabolite inactivation via 
generation of23- or 24-COOH end products (85;86). Acquisition of a C-24 hydroxyl group 
is required for emry into the oxidation pathway, which is followed by oxidation of the 24-
hydroxyl group to a keto (oxo) function. The 23- and 24-hydroxylase activities are usually 
eoexpressed in the same target cells, with the 24-hydroxylation constituting the major activity 
(87). 
1.2.2.3 Cellular expression 
The D3 24-hydroxylase enzyme displays a broad tissue distribution. A major route of 
enzyme induction involves the combined action of 1,25(OH)2D3 and of VDR to increase 
transcription of the CYP24 gene. Consequently, cellular expression of CYP24 is linked 
tightly to the coexpression ofVDR. Most cells that contain VDR, therefore, express a basal 
level ofCYP24 or respond to increased 1,25(OH)2D3Ievels by inducing the biosynthesis of 
the enzyme, particularly in kidney and small intestine (88;89). Basal expression under 
normal calcium-homeostatic conditions has been documented for kidney, intestine, bone, 
placenta, skin (keratinocytes), and macrophages (88-90). 
Particular attention has been given to expression of the enzyme in the kidney, which is 
one of the major sites of CYP24 activity. As this tissue is the major site of 1,25(OH)2D3 
synthesis, it seems likely that the high basal CYP24 expression in kidney represents induction 
by endogenous 1,25(OH)2D3. In the kidney, enzyme expression has been localized to the 
proximal tubule and does not display the more general distribution as noted for VDR (91). 
In parallel, CYP24 expression in bone occurs in osteoblasts and may play an important role 
in bone mineraI dynamics. The placenta expresses 24-hydroxylase activity and 
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developmental expression of CYP24 is controlled by 1 ,25(OH)2D3-dependent transcriptional 
induction (92). In addition, investigations with cultured cells have revealed induction ofthe 
CYP24 gene in many different cell types (93-95). 
This widespread distribution of the D3 24-hydroxylase supports a major role for the 
enzyme in regulating the local concentration and action of the hormone 1,25(OH)2D3. 
1.2.2.4 Regulation of expression 
Consistent with the general tissue distribution of CYP24, a broad spectrum of regulatory 
agents act to control cellular expression of the enzyme. Steroid and peptide hormones 
function through the signal transduction and transcription pathways to alter CYP24 activity. 
The enzyme level is also changed in response to age and several genetic mineraI metabolism 
disorders. 
The major regulators of the D3 24-hydroxylase are PTH and 1,25(OH)2D3. In vivo 
administration of PTH to thyroparathyroidectomized rats decreases renal production of 
24,25(OH)2D3, whereas administration of 1,25(OH)2D3 increases 24,25(OH)2D3 production. 
The mechanisms of action of PTH and 1,25(OH)zD3 on D3 24-hydroxylase appear to be 
similar to the actions of the respective hormones on 1 cx-hydroxylase in that PTH acts by a 
mechanism involving cAMP and the 1,25(OH)2D3 action requires new protein synthesis. 
Administration of a single dose of 1,25(OH)2D3 to rats markedly increases CYP24 
mRNA level in the kidney and intestine (96;97). In contrast, CYP24 mRNA is not induced 
by 1,25(OH)2D3 in hepatocytes, which do not express any 24-hydroxylase activity. Induction 
of CYP24 mRNA by 1,25(OH)2D3 has been further studied in primary cultures of rat tubular 
cells and human colon cancer cells (98;99). This induction is inhibited by the addition of 
actinomycin D, 5,6-dichloro-l-cx-D-ribofuranosyl benzimidazole, and cyc1oheximide, 
indicating that the de novo syntheses of CYP24 mRNA and protein are required (98). It has 
also been reported that phorbol 12-myristate 13-acetate (TP A) alone has no effect, but TP A 
produces a marked increase in the expression of CYP24 mRNA in the presence of 
1,25(OH)2D3 (98). TPA also shifted the stimulatory dose-response curve of 1,25(OH)2D3 
to the left. It is, therefore, hypothesized that the 1,25(OH)2D3 effect leading to CYP24 
induction may occur at a physiological concentration of the hormone by a mechanism 
18 
- involving prote in kinase C (PKC). 
1.2.3 VITAMIN D3lcx-HYDROXYLASE (CYP27Bl) 
1.2.3.1 THE VITAMIN D3lcx -HYDROXYLASEGENE 
Until recently, analysis of the expression and function of the D3 lcx-hydroxylase in the 
kidney has been dependent on relatively insensitive enzyme assays using tissue homogenates, 
mitochondrial enriched fractions, or single nephron sections obtained from D-deficient 
animaIs (100;101). Further studies also identified the D3 lcx-hydroxylase in the distal tubule 
and collecting ducts. 
In 1997, Takeyama et al. (1 7), using a VDR knockout model, isolated a candidate lcx-
hydroxylase 2.5kb cDNA corresponding to a 507 amino acid P450-like protein, with a 
predicted size of 55kDa. The overall sequence identity of this CYP27B 1 to related 
mitochondriai cytochrome P450 pro teins is limited, ranging from 39% (CYP27 A) to 33% 
(lli)-hydroxylase) (20). CYP27Bl gene spans approximately 6kb, consists of9 exons and 
has approximately 500bp of 5' untranslated mRNA. 
In paraUel with the original cloning of the human gene (20), St-Arnaud et al., (102) 
isolated the cDNA for the rat CYP27Bl, which was found to have 82.5% identity to human 
cDNA. The latter report also confirmed the location of the human CYP27Bl gene on 
chromosome 12q13-1-qI3-3. This provides further evidence that abnormal CYP27Bl gene 
expression is the cause ofhereditary pseudovitamin D-defieieney rickets, a disease reported 
to reside on the above mentioned chromosome. 
1.2.3.2 Renal distribution 
Data using normal human kidneys eonfirmed the expression of mRNA and protein for 
the D3 lcx-hydroxylase in proximal tubules (103). However prote in and mRNA were also 
expressed in distal tubules and in eolleeting duets (103). The specificity of the D3 lcx-
hydroxylase expression in the kidney was emphasized by stringent controls for both in situ 
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hybridization and immunohistochemistry analyses. The other key sites ofD3 lcx-hydroxylase 
expression along the nephron were the medullary collecting ducts and the papillary 
epithelium (104). 
Although previous studies of the renal function of D3 have focussed primarily on the 
production and function of 1,25(OH)2D3 in proximal tubules, there is increasing evidence of 
a role for the hormone in more distal parts of the nephron. In view of studies with D3 
deficient animaIs, it is speculated that production of 1,25(OH)2D3 in the proximal tubules 
acts in an endocrine fashion to support circulating levels of 1 ,25(OH)2D3, whereas in more 
distal areas of the nephron it may fulfill an autocrine or paracrine function. Indeed, previous 
studies have shown that 1,25(OH)2D3, as weIl as calcitonin and PTH, stimulate calcium 
reabsorption in the distal nephron (105-108). It is also important to recognize that in sorne 
cases, the impact of 1,25(OH)zD3 on renal function may occur through indirect mechanisms. 
In particular, the observation that the calcium-sensing receptor is primarily regulated by 
1 ,25(OH)2D3, and not by PTH or calcium suggests that this may be the key target for local 
production and action of 1,25(OH)2D3 in the distal nephron (109). 
1.2.3.3 Extra-renal expression 
The original description of extra-renal D3 1 cx-hydroxylase expression was based on 
studies of the granulomatous disease sarcoidosis, which is frequently associated with 
hypercalcaemia (110;111). Enzyme activity analyses using lymph no de homogenates and 
pulmonary alveolar macrophages from patients with sarcoidosis showed high levels of D3 
lcx-hydroxylase activity (112-114). Furthermore, addition of exogenous 1,25(OH)zD3 did 
not appear to inhibit macrophage D3 1 cx-hydroxylase as is c1assically observed with its renal 
counterpart. This would explain the apparently unregulated synthesis of 1,25(OH)2D3 which 
is characteristic ofthe more severe forms ofthis disease. However, these data also suggested 
that the expression and regulation of D3 1 cx-hydroxylase in extra-renal tissues was different 
from that observed with the kidney enzyme. It now appears that renal and extrarenal D31 cx-
hydroxylase activity is due to a single gene product. Therefore, the most likely explanation 
is that induction of extra-renal DJ lcx-hydroxylase involves regulatory pathways that differ 
20 
from renal, cAMP-mediated mechanisms, less sensitive to autoregulation by 1,25(OH)2D3. 
Induction of extra-renal D3 1 ex-hydroxylase frequently involves antigenic mediated 
activators such as lipopolysaccharide or inflammatory mediators such as interferon-y. Since 
these agents use nuclear factor NFKB as signaling mechanism, it can be postulated that this 
pathway activates D3 1 ex-hydroxylase in a manner unlike that of ca1ciotrophic factors and, 
as a consequence show a differential sensitivity to feedback control by 1,25(OHhD3. Further 
analysis of signal-transduction pathways involved in regulating D3 1 ex-hydroxylase will be 
crucial to the understanding of the way in which 1,25(OH)2D3 functions in extra-renal 
tissues. Using immunohistochemistry and Western analyses with renal D3 lex-hydroxylase 
antisera, the enzyme was detectable in tissues such as normal skin (stratum basalis) and 
sarcoid lymph nodes (115). The D31ex-hydroxylase was also highly expressed in skin from 
sarcoid patients. Immunohistochemistry also confirmed previous enzyme activity studies 
which indicated that D3 1 ex-hydroxylase was expressed in decidual cells (116; 117). 
However, the enzyme was also detectable in trophoblasts and syncytiotrophoblasts, 
suggesting potentially diverse functions for the hormone in placenta and feto-placental 
physiology (118). Novel sites for D3 lex-hydroxylase expression include the parathyroids, 
pancreas, adrenal medulla, colon and cerebellum, while negative tissues include the heart, 
liver (hepatocytes) and adrenal cortex. 
1.2.3.4 Regulation ofvitamin D3 metabolism 
The apparent widespread distribution of protein and mRNA for the D3 1 ex-hydroxylase 
in both renal and extra-renal tissues has raised important questions concerning the local 
enzyme activity at these sites. The relationship between expression of the CYP27B 1 and 
actual synthesis of 1,25(OH)2D3 in a particular tissue probably involves two specifie 
mechanisms, the first of these being substrate access, and the second being auto regulation 
ofD3 lex-hydroxylase activity by 1,25(OH)2D3 itself. The former questions the assumption 
that, in common with other steroid hormones, 1,25(OH)2D3 enters cells by a passive 
mechanism by virtue of its lipophilic nature. Circulating vitamin D (D) metabolites can bind 
to a variety of serum proteins, but by far the most important of these is the vitamin D binding 
21 
prote in (DBP), which is synthesized in the liver. DBP may play an active role in directing 
D responses (119) because of its relatively high capacity for binding 25(OH)D3, making it 
a likely key determinant of the availability of the substrate to CYP27B 1. Recent studies have 
shown that DBP and DBP-bound D metabolites are filteredthrough the glomerulus and 
reabsorbed by the luminal endocytic receptor megalin (gp330) in the proximal tubules (120). 
Megalin is also expressed in a variety of tissues (121). Thus megalin-mediated endocytosis 
of DBP-bound 25(OH)D3 may act as an additional mechanism controlling tissue-specific 
synthesis of 1,25(OH)2D3 by modulating the availability of substrate to the CYP27B 1 
protein. Recently, cubulin, a membrane-associated protein colocalizing with megalin, has 
been identified. It facilitates the endocytic process by sequestering steroid-carrier complexes 
on the cellular surface before megalin-mediated intemalization of the cubulin-bound ligand 
(122). Interestingly, dogs with an inherited disorder affecting cubulin biosynthesis exhibit 
abnormal D metabolism (122). 
During D sufficiency, 1,25(OHhD3 production by the kidney is very tightly regulated. 
On the other hand, there is a striking up-regulation of the D3 lcx-hydroxylase activity in 
proximal tubular cells in D-deficient states (123;124). This response appears to be a function 
of several direct and indirect mechanisms, including changes in accessory proteins such as 
ferrodoxin, or alterations in VDR or 24-hydroxylase expression. Studies in vivo suggest that 
the key activator of CYP27B 1 is PTH and that this effect is mediated, at least in part, by 
target-ceIl induction of cyclic adenosine-3', 5'-monophosphate (cAMP) production(125). 
This then acts through potential cAMP response elements in downstream areas (-1 Akb), 
which have been found to be PTH responsive in promoter-reporter assays (29;126). In both 
of these studies, the authors were unable to show any self-regulation of basal CYP27Bl 
promoter activity and no VDREs were identified in the 1Akb fragment. However, in each 
case 1,25(OH)2D3 was unable to suppress PTH-induced transactivation. This suggests either 
that the CYP27Bl gene promoter has an atypical VDRE, or that 1,25(OH)2D3 achieves its 
effects by an indirect mechanism. These reports contrast with analysis of the murine 
promoter, which demonstrated both positive (PTH) and negative (l,25(OH)2D3) 
responsiveness in a region downstream of -0,9kb (127). In this study, calcitonin was shown 
to be a potent stimulator of CYP27Bl expression, supporting previous reports in which 
ca1citonin was shown to stimulate CYP27Bl mRNA and enzyme activity under 
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normocalcemic conditions (128). This suggest that calcitonin (a noncoUagenous prote in 
secreted by osteoblasts), acting via distal areas of the nephron, may play an important role 
in the 'fine-tuning' of serum 1,25(OH)2D3 levels during D3 sufficiency. 
Amongst the most prominent inhibitorsof D3 1 ex-hydroxylase are calcium, phosphate, 
and 1,25(OH)2D3 itself. It seems likely that many ofthese effects are mediated indirectly 
through modulation of PTH production and secretion. However, as a consequence of the 
tight regulation of 1,25(OH)2D3 production, analysis of the precise mechanisms involved in 
controlling the D3 1 ex-hydroxylase has proved difficult, due to the very low enzyme levels. 
1.2.4 VITAMIN D METABOLISM IN PERINATAL DEVELOPMENT 
AU three D3 metabolites 25(OH)D3, 24,25(OHhD3 and 1,25(OHhD3 circulate in 
mammalian fetuses. The cord concentrations of all three metabolites are consistently lower 
than those measured in the mother's serum. However, 24,25(OH)2D3 is the dominant 
metabolite formed in fetopiacentai tissues (129). Moreover, fetomaternal relationships of 
1,25(OH)2D3 concentrations are quite compIex. In most studies, no correlation between fetai 
and maternaI concentrations has been observed (130; 131), whereas in the study by Ross et 
al., (132), a highly significant correlation in both full term and preterm sheep was described. 
Studies show that most of the 1,25(OH)2D3 in fetal plasma is due to the fetai kidney 
production of the hormone (133;134), suggesting fetai control and autonomy in hormone 
regulation. Indeed, cord blood concentrations of 1,25(OH)2D3 in fetal plasma from infants 
with Potter syndrome (renai agenesis) are one third those observed in healthy newborns. In 
addition, hepatic CYP27A mRNA levels have been detected in 17 to 19 week old human 
fetuses (135), further implying the possibility of fetal autonomy in D metabolism. However, 
a maternaI contribution to fetai 1,25(OH)2D3 cannot be eliminated, since radioactive 
1,25(OH)2D3 administration to pregnant monkeys (136), sheep (137) and rats (138) can be 
detected in fetal tissues. Parathyroid related peptide (PTHrP) is an important autocrine and 
lor paracrine growth factor regulator in fetal development. Its presence has been 
demonstrated in the placenta and fetal tissues in various species (139;140). In addition, it 
is implicated in the transfer of calcium across the placenta (139). 
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With respect to calcium homeostasis, the fetal-placental unit has a remarkable ability to 
meet its needs irrespective of maternaI calcium or calciotropic hormones (141;142). 
Specifically, the fetal-placental unit has adapted to rapidly extract calcium from the maternaI 
blood stream in sufficient amounts to mineralise the fetaI skeleton in late gestation (143;144). 
Indeed, the fetus has a higher blood calcium than the ambient maternaI calcium level 
(130;145). Furthermore, the newboms of hypocalcemic D-depleted female rats are 
normocalcemic (unpublished results from our laboratory), and newbom VDR-/- mice are 
normocalcemic until the time ofweaning (146). 
1.2.5 GENDER DIFFERENCES IN VITAMIN D METABOLISM 
A microsomal D 25-hydroxylase, CYP2Cll, is known to exist in male rat liver 
microsomes but not in those of females (147). This observation may well explain why 
microsomes (or P450 purifies from the microsomal fraction) obtained from female livers 
have consistently been shown to exhibit significantly far less activity in C-25 hydroxylation 
of D3 than preparations obtained from male counterparts (148-150). 
Furthermore, estrogen deficiency leads to a decrease in serum 1,25(OH)2D regardless 
of age (151; 152). Estrogen replacement in postmenopausal women can increase both total 
and free serum 1,25(OH)2D (152;153), suggesting that menopause and the accompanying 
estrogen deficiency may remove an important trophic factor for the maintenance of serum 
1,25(OH)2D in aging women. 
In parallel, serum total and free testosterone levels decrease with advancing age 
(154;155) and testosterone treatment has been shown to increase modestly both serum total 
and free 1 ,25(OH)2D in hypogonadal men (156). 
1.3 ROLE OF THE LIVER IN VITAMIN D3 HOMEOSTASIS AND METABOLISM 
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1.3.1 HEPATfC STRUCTURE AND FUNCTfON 
The liver consists mainly of hepatocytes, the main parenchymal cell population. The 
non-parenchymal cells include sinusoidal, endothelial, Kupffer and stellate (Ito) cells. The 
hepatocytes represent 60% of the cell population. They are, however, more voluminous than 
other cells and consequently make up 80% of the parenchymal volume (157). The 
hepatocytes are organised in three-dimensional structures called acini (158). The hepatic 
acinus represents a structural and functional unit of the hepatic parenchyme whose main 
function consists of regulating the metabolism of the various substances exported to the 
systemic circulation (159). 
The liver's microcirculation is composed of sinusoids, which are specialized capillaries 
who se discontinuous basal membrane is bordered by the sinusoidal cell population 
mentioned above. The sinusoidal endothelial cells form a selective semi-permeable barrier 
between the blood and the hepatic parenchyme, as described by De Zanger and Wisse (160). 
The Kupffer cells' main role is to endocytose many substances originating from the systemic 
circulation such as endotoxins (161). There also exists an intercellular space between the 
hepatocyte's plasma membrane and the endothelial cells called the space of Disse. This 
space encompasses the perisinusoidal stellate ceIls, which metabolize and store vitamin A 
(162), and synthesize the hepatocyte growth factor (HGF) (163). Stellate cells are also 
responsible for the synthesis of collagen, thus preventing cirrhosis of the liver. 
The cells in zone 1 (or periportal area) are situated close to the supplying vessels and are 
bathed by blood of a composition similar to that in the afferent vessels. The cells in zone 3 
(or perivenous area) are situated at the microcirculatory periphery of the acinar unit and 
receive blood that has already exchanged gases and metabolites with cells in zones 1 and 2 
(midzonal). 
1.3.2 VITAMIN D3 UPTAKE: REGIONALISATION ALONG THE HEPATIC ACINUS 
There exist two distinct me chanis ms that can provide D3 to the body. First, synthesis 
from UV light-dependent biosynthetic sites in the skin and secondly, through intestinal 
absorption from dietary sources of the vitamin. 
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Following these initial steps, efficient hepatic delivery of D3 is necessary for the 
important C-25 hydroxylation step to occur (164). The production of 25(OH)D3 is best 
served by a steady delivery of substrate, since rapid or pulse delivery leads to less 25(OH)D3 
production due to the likely overspill of D3 to esterification enzymes, and possibly to extra-
hepatic lipid storage sites (165; 166). 
Chylomicrons play an important role in D3 transport, since they transport the vitamin 
after intestinal absorption (167). Following an i.v. injection of D, the vitamin is initially 
bound to lipoproteins (168) before transferring to the DBP (169), suggesting that D3 is prutly 
delivered to the hepatocytes via the DBP. 
Although remnants or low density lipoproteins (LDL) have been shown to optimize 
uptake ofD in vitro (170), manipulation of the diet in order to obtain different proportions 
of putative D3 carrier proteins in vivo were found not to significantly affect the hepatic 
extraction ofD3 (171), an observation also made in vitro by Ziv et al. (172). 
The hepatic handling ofD3 has been studied by manY laboratories and most studies"have 
reported that the fractional hepatic uptake of D varies between 40 to 60% in adult normal or 
D-depleted rats or dogs (171;173;174). The liver also has a considerable uptake capacity for 
the hormone 1,25(OH)zD3, which is estimated to be between 19.7 and 34% (175;176). 
Moreover, the hepatic extraction of D3 has been shown to be independent of its hepatic 
venous or arterial route of delivery (175) and its hepatic clearance is estimated at 357mllmin 
in dogs (176). Studies in which total uptake has been investigated for periods varying from 
18 sec to 70 min have revealed that the liver does not accumulate significantly more D3 than 
that observed during the [Ifst pass across the organ (177). In addition, data indicate that there 
is no stringent regulation ofuptake by the D3 status (178). 
Both regions of the acinus are equally able to extract D3 which implies that the C-25 
hydroxylation of the vitamin would, due to the concentration gradient across the hepatic 
acinus predominate in hepatocytes of the periportal area under normal basal conditions (179). 
In addition, both the hepatocytes and the nonparenchymal cells of the rat liver have a 
high capacity to take up D3 both in vivo and in vitro (174). The further metabolism to 
25(OH)D3 however, takes place almost exclusively in hepatocytes (174). It is postulated that 
the nonparenchymal cells may serve as a site of storage for the D3; when the need for more 
25(OH)D3 arises, the stored D3 might subsequently be transferred to the hepatocytes for 
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hydroxylation. 
CYP27A is heterogeneously distributed within the liver acinus, with higher perivenous 
than periportal mRNA levels (58). Interruption of the enterohepatic circulation by a bile salt 
sequestrant increases the production of 27-hydroxycholestrol, steady-state CYP27A mRNA 
level and gene transcription (57;58). This data clearly indicates that CYP27A is subject to 
feedback inhibition at the transcriptionallevel by bile acids returning via the portal blood. 
Whether malabsorption-induced D3 depletion leads to a similar regulation of the 25-
hydroxylation of D3 as that observed on the 27-hydroxylation of cholesterol following bile 
acid depletion (57) remains to be investigated. Moreover, the action of bile acids on the total 
hepatic output of 25(OH)D3 is unclear, since both the absence (180) and the presence of an 
effect (181) have been observed. 
The anabolic function of the liver is particularly important since, under normal 
physiological conditions, it is the only organ involved in the C-25 hydroxylation ofD3 (164) 
giving rise to the most abundant circulating form of D3 in normal individuals, 25(OH)D3. 
The circulating levels of 25(OH)D3 are the best indicator of the nutritional status of the 
vitamin. The liver is also involved in the biliary excretion of the main circulating D3 
metabolites such as 25(OH)D3, 1,25(OH)2D3 and 24,25(OH)2D3 (171 ;173) as well as many 
degradation products of D3 metabolism (182). The liver can thus be considered as an organ 
involved in the whole body homeostasis of the D nutritional and endocrine systems through 
its anabolic as weil as excretory functions. 
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Figure 1.4 How the liver handles vitam in D and its metabolites. Vitamin D (D) and its 
metabolites (0) exist in blood largely bound to proteins (lipoproteins, chylomicrons, and D 
binding protein (0)). Bound metabolites can enter the space of Disse through fenestrations 
in the sinusoidal endothelium. Bound metabolites can then enter the hepatocyte and be 
converted to more water-soluble metabolites (e) by enzymes present in the endoplasmic 
reticulum or mitochondria. The metabolites are then either regurgitated back into the 
sinusoidal blood or are sorted to the biliary canaliculus. Cell sizes illustrated are not drawn 
to scale. Hepatocytes have a mean diameter of 17-18)lM, whereas Kupffer, endothelial and 
bile duct cells have diameters of Il, 8 and 6)lM respedively. 
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1.3.3 The /iver: a non-classic vitamin D responsive organ 
Evidence for a role for 1,25(OH)2D3 and other parameters of calcium homeostasis in the 
liver began with studies of their requirements in response to hepatotoxic injury in liver 
regeneration (183). Extensions ofthese studies have shown that 1,25(OH)2D3 is required for 
DNA synthesis after partial hepatectomy (184; 185). 1,25(OH)2D3 is also required for mitosis 
and compensatory liver growth (186) and is associated with an efficient transit across the G 1 
phase of the ceIl cycle (187). In addition, 1,25(OH)2D3 induces several DNA replication 
enzymes, including DNA polymerase ex (184; 185), ribonucleotide reductase and probably 
thymidylate synthase (185). cAMP-dependent protein kinases are involved (184) in, but not 
solely responsible for, the 1,25(OH)2D3 effects (184-186). Furthermore, the hormone has 
also been shown to stimulate the hepatic glycogen synthetic pathway and the synthesis of 
transferrin (188). Interestingly, the absence ofactinomycin D inhibition of the latter effect 
has led to the suggestion that it occurs via a nongenomic pathway (189). To date, 
controversial data exists conceming the presence of VDR in the liver, with sorne 
investigators reporting its presence (190; 191), whereas others doubt its importance (192). 
1.3.3.1 Presence ofvitamin D receptor in the liver 
Thus, while sorne authors using biochemical and immunocytochemical techniques 
detected VDRs in liver (193; 194), others failed to find detectable levels (195), and sorne used 
liver as a negative control of VDR gene expression (196; 197). However VDR has been 
recently detected using a combination of sensitive molecular biological techniques, such as 
RT -peR, with standard immunocytochemical methods in order to clarify VDR expression 
in rat liver(190; 191). 
1.4 THE INTESTINE: A CLASSIC VITAMIN D RESPONSIVE TISSUE 
1.4.1 ANATOMY AND FUNCTION OF THE SMALL INTESTINE 
29 
The primary function of the small intestine is to absorb nutrients, electrolytes and water. 
This is achieved by mixing food with digestive enzymes to increase the contact of chyme 
with the absorptive cells of the mucosa. Absorption and movement of the contents are 
brought about by the activities of the absorptive cells of the mucosa and by the coordinated 
contraction of the smooth muscle cells of the muscularis extem (198; 199). In addition to this 
fundamental role, a secondary function of the small intestine arises from the fact that it is 
also a major route of entry into the body for many xenobiotics including drugs. 
The small intestine is divided arbitrarily into three parts: duodenum, jejunum and ileum. 
These regions are not anatomically distinct although there are differences in their absorptive 
and secretory capabilities. AIl three regions share a common histological pattern. Their 
wall, from inside outward is composed of the mucosa, the submucosa, the muscle layers and 
the serosa. The serosa is an extension of the peritoneum and consists of a single layer of 
flattened mesothelial cells overlying sorne loose connective tissues. The muscularis has an 
outer longitudinal layer and an inner circular layer of muscle. The submucosa is composed 
of a network of loose connective tissue rich in small blood vessels, lymphatics and nerve 
plexus. Furthermore, the mucosa has three components: a superficiallining of epithelium, 
the lamina propria, and the muscularis mucosa. 
The epithelium is the innerrnost layer of mucosa facing the lumen of the bowel and 
consists of a single layer of columnar epithelial cells (enterocytes), which line both the crypts 
and the villi. Unlike hepatocytes, which regenerate only when death occurs, epithelial cells 
of the intestinal mucosa have a prograrnmed limited lifespan. The villus epithelial cells are 
functionally mature and nondividing, whereas the crypt cells are immature and evolving. The 
crypt cells continue to mature as they ascend toward the villus and are extruded at its tip. The 
time required for migration from the base to the tip has been estimated to be 2 to 6 days 
(200). Interestingly, the rapidity of enterocyte migration and maturation may provide a 
protective mechanism against carcinogenic toxins (201). 
1.4.2 ONTOGENY OF THE SMALL INTESTINE 
In the human, the intestinal tract begins to develop from the premature entoderrn and 
the surrounding splanchnic mesoderrn at the end of the second week of gestation. A tubelike 
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structure is formed, and by day 18 the primitive gut is lined with non differentiated cuboidal 
cells which proliferate, obliterate the lumen, and then the intestine is recanalized (202). 
Homeotic genes (hox genes) regulate the patterning of the gastrointestinal tract. lndeed, 
regional differences in expression of hox genes in the mouse intestine have been 
demonstrated (203). The hox genes are critical early regulators of proximal to distal organ-
specific patteming in mammalian gastrointestinal development. 
During the fourth and fifth week of gestation the intestine elongates more rapidly than 
the embryo does and begins to form a loop which protrudes into the umbilical cord. At this 
stage the duodenum can be recognized by its contiguity with the craniallimb of the intestinal 
loop. Between the fifth and sixth week of gestation, the small intestine rotates around the 
axis of the superior mesenteric artery, moving counterclockwise. Further rapid elongation 
and coiling beyond the capacity of the slower growing abdominal cavity force the bulk ofthe 
developing intestine into the umbilical cord. At about 10 weeks of gestation the intestine re-
enters the abdominal cavity and by the seventh to eighth week villi begin to form in the 
duodenum and proximal jejunum. Between 9 and 20 weeks of gestation, the human gut 
acquires many of the morphological and functional characteristics found in the adult (204). 
Furthermore, the highest epithelial proliferative activity is recorded between 9 and 20 weeks 
of gestation (205). The epithelium becomes columnar, and by the 12th week of gestation a 
single layer of epithelial cells lines the villi (206). After the 14th week the entire small 
intestinal mucosa is lined by villi. Primitive crypts begin to appear between 10 to 12 weeks 
and between the 5th and 40th week of gestation the intestine elongates approximately 1000-
foid. 
By the time of birth the intestine has acquired the digestive and absorptive functions 
necessary to cope with the neonatal diet, the maternaI milk (207). The intestinal mucosa of 
the neonate displays a high level of structural development characterized by villi lined with 
a single layer of columnar epithelial cells, which have their absorptive well defined brush 
border (208). 
In the rat, the length of the gut achieves 90% of its adult value by day 40, whereas body 
weight increases in a linear fashion (209). Between 20 and 40 days of age, the body weight 
of the animaIs continues to rise, but the ratio of the small intestine to body weight faIls. lt is 
well established, by morphological and biochemical criteria, that the human fetai intestine 
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is more mature at term than that of commonly examined mammalian models. 
1.4.3 DRUG METABOLlZING ENZYMES lN THE SMALL INTESTINE 
Numerous metabolic reactions occur in the gut wall, inc1uding those typically referred 
to as phase 1, and phase 2 processes. Aimost aU of the drug metabolizing enzymes present 
in the liver are aiso found in the small intestine, although their levels generally are much 
lower in the latter than in the former. Kinetically, the rate of intestinal metabolism of a drug 
is determined by the content of a particular catalytic enzyme within the enterocytes and the 
intracellular residence time of the drug subject to biotransformation. 
Unlike the liver, in which the distribution of the P450 enzymes is relatively 
homogeneous (210), the distribution of these enzymes is not uniform along the villi within 
a cross-section of mucosa. Both the content and activity of P450s is higher in the proximal 
than in the distal sm aIl intestine (211). P450 content varies along the villus in rats, where 
P450 content at the villus tip is approximately 10 foid higher than at the crypts (211). 
Consistent with the P450 enzyme protein levels, the enzyme activities ofP450 isoforms also 
are higher in the liver than in the small intestine. 
1.4.4 BIOLOGICAL ACTIONS OF VITAMIN D3 
The small intestine is a major target of 1,25(OH)2D3. In general, the se actions take 
several hours and are mediated by the VDR. However, sorne effects of 1,25(OH)2D3 are 
rapid, may involve a membrane-bound rather than a cytosolic VDR, and may be mediated 
by the PKC pathway (212). 
The most critical role of 1,25(OH)2D3 in mineraI homeostasis is to enhance the efficiency 
of the small intestine to absorb dietary calcium and phosphate as demonstrated conc1usively 
by studies in the VDR null mice (2l3). In the absence ofVDR, normalization of circulating 
levels of calcium and phosphorus through dietary supplementation corrects most of the 
phenotypic features of D3 resistance inc1uding parathyroid gland growth, bone 
mineralization, and growth plate histology. These findings concur with prior clinical 
observations in patients with vitamin D-resistant rickets whose bone abnormalities were 
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resolved by calcium infusions. 
1,25(OH)2DJ increases the entry of calcium through the plasma membrane in the 
enterocyte, followed by the movement of calcium through the cytoplasm, and the transfer of 
calcium across the basolateral membrane into the circulation. 1,25(OH)2DJ is the only 
hormone known to stimulate intestinal calcium transport directly. Other DJ metabolites can 
stimulate calcium transport, but only at higher doses, consistent with their lower affinity for 
the VDR. The mechanism for stimulation oftranscellular calcium transport is not entirely 
c1ear, but induction of a cytosolic calcium-binding protein (calbindin D) and the basolateral 
calcium pump undoubtedly are important components (214). Increasingly, evidence suggests 
that the VDR-mediated effects of 1 ,25(OH)2DJ may not be the only mode of action by which 
the hormone stimulates calcium absorption by the enterocyte. Rapid effects of 1,25(OH)2DJ 
appear to mediate an increase in both the vesicular and paracellular pathways for intestinal 
calcium absorption. The actual contribution of these nongenomic pathways to intestinal 
calcium absorption in vivo is unc1ear. 
In addition to its effects on calcium absorption, 1,25(OH)2DJ increases active phosphate 
transport. However, significant phosphate absorption also occurs in 1,25(OH)2DJ-deficient 
states (215). The sterol directly stimulates the expression of the Na-Pi cotransporter (216) 
and affects the composition of the enterocyte plasma membrane, increasing fluidity and 
phosphate uptake. Sodium-independent entry of phosphate occurs independently ofD status 
(217). Little is known, however, conceming the molecular mechanisms involved in the 
extrusion of phosphate across the basolateral membrane into the circulation. 
1,25(OH)2DJ has also been shown to alter the proliferation and differentiation of cell 
lines, inc1uding colon cells (218). Most of these effects are mediated by the cytosolic VDR. 
However, sorne effects of 1,25(OH)2DJ are rapid, may involve a membrane-bound rather 
than a cytosolic VDR, and may be mediated by the PKC pathway (219). 
An important action of 1,25(OH)2DJ in the intestine is to increase intestinall,25(OH)2DJ 
24-hydroxylase activity. The DJ-24 hydroxylase enzyme is found in tissues that are targets 
for 1,25(OH)zDJ and 1,25(OH)zDJ production, as discussed previously. It is thought to be 
the first step in the degradation of 1,25(OH)2DJ. Thus, the activity of the DJ-24 hydroxylase 
may regulate the action of 1,25(OH)2DJ in the intestine. 1,25(OH)2DJ markedly increases 
the mRNA levels of CYP24 in the intestine of intact animaIs (88;96) as well as in intestinal 
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celllines (220;221). 
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VITAMIN D ENDOCRINE SYSTEM: BASIC VIEW 
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Figure 1.5 Overview of the vitamin D system. 
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CHAPTER 2: EXPERIMENTAL SECTION (STUDIES IN LIVER) 
2.1 EFFECT OF THE VITAMINE D3 HORMONAL AND NUTRITIONAL STATUS ON 
CYP27A, THE HEPATIC VITAMIN D3 25-HYDROXYLASE 
2.1.1 Preliminary findings 
It has long been established that the liver is the primary and main organ involved in 
the hydroxylation ofD3. The C-25 hydroxylation ofD3 has been shown to occur in both the 
mitochondria and endoplasmic reticulum. Previous studies have shown 1,25(OH)2D3 
inhibits the in vitro synthesis of 25(OH)D3 by liver homogenates and perfused liver from 
rachitic rats (222). In addition, in vivo experiments indicate that in both humans and animaIs, 
1,25(OH)2D3 administration is associated with decreases in serum 25(OH)D3 concentrations 
(223-225). To date, regulation studies on the CYP27A gene, the mitochondrial D3 25-
hydroxylase, have focused primarily on bile acid metabolism. Studies in rat (both in vivo and 
in vitro) have shown that CYP27A is downregulated at the transcriptional level by 
hydrophobic bile acids (57;226;227). Furthermore, CYP27A in rat has been shown to 
undergo diurnal variation, upregulation by glucocorticoids and downregulation by insulin 
(43;57;59). No studies have examined the effect of the D3 hormonal and/or nutritional status 
on the hepatic CYP27A. 
2.1.2 Hypotheses 
Previous studies have indicated that 1,25(OH)2D3 significantly reduces circulating 
25(OH)D3 levels by inhibiting hepatic production of 25(OH)D3 (228). However, the 
molecular mechanisms involved in the regulation ofhepatic production of 25(OH)D have 
not been addressed thus far. Since CYP27A, the mitochondrial D3-25 hydroxylase, has been 
shown to be inducible by D3 in keratinocytes in vitro (65), we hypothesize that regulatory 
mechanisms related to the D3 status may affect the CYP27A gene expression level in the 
liver. 
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2.1.3 Objectives 
- Evaluate the effect of the D3 honnonal and/or nutritional status on the rat hepatic 
CYP27A gene transcript. 
- Evaluate the steady state expression level of the CYP27A in hurnan liver and kidney 
specimens. 
2.2 RESULTS 
2.2.1 Article 1: High sensitivity of the rat hepatic vitamin D3 25-hydroxylase CYP27A to 
1, 25-dihydroxyvitamin D3 administration. 
Article in press, American Journal of Physiology. 
(ARTICLE 1) 
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Catherine Theodoropoulos, Christian Demers, 
Jean-Luc Petit, and Marielle Gascon-Barré 
.37 
Centre de recherche, Hôpital Saint-Luc, Centre Hospitalier de l'Université de Montréal, 
Département de Pharmacologie, Faculté de médecine, Université de Montréal, 
Montréal, Québec, CANADA 
Short title: Hepatic mitochondrial D)-25 hydroxylase 
Corresponding author: 
Marielle Gascon-Barré, PhD, MBA 
Centre de recherche, Hôpital Saint-Luc, 
Centre Hospitalier de 1'Université de Montréal, 
264 René-Lévesque Blvd. East, 
Montreal (Quebec) CANADA, H2X IPI 
Tel.: (514) 890-0000 #35707 FAX: (514) 412-7314 E-mail:
38 
ABSTRACT 
CYP27 A is considered the main vitamin D3 (D3)-25 hydroxylase in humans. Our 
purpose was to evaluate the effect of the D3 nutritional and hormonal status on hepatic 
CYP27A mRNA, cellular distribution, transcription rate and enzyme activity. Studies 
were carried out in normal and in D-depleted rats supplemented with D3, 250HD3 or 
1,25(OHhD3. CYP27A exhibited a significant gender difference and was observed 
throughout the hepatic acinus not only in hepatocytes but also in sinusoidal endothelial, 
stellate and Kupffer cells. Neither D3 nor 250HD3 influenced CYP27A mRNA levels. 
However, 1,25(OH)2D3 repletion led to a 60% decrease in CYP27A mRNA which was 
accompanied by a 46% decrease in mitochondrial D3-25 hydroxylase activity. The effect 
of 1,25(OHhD3 was mediated by a significant decrease in CYP27A transcription while its 
mRNA half-life remained unchanged. Our data indicate that CYP27A is present in hepatic 
parenchymal and sinusoidal cells, and that the gene transcript is not influenced by the D3 
nutritional status but is transcriptionaUy regulated by 1 ,25(OH)2D3 exposure. 
Key words: CYP27 A, vitamin D3, 250HD3, 1,25(OH)2D3, bile acid biosynthesis, 
Kupffer ceUs, stellate ceUs, hepatocytes, sinusoidal endothelial ceUs, D3 
25-hydroxylase. 
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INTRODUCTION 
The secosteroid vitamin D3 (D3) of endogenous or exogenous origin has, in its 
native form, no biological activity. Once in circulation, D3 is efficiently taken up by the 
liver (26) and hydroxylated at C-25 by a mitochondrial mixed function oxidase CYP27 A 
(C27 sterol hydroxylase (EC 1.14.13.15)) (15). In humans, the enzyme is presumed to be 
the only D3-25 hydroxylase (51). However, a microsomal D3-25 hydroxylase has also 
been reported in rodents (11), chickens (12) and pigs (35) but only the porcine enzyme 
(which has been termed CYP2D25) has been cloned to date (34;44). 
CYP27 A is a cytochrome P450 that catalyses the first step in the oxidation of the 
cholesterol side chain in the secondary "acidic" bile acid biosynthesis pathway (13). 
CYP27A is also able to hydroxylate D3 and D3 metabolites at position C-25 (51) as well 
as at other positions on the secosteroid side chain (29;54). It has also been reported to be 
able to catalyse the lcx-hydroxylation of 25-hydroxyvitamin D3 (250HD3) albeit at a 
much lower rate than the transformation of D3 into 250HD3 (3). However, unlike the 
tight regulation by the D3 endocrine system associated with the renal 25-hydroxyvitamin 
D3-1cx-hydroxylase, the sensitivity of the gene encoding CYP27A to D3 or to D3 
metabolites has not been characterized. The presence of regulatory mechanisms related to 
the D3 status as a modulator of the 25-hydroxylation of the vitamin is, however, a widely 
accepted notion which rests on the studies of DeLuca's group in the early 1970s (10;12). 
Several laboratories have attempted to evaluate the mechanism(s) involved in the 
regulation of the activity of the D3-25 hydroxylase. In the early 1980s, two independent 
reports (5;8) raised the possibility that 1,25(OHhD3 might be an inhibitor of the enzyme 
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in rats as weIl as in humans. Indeed, Bell et al. (8) reported that D3 administration to 
human subjects significantly increased me an serum 250HD3 whereas the concomitant 
administration of 1,25(OH)2D3 completely prevented the increase in serum 250HD3 in 
response to the same dose of D3. Subsequent studies revealed that the response of the D3-
25-hydroxylase to various challenges in vitro was greatly influenced by the in vivo 
calcium and/or D3 status of the animaIs (9). However, supplementation with 1,25(OH)2D3 
was shown to influence the in vivo handling of D3 by accelerating its biotransformation as 
well as by increasing the metabolic and biliary clearances of D3 and/or D3 metabolites 
(18;24;31 ;32). The latter studies suggest the presence of a 1,25(OH)2D3-mediated 
increase in the utilisation of the substrate and/or in its turnover but do not, in any way, 
directly address the effect of 1,25(OH)2D3 on the hepatic mitochondrial D3-25 
hydroxylase CYP27A. 
To date, studies examining the regulation of the gene encoding CYP27A have 
focussed on its role as a mixed function oxidase involved in bile acid biosynthesis (56). 
The aim of the studies was, therefore, to investigate the influence of the D3 nutritional 
and endocrine status on CYP27A as a D3-25 hydroxylase in the rat liver. We now report 
that 1,25(OH)2D3 is a major regulator of the hepatic CYP27A which translates into 
significant decreases in CYP27A steady state mRNA levels and transcription rate, as weIl 
as into a significant decrease in the mitochondrial C-25 hydroxylation of 1 (X-
hydroxyvitamin D3. 
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MATERIALS AND METHODS 
EXPERIMENTAL DESIGN 
The influence of the D3 endocrine system on the handling of the gene encoding 
the hepatic mitochondrial D3-25 hydroxylase CYP27A was evaluated in D depleted rats, 
and in D depleted rats following in vivo repletion with physiological concentrations of 
either D3, 250HD3 or 1,25(OH)2D3. D depletion as weIl as aIl repletion procedures were 
carried out as previously reported (59). The specifie end points of the studies included 
evaluation of the i) gender differences, and response to cytochrome P450 inducers on 
CYP27A mRNA levels, ii) presence of CYP27A in the main hepatic cell populations, and 
iii) effect of 1,25(OH)2D3 on CYP27A steady state mRNA levels, rnRNA half-life, 
transcription rate, and the mitochondrial CYP27A hydroxylation activity at C-25. 
A CYP27A gene fragment corresponding to base pairs 399 to 803 of the N-
terminal coding region of the rCYP27A sequence of Su et al. (58) (GenBank, accession 
number M38566) was generated by RT-PCR as previously reported (59). Northem blot 
analyses of rat livers hybridized with the rCYP27A gene fragment generated consistently 
revealed a single band of2.3 kb. 
AnimaIs were treated according to the standards of ethics for animal 
experimentation of the Canadian Council on Animal Care and aU protocols were 
approved by the local animal ethics committee. 
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REPLETION WITH D3, 250HD3, OR 1,25(OHhD3 
Expression of the hepatic CYP27A gene transcript was studied in normal control 
rats fed a commercial rat chow diet (Harlan Tekland Global Diet, Madison, WI, USA), D 
depleted animaIs fed a semi-synthetic diet as described previously (30), and in animaIs 
repleted with D), 250HD), or 1,25(OH)2D) but kept on the D depleted diet through out 
the repletion procedure. The repletion protocols were identical to those used to evaluate 
the effect of the D3 status on the intestinal CYP27A (59). Briefly, aIl compounds were 
administered by intraperitoneal (i.p.) osmotic mini-pumps (Alza Corporation, Palo Alto, 
CA, USA) containing either D3 (6.5 nmol/day (low dose), or 32.5 nmol/day (high dose)), 
250HD3 (28 pmol/day), or 1,25(OHhD3 (28 pmol/day). At the time of osmotic mini-
pump implantation a loading dose of 3.2 (low dose), 16.2 (high dose) nmol DJ, 14 pmol 
250HD3, or 14 pmol 1,25(OH)2DJ was administered to rapidly raise serum 
concentrations of DJ, 250HD), or 1,25(OHhD3 and hence accelerate the establishment of 
steady state conditions. AnimaIs were killed l, 3, 5 or 7 days foIlowing initiation of the 
repletion protocols. The serum ionized calcium, and vitamin D3 metabolites 
concentrations achieved under aIl repletion protocols (except for the high dose of D3) 
have been previously reported (59). 
TREATMENT WITH CYTOCHROME P-450 INDUCERS 
Studies on the induction of the gene encoding CYP27A were achieved using 
xenobiotics known to induce cytochrome P-450 izozymes. Normal male rats were 
exposed to either i) dexamethasone (two daily i.p. injections, 100mg/kg), ii) 3-
methylcholanthrene (one single i.p. injection, 30 mg/kg), iii) p-naphtoflavone (three daily 
i.p. injections, 80mg/kg), iv) acetone (1 % v:v in drinking water) for a period of 10 days, 
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or v) phenobarbital (350 mg/ml in drinking water) for a period of 10 days (45). 
EXPERIMENTAL PROCEDURES 
DETERMINATION OF CIRCULATING Ca2+ AND D3 METABOLITES 
Serum Ca2+ concentrations were measured with an ICA2 ionized Ca2+ analyzer 
(Radiometer, Copenhagen, Denmark). Serum 250HD3 and 1,25(OH)2D3 concentrations 
were measured using the IDS 250HD3 and 1,25(OHhD3 assay Kits (IDS, Boldon, Tyne 
and Wear, UK) according to the manufacturer's instructions. 
HEPATIC CELL ISOLATION 
At the time of euthanasia, the livers were flushed with saline and processed for 
isolation of the individual cell populations. Cells used for RNA analysis were placed in 
Trizol solution (Burlington, ON, Canada) and RNA was extracted as described by the 
manufacturer. 
Hepatocytes were isolated from non-fasting animaIs as mentioned elsewhere 
(25). Rat sinusoidal cells were isolated by the method of Knook and Sleyster (37) with 
the following modifications. After Metrizamide density gradient, cells were washed in 
GBSS, pH 7.4 at 4°C, resuspended, and introduced in a type J2-21M centrifuge (Beckman 
Instruments, Palo Alto, CA) equipped with a JE-6B elutriation rotor and a Sanderson 
chamber. While centrifugation at 2500 RPM, cells were washed out at pump flows of 13, 
23, and 42 ml/min to colleet stellate, endothelial and Kupffer cells respeetively using 
GBSS, pH 7.4 at 4°C. Cells were centrifuged, counted and viability evaluated. Sinusoidal 
cells had a viability greater than 95% and were freed of hepatocytes. Cell populations 
were identified by immunocytochemistry and found to be >88% pure (43). 
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Cell viability and yield were evaluated by the Trypan blue exclusion test and by 
counting viable cells in each cell population respectively. 
NORTHERN BLOT ANALYSIS 
At the time of euthanasia, the livers were isolated and immediately frozen in 
liquid nitrogen and stored at -80DC until RNA extraction. Total liver RNA was extracted, 
blotted onto nylon membranes (Qiagen, Mississauga, ON, Canada) and processed for 
Northem analyses using the radiolabeled 404 base rCYP27A cDNA probe generated in 
our laboratory (59). 
RT-PCR 
After Dnase treatment, 1 Ilg of total RNA from sinusoidal cells was converted in 
cDNA (First-Strand cDNA synthesis Kit) using pd(N)6 as primer; 2.01lL of RT reaction 
was amplified for either 25 (CYP27A) or 20 cycles (GAPDH) using specifies primers and 
Taq PCR Master Mix and 0.1 ilL of [a:_32p] dCTP (3 000 Ci/mol) in a Touchdown 
Thermal Cycling system (Hybaid, Teddington, D.K.). Design of primers to generate 
rCYP27A and GAPDH cDNA fragments was made with the Primers Software of 
Williamstone Enterprises (http://www.williamstone.com) and the sequence of Su et al. 
(58) (CYP27A) and Tso et al.(62) (GAPDH). cDNA PCR products were loaded and 
separated onto a non-denaturing 8% polyacrylamide TBE gel. The gel was dried and 
exposed to Kodak X-Omat AR film at -80DC in the presence of an intensifying screen for 
4 to 16 hours. Densitometry was performed as described previously. (20;38). 
HALF-LIFE OF THE CYP27A GENE TRANSCRIPT 
Studies on the half-life of the CYP27A gene transcript were achieved in D 
depleted rats subjected to i.p. injections of 0.5mg/kg actinomycin D dissolved in 95% 
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ethanol:saline (1:1 v:v) administered 6, 12, 18 and 24 ho urs before sacrifice. In studies 
carried out in 1,25(OH)2D3 injected (12 nmol/kg, i.v.) animaIs, actinomycin D was first 
administered half an hour before 1,25(OHhD3 and subsequently every six hours over a 24 
hour-period. 1,25(OH)2D3 continued to be administered every 6 hours. CYP27A mRNA 
levels were evaluated as described above. 
NUCLEAR RUN-ON TRANSCRIPTIONAL ASSAY 
Nuclei were isolated from hepatic of D-Ca- or of 1,25(OH)2D3 repleted rats by 
the method of Widnell and Tata (67) using successive sucrose gradient centrifugations. 
The rate of CYP 27 A gene transcription was measured using a previously described 
nuc1ear mn-on transcriptional assay (50) with the modifications described in 
Theodoropoulos et al.(59). The labelled RNA was hybridized to nylon membranes on 
which 300 ng of the 404 bp D3-25 hydroxylase cDNA fragment 150 ng of 18S ribosomal 
RNA cDNA fragment as a positive control, and 100 ng of pBS as negative control in 
hybridization solution (5% SDS, 400 mM NaP04 pH 7.2, ImM EDTA, Img/ml BSA, 
50% formamide and 240 Ilg/ml of salmon sperm DNA). The membranes were 
prehybridized for 4 hours at 52°C in hybridization solution without labelled RNA, then 
hybridization was performed at 52°C for 72 hours. The membranes were washed and 
exposed to x-ray films for 7 days and densitometry was performed as previously 
described (20;38). 
IN SITU Rt-PCR HYBRIDIZATION 
Paraffin liver sections were mounted onto slides pre-treated with 3-
aminopropyltriethoxysilane (APES), dewaxed in xylene and then rehydrated through a 
series of ethanol baths, and finally immersed in DEPC-treated water. Slides were 
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incubated as described in Gascon Barré et al., 2001 (23). 
In situ RT-PCR were performed by the method of Mee et al. (40) with the 
modifications previously described (23). The reaction was carried out in 25 ilL with 
OneStep RT-PCR kit and 0.61lM rCYP27A specific primers (58) using a Hybaid thermal 
cycler provided with a in situ block (Hybaid, Teddington, UK). Sections were heated for 
30 min. at 50°C, 15 min. at 95°C and then 10 cycles of 95°C for 30 sec., 62°C for 30 sec., 
and 72°C for 30 sec. were performed; finally slides were heated for 10 min. at 72°C. 
Sample were washed twice in PBS and fixed in 4% paraformaldehyde-PBS for 20 min. at 
4°C and incubated with 0.25% acetic anhydride in 0.1 TEA for 10 min. and rinsed in 90% 
ethanol and allowed to dry. 
An in situ hybridization was performed using the rCYP27A antisense riboprobes 
(using linearised CYP27A cDNA as template) were generated by the single strand RNA 
synthesis technique using T7 RNA polymerases and [ex_33p]UTP (800 Ci/mmol). 
Hybridization was performed at 42°C for 16 ho urs with 100,uL of hybridization solution 
(50% formamide, 2XSSC, IX Denhart's, 0.25M Tris-HCl, pH 7.5, 10% dextran sulfate, 
0.5M Na pyrophosphate, 0.5% SDS, 25,ug/mL denatured salmon sperm DNA, 250 
,ug/mL yeast tRNA) and 1 X107 cpm/mL of antisense. After washing, autoradiography 
was performed with NBT-2 emulsion (lnterscience, Mississauga, ON, Canada). Slides 
were exposed for 5 days at 4°C, developed with D19 (Interscience, Mississauga, ON, 
Canada) developer and counterstained with hematoxylin and eosin. 
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MITOCHONDRIAL DJ-25 HYDROXYLASE ENZYME ACTIVITY 
Liver from hypocalcemic D depleted and 1,25(OH)2D3 treated rats (28pmol/d, 
for 7 days) were homogenized in 10 volumes of 0.25M sucrose, 1mM EDTA, 10mM 
Tris, 10M KCI, heparin 3U/ml, pH 7.4. Mitochondria were isolated according to 
Rosenberg and Kappas (48) with the modifications described previously (59). The final 
mitochondrial pellet was resuspended in 0.25M sucrose, 1mM EDTA, 10mM Tris, 10M 
KCI, heparin 3U/ml, pH 7.4. 
Incubation reactions contained 0.5mg mitochondrial proteins suspended in 
40mM potassium phosphate, 0.25M sucrose, 200mM EDTA, 20mM MgClz, pH 7.4, 
0.2mg bovine serum album in, 21lg N,N'diphenylphenylelenediamine (Aldrich Chem. Co., 
Milwaukee, WI) and 10mM isocitric acid (Sigma Chemicals, St.Louis, MO, USA). The 
enzyme reaction was started with 20 nmol 1cx-hydroxyvitamin D3 (Leo Pharma, Ajax, 
ON, Canada) and continued for 40 min at 37°C with gentle shaking. Control conditions 
were carried out using boiled mitochondria. The reaction was terminated with 3.75ml 
chloroforrn/methanol (1:2 v/v) and 6000 cpm eH]lcx,25(OH)2D3 was added to monitor 
recovery during the extraction and chromatographie procedures (16). After extraction and 
evaporation, the residue was dissolved in 150 III hexane and injected into a Beckman 
model 160 fitted with an absorbance detector at 254 nm (Beckman Instruments, Palo 
Alto, CA). A Zorbax-Sil column (4.6 x 250mm) (Dupont Instruments, Wilmington, DE) 
was used. Elution was done in hexane /isopropanol ( 9: 1 v/v) at a flow rate of 2ml/min. 
The fractions corresponding to authentic 1cx,25(OH)2D3 (retenti on time 15 min, without 
overlap from 1cxOHD3), were collected and counted in a beta spectrometer (Beta LS1801, 
Beckman Instrument, Palo Alto, CA). Identity of the product was further confirmed by a 
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second HPLC on a C-18 column eluted with hexane:isopropanol (8:2, v:v). 
STATISTICAL ANALYSES 
Data are presented as means ± S.E.M. Statistically significant differences 
between group means were evaluated by ANOVA, or the Student's "t" test as indicated in 
the figure legends. lndividual between-group contrasts were evaluated using the 
Bonferroni test. 
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RESULTS 
P ARAMETERS OF THE D3 NUTRITIONAL AND ENDOCRINE STATUS 
Table 1 presents the circulating concentrations of 250HD3 and 1,25(OHhD3 as 
weIl as those of the circulating Ca2+ concentrations. Serum 250HD3 concentrations were 
significantly increased in both D3-supplemented rats compared to the D depleted, 
250HD3 and 1,25(OH)2D3-repleted rats but both doses of D3 lead to serum 250HD3 
within the normal physiological range 28 and 75 nmol/L in animaIs receiving the low and 
high doses respectively. Serum 1,25(OH)2D3 concentrations increased in allrepleted 
groups compared to the D-depleted controls. However, serum 1,25(OH)2D3 
concentrations were found to be significantly higher in both D3 repleted groups than in 
those receiving either 250HD3 or 1,25(OH)2D3. 
CELLULAR LOCALIZATION 
Investigation of the intrahepatic cellular localization of the gene encoding 
CYP27A revealed that the transcript was expressed not only in hepatocytes but also in 
sinusoidal cells. lndeed, the CYP27A gene transcript was clearly found in freshly isolated 
sinusoidal endothelial, stellate (Ito) as weIl as in Kupffer cells as illustrated in Figure 1. 
However, hepatocytes exhibited the highest abundance of the CYP27A gene transcript 
with an averaged CYP27A mRNA levels of 53%,23%, and 9% in sinusoidal endothelial, 
stellate, and Kupffer cells respectively compared to the levels found in hepatocytes 
(100%). 
GENDER DIFFERENCES AND DRUG INDUCIBILITY 
Evaluation on the gender differences in CYP27A mRNA levels reveals that 
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female rat li vers exhibit a 43% higher levels of the gene transcript than their male 
counterparts (p<0.01) as illustrated in Figure 2A and B. In addition, the hepatic steady 
state levels of the CYP27A transcript were found to be significantly induced by the two 
c1assical cytochrome P-450 inducers dexamethasone (+45% over basal values) and p-
naphtoflavone (+41 % over basal values) (Fig. 2B and D). 3-methylcholanthrene, acetone, 
and phenobarbital did not significantly affect the steady state abundance of the CYP27A 
transcript. 
EFFECT OF D3, 250HD3 OR 1,25(OHhD3 
CYP27A mRNA levels during long-term expoSlire to DJ or 250HDJ 
Repletion ofD depleted rats with either D3 (low dose) or 250HD3 was found not 
to significantly influence the liver CYP27A mRNA levels following 1,3, 5 or 7 days of 
repletion as iIlustrated in Figure 3 for data obtained on day 7 of the repletion protocol. 
Rats fed the high dose ofD3 exhibited a transient 55% decrease in CYP27A mRNA levels 
at the 3 day time-point but not at any other time-points as illustrated for values obtained 
following one week of repletion. Serum calcium were normalized in aIl repleted groups 
and hypercalcemia was not observed in any of the groups. 
CYP27A mRNA levels during long-term exposure to 1,25(OHhD3 
By contrast, as illustrated in Figure 4, the hepatic CYP27A gene transcript was 
very sensitive to the continuous administration of 1,25(OH)2D3 leading to normal 
circulating Ca2+ and 1,25(OH)2D3 concentrations as previously reported (59). Indeed, 
CYP27A mRNA levels progressively decreased throughout the week of 1,25(OH)2D3 
repletion with a decrease of 23% compared to values observed in D depleted animaIs 
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after one day of repletion to attain a 60% decrease after 7 days of continuous 
1,25(OH)2D3 exposure (p<0.0007). 
Intra-acinar localisation of the CYP27A gene transcript 
Figure 5 presents data on the in situ hybridization of liver specimens ohtained 
from D depleted, normal D replete controls and 1,25(OH)2D3 repleted rats. As illustrated, 
in liver specimens obtained from D depleted (Fig. 5A and B) and from normal controls 
(Fig. 5D and E), the CYP27A gene transcript was found to be present throughout the 
hepatic acinus with CYP27A mRNA hybridization being observed in both the periportal 
and the perivenous regions of the acinus, The intensity of the CYP27A mRNA signal was 
found to he only slightly more intense in liver specimens obtained from D depleted than 
in those obtained from normal controls. After one week of 1,25(OH)2D3 repletion, 
however, a c1ear decrease III the intensity of the CYP27A mRNA 
hybridization signal was observed in both periportal and the perivenous region of the 
hepatic acinus (Fig. 5G and H). Negative in situ hybridization controls using the 
rCYP27A sense riboprobes on hepatic specimens obtained from in D depleted, normal 
controls, and 1,25(OH)2D3 repleted rats are presented in Figure 5C, F and 1 respectively. 
Activity of the mitochondrial D3-25 hydroxylase 
Figure 6 illustrates the effect of one-week exposure to 1,25(OH)2D3 on the 
hepatic mitochondrial D3-25-hydroxylase activity. 1,25(OH)2D3 repletion had a 
significant influence on CYP27 A activity with an averaged 46% decrease in 
lcx,25(OH)2D3 production following incubation with lcxOHD3 in liver mitochondria 
obtained form 1,25(OH)2D3 repleted compared to those obtained from D depleted rats 
(p<0.03). 
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MECHANISMS OF 1,25(OH)2D3 ACTION 
CYP27A mRNA Izalf-life 
As illustrated in Figure 7, actinomycin D treatment of D depleted rats with 
O.5mg/kg progressively decreased CYP27A mRNA levels throughout the 24h time-frame 
studied to nearly undetectable levels at the 24h time-point (p<O.OOOl). Under our 
experimental conditions, the half-life of the CYP27A gene product was estimated to be 
12.7h. 1,25(OH)2D3 administration was found to influence CYP27A mRNA levels in a 
manner similar to that observed in animais treated with actinomycin D alone. In addition, 
over the time-period studied, the concomitant administration of the hormone and 
actinomycin D did not significantly affect CYP27A mRNA levels over that observed with 
the hormone or actinomycin alone. 
Transcription rate oftlze CYP27A gene 
Nuclear transcription mn-on assays were performed on nuclei isolated from 
livers of D depleted rats as weIl as on nuclei obtained from livers of D depleted animaIs 
exposed to a single 12 nmol/kg i.v. dose 1,25(OH)2D3 6h before euthanasia (Fig. 8). The 
18S ribosomal gene was used as control gene for both the untreated and treated groups. 
, 
Quantification for the nuclear mn-on assays indicated that within 6 ho urs of 1,25(OH)2D3 
exposure, the transcription rate of the gene encoding the CYP27A was decreased to nearly 
undetectable levels compared to the level of expression observed in controllivers. Non-
specific hybridization, estimated by hybridization to pBS plasmid DNA, did not account 
for the observed CYP27A mRNA decrease in transcription rate. 
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DISCUSSION 
Our data show for the first time the presence of the CYP 27 A gene transcript in 
hepatic sinusoidal cells. Although, hepatocytes were found to harbor the highest level of 
the transcript, the observation indicates that cell populations other than hepatocytes may 
also be involved in the production of 250HD3 in the normal rodent liver. These data 
indicate that CYP27A is more widely distributed than originally thought as the intestine, 
kidney, calvaria, long bones, lung, spleen, adrenals, epidermis, and the central nervous 
system have also been shown to express the CYP27A gene transcript (14;36;55;59;60). 
Circulating macrophages and vascular endothelial cells are also known to harbor the 
CYP27A gene product and to hydroxylate cholesterol at C-25 as a mean of excreting 
cholesterol (14). These observations indicate that although the liver is the main 250HD3 
production site under normal physiological circumstances, many organs and· cell types 
also harbor the enzyme and hence possess the capacity to metabolize D3 to 250HD3 as 
clearly illustrated in previous studies on the rat duodenum and human fetal jejunum and 
colon (59;60). 
The present studies also reveal a significant gender difference in the expression 
of the gene with a 43% higher steady state mRNA levels in female than in male rat livers. 
The latter observation is in agreement with the data reported by Andersson and Jomvall 
(2) and Saarem and Pedersen (52) where the activity of CYP27 A was found to be higher 
in female than in male rats as well as those of Addya et al. (1) who reported that the 
enzyme was highly influenced by sex hormones. This observation is also in line with the 
higher expression of the gene in normal human liver specimens obtained from women 
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compared to those obtained from men (23). InterestingIy, data on the intra-acinar 
distribution of the CYP27A gene transcript show that in D depleted as well as in normal 
rats, CYP27A mRNA was widely distributed within the liver parenchyma with a rather 
diffuse distribution aIl along the hepatic acinus. 1,25(OH)2D3 repletion significantly 
decreased the CYP27A gene transcript as evidenced by both Northern blot analysis and in 
situ hybridization. The decrease in CYP27A mRNA was observed in both the periportal as 
weIl as the perivenous regions of the hepatic acinus and translated into a significant 
reduction in mitochondrial C-25 hydroxylation activity. 
Hepatic CYP27A has previously been shown to be transcriptionally regulated by 
glucocorticoids, growth hormone, cholic acid, cyclosporine A, insulin and the 
physiological state of the animal (42;56;58;64-66). In the present studies, the gene, as 
expected (57), was found to be induced by dexamethasone, a known inducer of the 
CYP3A family of cytochrome P450s (28). In addition, CYP27A was shown to be 
upregulated by p-naphtoflavone, a known inducer ofCYPlAl and 1A2 (17). On the other 
hand, other classical cytochrome P-450 inducers (phenobarbital, acetone, ethanol) did not 
influence the abundance of the CYP27A gene transcript. Our data, however, clearly show 
that 1,25(OH)2D3 Ied to a significant decrease in the transcription rate of the CYP27A 
gene without significantly affecting the stability of its message as evidenced by a similar 
decrease in CYP 27 A abundance in D depleted animaIs and in animaIs exposed to 
1,25(OH)2D3. The aimost complete inhibition of CYP27A transcription within 6h after a 
single 1,25(OHhD3 i.v. dose suggests that the action of the hormone involves receptor 
interactions. The normal rat liver has been shown to harbor a low abundance of the 
nuclear vitamin D3 receptor (VDRn) (53) and the presence of a membrane receptor 
55 
(VDRm) (7) has previously been suggested in rat hepatocytes (4;6). However, the 
participation of either receptors in the regulation of the gene encoding CYP27A still 
remains to be demonstrated. Indeed, to date the mode of action, most particularly at the 
nuclear level, of the putative VDRm still remains to be demonstrated while the CYP27A 
gene promotor has not been shown to harbor the VDRE DR3 consensus sequence 
([G/A]GGT[G/C]A) (21;56). Interestingly, however, 1,25(OHhD3 has lately been shown 
to influence the expression of the gene encoding CYP3A4 by a mechanism which did not 
involve a direct VDRn-RXR-VDRE interaction but involved rather a VDRn-RXR-PXRE 
interaction through an ER6 motif indicating that 1,25(OHhD3-signaling can also be 
mediated through complexed nuclear cross talk with several response motifs (61). 
The long CYP27A mRNA half-life as weIl as the slight, albeit not significant, 
1,25(OH)zD3-mediated increase in its mRNA half-life in the presence of a significant 
inhibition in the expression of the gene transcript may explain the rather slow. and 
progressive decrease in CYP27A mRNA levels observed over the 7 day period studied. 
The later observations, combined with the known long (several weeks) serum 250HD3 
half-life, suggest that exogenously administered 1,25(OH)2D3 would most likely not 
translate, in the short fUn, into a functional D deficiency in vivo. In addition, it is not 
excluded that in the presence of low CYP27A levels, other cytochrome(s) P-450 could 
contribute to the production of the prohormone. Indeed, depending on the experimental 
design and substrate doses used, data on the effect of D3 or D3 metabolites on the 
production of 250HD3 have led to conflicting results with evidence of regulation 
(10;12;41), absence of regulation (19;33;46;63), or regulation not directly involving the 
enzyme but other mechanisms such the metabolic or biliary clearances of the vitamin 
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and/or its metabolites (9; 18;31 ;32). Moreover, patients suffering form cerebrotendinous 
xanthomatosis (CTX) have aiso been reported to have a wide range of circulating 
250HD3 concentrations (from very Iow to near normal) (22) indicating that enzyme(s) 
other than CYP27A can transfrom D3 into 250HD3 as illustrated in a CYP27A-ablated 
mouse model (47). 
Exogenously administered low dose D3 (which led, however, to the 
normalization of serum Ca2+ and the secondary hyperparathroidism (data not shown)) or 
250HD3 administration were found not to significantly affect CYP27A mRNA. A higher 
dose of D3 only led to a transient decrease in CYP27 A which promptly retumed to D 
depleted values following one week of repletion despite elevated serum Ca2+ 
concentrations. The data indicate that the D3 nutritional status has no significant effect on 
the total hepatic CYP27A. Paradoxically, evaluation of the D3 encodrine status revealed 
that the circulating 1,25(OH)2D3 concentrations and circulating Ca2+ were significantly 
higher in D3-repleted animaIs compared to 1,25(OHhD3-repleted animaIs. This 
observation indicates that the circulating 1,25(OHhD3 concentration is not a good 
predictor of the hepatic action of the hormone and that the protective effect against the 
down-regulatory effect on CYP27A may rest on the circulating or cellular levels ofD3 or 
250HD3. It is aiso postulated that D3 or 250HD3 may compete with 1,25(OH)2D3 for 
uptake by the liver. In fact, the season of the year (summer/fall), or the circulating 
concentrations of 250HD3 and the hepatic mRNA levels of CYP27A have already been 
reported in human subjects while no correlation was observed between the circulating 
1,25(OH)2D3 concentration and the CYP27A gene transcript (23). 
Interestingly, we recently reported a negative regulation of the intestinal CYP27A 
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foHowing repletion with D3, 250HD3 as well as 1,2S(OHhD3 (59) indicating differences 
between the two organs in the overall regulation of CYP27A by the D3 
nutritionallendocrine system. Moreover, the sensitivity of the hepatic CYP27A to 
1,25(OH)2D3 was also shown to be higher (with a 60% decrease CYP27A rnRNA) than 
that found in the intestine (40% decrease). The reasons for the observed differences 
between the two organs in the regulation of the gene encoding CYP27A by the nutritional 
status rnay rest in the fact that the intestine, but not the liver, harbors the 1 cx-hydroxylase 
aIlowing intestinal cells to 10caIly produce 1,25(OHhD3 following D3 or 250HD3 
administration. On the other hand, the influence of 1,25(OH)2D3 on the CYP27 A rnRNA 
half-life as weIl as on the CYP27A transcription rate was also shown to be much more 
pronounced in liver than in intestine. It is postulated that the high sensitivity of the liver 
to 1,25(OH)2D3 administration rnay be due to a combination of factors such as the 
efficient hepatic capture of exogenously administered 1,25(OH)2D3 (27) combined with 
the absence of the D3-24 hydroxylase which is, however, present in intestine (20;49) and 
which could contribute to the intestinal catabolism of exogenously administered 
1,25(OHhD3, as weIl as in differences in cellular life span with hepatocytes having a life 
span of several months while the turnover of intestinal cells is only a matter of days. 
The present studies thus clearly show that in rodent liver, the gene encoding 
CYP27A is expressed not only in hepatocytes but also in aH sinusoidal cells. Theyalso 
illustrate a significant gender difference in steady-state CYP27A mRNA levels, and show 
that 1,25(OH)2D3 administration significantly influence the transcription of the CYP27A 
gene which was accompanied by a significant decrease in the mitochondrial C-25 
hydroxylation of the model D3 compound lcxOHD3. Our data also illustrate that 
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1,25(OH)2D3 stands to also affect the synthesis of bile acids via a down-regulation of the 
secondary "acidic" pathway. 
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TABLE 1 
Serum vitamin D metabolites and Ca2+ concentrations 
Groups 250HD3 1,25(OH)2D3 Ca
2+ 
(mmollL) (pmol/L) (mmol/L) 
D-Ca- 9± 0.8 28 ± 2 0.85 ± 0.006*** 
D3 (6.5 mmol/d) 28 ± 3* 1019 ± 77** 1.24 ± 0.003 ** 
D3 (32.5 mmol/d) 75 ± 12* 1308 ± 130** 1.45 ± 0.05*** 
250HD3 (28 pmol/d) 3±2 533 ± 91 1.13 ± 0.04 
1,25(OHhD3 (28 pmol/d) 9±4 565 ± 132 1.11 ± 0.04 
Serum 250HD3 and 1,25(OH)2D3 concentrations following 7 days of repletion with D3, 
250HD3 or 1,25(OH)2D3 administrated i.p. by osmotic mini-pumps. Data are presented 
as means ± S.E.M. n = 3 rats/group. Statistically significant differences between group 
means were evaluated by the Student's "t" test in relation the values obtained in 
1,25(OHhD3 repleted animaIs. * p<O.OOOl, ** p<0.05, *** p<0.005. 
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LEGEND TO FIGURE 1 
Steady state expression of the gene encoding the CYP27A gene transcript in 
freshly isolated hepatocytes and in hepatic sinusoidal cells obtained from D depleted male 
rats. Representative RT-PCR of the CYP27A gene transcript in hepatocytes (He), stellate 
cells (SC), endothelial cells (E) and Kupffer cells (KC). The illustration is a modification 
based on McCuskey (39). 
Figure 1 
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LEGEND TO FIGURE 2 
Influence of gender and cytochrome P-450 inducers on the steady state 
expression of CYP27A mRNA level. Representative Northem blot analyses of of the 
CYP27A gene transcript in male and female rat livers (A), and following exposure to 
cytochrome P450 inducers (C). B. and D. Means ± S.E.M. of CYP27 A/18S mRNA ratio 
assed by densitometric scanning. n = 4-5 animaIs/group for the studies on gender 
differences and n = 3 animaIs/group for the studies on cytochrome P-450 inducers. 
Statistically significant differences were evaluated by the Student's "t" test, * p<O.05, ** 
p<O.0003. 
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LEGEND TO FIGURE 3 
Influence of D3 and 250HD3 repletion of the hepatic expression of the gene 
encoding CYP27A. A. Representative Northern analyses of the CYP27A steady-state 
CYP27A mRNA levels in D-depleted, and in D3 (6.5 nmol/day (low dose) or 32.5 (high 
dose) nmol/day), or 250HD3-repleted (6.5 nmol/day) rats following 7 days ofrepletion by 
osmotic mini-pump (i.p.). B. Densitometric analyses of the data obtained are presented as 
Means ± S.E.M. D-depleted rats, n = 15, D3 and 250HD3 n :::: 3 animaIs/group. 
Statistically significant differences between group means were analysed ANOV A with 
individual contrasts evaluated by the Bonferronni post hoc test. 
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LEGEND TO FIGURE 4 
Steady-state levels of hepatic CYP27A mRNA in D-depleted rats repleted with 
1,25(OH)2D3 rats following 1 to 7 days of repletion. A. Representative Northern blot 
analyses of the CYP27A gene transcript. B. Densitometric analyses. Data are presented as 
means ± S. E. M. Statistically significant differences between group means were analysed 
by ANOV A with individual contrasts evaluated by the Bonferonni post hoc test. Main 
effect p<O.OOOl. Statistically significantly different from D-Ca-, *p<O.OOl, **p<O.OOOl. n 
= 3 animaIs/group. 
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LEGEND TO FIGURE 5 
Representative photomicrographs of rat liver sections obtained following in situ 
hybridization using a rCYP27A antisens riboprobe. A 10 RT-PCR cycle amplification 
was used. Liver sections were obtained from D depleted rats (A, B), normal control rats 
(D, E) and 7 day 1,25(OHhD3 repleted rats (G, H). Negative in situ hybridization control 
using the rCYP27A sense ribobrobe are presented in panels C, F, and 1 for livers obtained 
from D depleted, normal and 1 ,25(OHhD3 repleted rats respectively. 
Figure 5 
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LEGEND TO FIGURE 6 
Effeet of 1,25(OHhD3 on the hepatie mitoehondriai C-25 hydroxylation aetivity. 
Hepatie mitoehondriai proteins from hypoealeemie D depleted and 1,25(OH)2D3-
repleteded (28 pmol/d for 7 days) were ineubated with 20 nmoi of 1aOHD3. The produet 
of the reaetion 1Ct,25(OH)2D3 was evaluated by HPLC. Data are presented as means ± 
S.E.M. Statistieally signifieant differences between group means were analysed by the 
Student's "t" test, n = 8-11 animaIs/group, p<0.03. 
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LEGEND TO FIGURE 7 
ln vivo influence of 1,25(OH)2D3 on the half-life of CYP27A mRNA. AnimaIs 
received i.p. doses of actinomycin D (O.5mg/kg) every 6 hours and were kept either 
untreated or received 12 nmol/kg i.v. dose 1,25(OHhD3 every 6 hours. AnimaIs were 
killed 6, 12, 18 and 24 ho urs after actinomycin D administration. Data are presented as 
means ± S. E. M. n = 4-5 animaIs/group. Statistically significant differences between 
group means were analysed by A VOY A with individual contrasts evaluated by the 
Bonferonni post hoc test. No significant differences were observed between the different 
groups. 
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LEGEND TO FIGURE 8 
Rate of transcription of the CYP 27 A gene transcript in livers obtained from D 
depleted and 1,25(OH)2D3 injected rats. AnimaIs received a single i.v. dose (12nmol/kg) 
of 1,25(OH)2D3 6 hours before euthanasia. Transcriptional activity was measured in 
quadruplicate using 2-3 rat livers/group. The illustration presents a representative nuclear 
run-on transcriptionai assay. 
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2.2.2 Article 2: Expression ofCYP27A, a gene encoding a vitamin D-25 hydroxylase in 
human /iver and kidney. 
Article published in the Journal of Clinical Endocrinology, volume 54, pages 107-
115 (2001). 
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SUMMARY 
OBJECTIVES Vitamin 0 3 (03) is not active but must be hydroxylated at C-25 in liver 
before acquiring its hormonal potential in the kidney. The sterol-27 hydroxylase (gene 
symbol: CYP27 A) catalyses the oxidation of sterol side chain in bile acid synthesis but the 
enzyme is also known as a D3-25 hydroxylase. Aims: The study examined the expression of 
the gene encoding CYP27A in adult and fetal human livers and kidneys. SUBJECTS 39 adults 
(18 men and 21 women) (mean age 58 years in men and 57 years in women) and 3 normal 
fetuses gestational age 17-19 weeks were studied. RESULTS 1) Normal specimens: CYP27A 
transcript was found to be higher in adult than in fetallivers but its expression was similar 
in aduit and fetai kidneys. In fetuses, no difference was observed between CYP27A levels in 
livers and kidneys. In adult li vers CYP 27 A Ievels were higher in women than in men. Hepatic 
CYP27 A mRNA and serum 250HO concentrations were both found to be higher in summer 
than in winter. Multiple correlation analyses indicate that the season of the year and the 
serum 250HD concentrations (but not 1,25(OH)2D concentrations) are the best predictors 
of CYP27 A mRNA abundance in normal adult livers. In situ hybridization illustrates a c1ear 
label in hepatocytes which increases in intensity in the perivenous region of the hepatic 
acinus. II) Pathological specimens: In one man, an hepatic carcinoma exhibited a very large 
increase in CYP27 A (> 1000 fold) compared to the level found in the normal area. In that 
patient, serum 250HD concentrations were found to be high considering the level of 
CYP27A mRNA in the normal hepatic area suggesting that the neoplastic tissue contributed 
to the C-25 hydroxylation of vitamin D. Specimens obtained from two patients suffering 
from focal hepatic hyperplasia indicate that in one case, the level of CYP27A mRNA was 
twice as high in the pathological than in the normal area while in the other its levels were 
similar in both areas. No difference in the CYP27A transcript was observed between 
specimens obtained from normal areas and those obtained form either an hepatic adenoma 
or from two intrahepatic colon metastases. CONCLUSION CYP27A is present not only in the 
human adult liver but also in the adult kidney, and in the fetalliver and kidney. The findings 
illustrate that CYP 27 A can be significantIy upregulated in certain pathological situation such 
as in hepatic carcinoma and that the neoplastic tissue could contribute to the circulating 
concentration of 250HD. 
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INTRODUCTION 
Vitamin D3 (D3) is an endogenous secosteroid synthesized in the skin under the 
ultraviolet rays of the sun. D3 is not active but must be hydroxylated at position C-25 in the 
liver before acquiring its full hormonal potential through a C-l ex hydroxylation in kidney 
mitochondria (Gascon-Barré, 1997). Animal studies have identified two intra-hepatic 
organelles, the smooth endoplasmic reticulum and the mitochondrium as sites possessing 
fully active but distinct D3-25 hydroxylases (Gascon-Barré, 1997). The mitochondrial 
enzyme has been identified in a small number of human livers (Bjorkhem et al. 1975; 
Bjorkhem & Holmberg, 1978; Oftebro et al. 1981) and claimed to be the unique site for the 
C-25 hydroxylation of D3 in humans (Saarem et al. 1984; Saarem & Pedersen, 1985). 
The mitochondrial D3-25 hydroxylase was first identified as the C-27 sterol 
hydroxylase which catalyses the first and rate-limiting step in the oxidation of the sterol side 
chain in the «acidic» bile acid biosynthesis pathway (Bjorkhem, 1985). Cali and Russell (Cali 
& Russell, 1991) termed the enzyme sterol-27 hydroxylase although the enzyme exhibits low 
substrate specificity. Cloning of the rabbit (Andersson et al. 1989), rat (Usui et al. 1990; Su 
et al. 1990), and human (Cali & Russell, 1991; Guo et al. 1993) sterol-27 hydroxylase was 
achieved between 1989 and 1993 and the gene encoding the enzyme has been termed 
CYP27A. A porcine microsomal vitamin D 25-hydroxylase (CYP25) exhibiting an 86% 
homology with the human CYP2D6 has been cloned by Wikvall and his group (Postlind et 
al. 1997) but Gill et al. (Gill et al. 2000) have lately orally reported that the porcine CYP25 
could not be found in any other species. 
Evaluation of D3-25 hydroxylase activity revealed that 250HD3 production was 
present not only in li vers but also in extra-hepatic tissues (Tucker, III. et al. 1973; 
Bhattacharyya & DeLuca, 1974). Support for the extra-hepatic presence of a D3-25 
hydroxylase first came from in vivo studies reporting that hepatectomy markedly reduced but 
did not eliminate the plasma appearance of250H[3H]D3 after [3H]D3 injection (Ponchon et 
al. 1969; OIson et al. 1976). These observations have now been confirmed at the molecular 
level with demonstration of the presence ofCYP27A mRNAs in several tissues and organs 
(Cali & Russell, 1991; Ichikawa et al. 1995; Andersson et al. 1989; Mullick et al. 1995). The. 
participation of the extra-hepatic enzyme to the production of250HD3 or its contribution to 
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the circulating concentration of 250HD3 under normal physiological conditions is not, 
however, presently known. Moreover, Axén et al. (Axén et al. 1994) have reported that the 
sterol-27 hydroxylase purified from pig and rabbit livers as weIl as recombinant human 
CYP 27 A expressed in Escherichia coli or monkey COS cells was also able to catalyse the 1 a-
hydroxylation of250HD3 albeit at a much lower rate than that observed for the conversion 
of D3 into 250HD3 (Axén et al. 1995) and at several order of magnitude lower than the 
250HD3-1a hydroxylase (CYP27Bl) (Pikuleva et al. 1997). 
The aim ofthe present studies was to examine the steady-state expression of the gene 
encoding CYP27A in the adult and fetal human livers and kidneys and, in adult volunteers, 
to evaluate its level of expression in relation to the vitamin D status as weIl as to compare 
its level of expression in normal and pathological hepatic specimens in a subset of patients. 
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MATERIALS AND METHODS 
CHEMICALS 
pBluescript SK (-) vector used for Northem analyses was obtained from Stratagen, . 
LaJoIla, CA, USA. WiIliam's medium E and Trizol LS reagents, yeast tRNA were from 
Gibco BRL (Burlington, ON, Canada). Hep G2 and Hep 3B celllines were obtained from 
American Type Culture Collection (Rockville, MD). Klenow fragment, T7 RNA polymerase 
and dextran sulfate were from Amersham Pharmacia Biotech (Baie D'Urfé, Qc, Canada), 
proteinase K, ribonuclease A and salmon sperrn DNA from Sigma Chemical Co. 
(Mississauga, ON, Canada), OneStep RT -PCR from Qiagen (Mississauga, ON, Canada), [a-
32p] dCTP and [a_33p] UTP from ICN Biomedicals Inc (Mississauga, ON, Canada), Kodak 
NBT-2, D19 developer and fixer from Interscience (Mississauga, ON, Canada). 
1,25(OH)2D3 was a gift from Hoffmann-LaRoche Company (Nutley, NJ,USA). AlI other 
materials were of analytical grade or better. 
SUBJECTS CHARACTERISTICS 
Protocols were approved by the Institutional Ethics Review Board and informed 
consents were obtained from aIl subjects. Adult subjects were chosen from patients referred 
for hepatic or renal surgery while normal fetal tissues were obtained foIlowing voluntary 
termination ofpregnancy. Description of the population studied is presented in Figure 1. As 
indicated, 39 adults (18 men, mean age: 58.1 years ± 2.0, and 21 women, mean age: 57.1 ± 
3.7 years) and 3 normal fetuses gestational age 17 to 19 weeks were incIuded in the study. 
In adults, specimens were obtained form normal and, when possible, from pathological areas 
of the liver as weIl as from normal kidney tissue. In fetuses, normal liver and kidney 
specimens were obtained. 
LABORA TORY METHODS 
Evaluation of the CYP27A gene transcript 
Total liver or renal RNA (15 ~g) was blotted onto membrane and processed for 
Northern analyses as described earlier (Demers et al. 1997). The radiolabeled probes were: 
CYP27A, a 2.1 kb humancDNA insert from the EcoRI site of the pBluescript SK (-) vector; 
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ribosomal18S RNA a 1.5 kb human cDNA insert from the EcoRI site of the pBluescript SK 
(-) vector (ATCC (#77242). The probes were labelled by random oligo-priming (1913) using 
[a-32P] dCTP (3000 Ci/mol) and Klenow fragment. Blot hybridization, washing, exposure, 
and photodensitometric evaluation were performed as described previously (Demers et al. 
1997). 
Normal human hepatocytes were isolated by the method of Guguen-Guillozo et al. 
(Guguen-Guillouzo et al. 1982), and the freshly isolated hepatocytes were equilibrated in 
WilIiam's E medium. Total RNA from normal human hepatocytes and from the 
hepatocellular celllines Hep G2 and Hep 3B were extracted by Trizol LS reagent and used 
for Northem analyses as mentioned above. 
In sitll.RT-PCR hybridization 
Paraffin liver sections were mounted onto slides pre-treated with APES, dewaxed in 
xylene and then rehydrated trough a series of ethanol baths, and finally immersed in DEPC-
treated water. Slides were incubated for 30 min. with 100~L 0.1 M Tris-HCl pH 8.0, 50 mM 
EDTA and 50~g/mL proteinase K, fixed in fresh 4% paraformaldehyde-PBS solution for 20 
min., rinsed in PBS and then rinsed in 90% ethanol and allowed to dry. Negative control 
samples were obtained bytreatment of sections with 100llg/mLRNase A in2 x SSC at 37°C 
for 30 min. and washed in PBS prior to RT-PCR reaction. AlI other treatments were the 
same. 
In situ R T -PCR were performed by the method of Mee et al. (Mee et al. 1996) with 
the following modifications. Reaction was carried out in a volume of 50llL with OneStep 
RT -PCR kit and 0.61lM hCYP27 A specific primers based on the published sequence of Guo 
et al. (Guo et al. 1991) using a Hybaid thermal cycler provided with a in situ block (Hybaid, 
Teddington, UK). Sections were heated for 30 min. at 50°C, 15 min. at 95°C and 10 cycles 
of95°C for 30 sec., 62°C for Imin. and noc for 1 min. were performed, finalIy slides were 
heated for 10 min. at n°c. Sample were washed twice in PBS and fixed in 4% 
Paraformaldehyde-PBS for 20 min. at 4°C and incubated with 0.25% acetic anhydride in 0.1 
TEA for 10 min. and rinsed in 90% ethanol and allowed to dry. 
An in situ hybridization was performed using a previously described method (Roy 
& Tenenhouse, 1996) with sorne modifications. The hCYP 27 A anti-sense riboprobes (using 
linearised CYP27A cDNA as template) were generated by the single strand RNA synthesis 
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technique using T7 RNA polymerases and [a_33P]UTP (800 Ci/mmol). Hybridization was 
performed at 42°C for 16 hours with 100).lL of hybridization solution (50% formamide, 
2XS SC, 1 X Denhart' s, 0 .25M T ris-H Cl, pH 7.5, 10% dextran sulfate, O. 5 Na pyrophosphate, 
0.5% SDS, 25).lg/mL denatured salmon sperm DNA, 250 ).lg/mL yeast tRNA) and 1 XIO? 
cprnlmL of antisense. After washing, autoradiographywas performed with NBT -2 emulsion. 
Slides were exposed for 7 days at 4°C, developed with D 19 developer and counterstained 
with heamatoxylin and eosin. 
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BiocJlemical analyses 
Concentrations of ionized calcium in whole blood were measured with a ICA2 
ionized calcium analyser (Radiometer, Copenhagen, Denmark). Total calcium, phosphate, 
bilirubin, AST, AL T, albumin, and alkaline phosphatase were determined by automated 
colorimetry (Baxter, Paramax, lrvine, CA, USA) by the Clinical Biochemistry Department 
of the CHUM St-Luc Hospital. Serum D metabolites 25(OH)D and 1,25(OH)2D were 
measured using the lncstar 25(OH)D and 1,25(OH)2D RIA kits (Incstar Corporation, 
Stil1water, MN) containing aradio-iodinated 25(OH)D and 1 ,25(OH)zD analog respectively. 
STATISTICAL ANAL YSIS 
Results are presented as means ± SEM. Statistically significant differences between 
group means were evaluated by analysis of variance or the Student's «t» test as indicated in 
the Figure legends. 
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RESULTS 
Values for the serum biochemical analyses obtained from adult volunteers are 
presented in Table 1. As indicated, most biochemical parameters studied were within the 
normal range except for the ionized calcium and albumin concentrations which were found 
to be lower than normal, and the concentrations of AST and ALT in women.and alka1ine 
phosphatase in men which were found to be higher than normal. In an cases, however, no 
significant differences between the values obtained in men and women were observed. 
Figure 2 presents the level of the CYP27A gene transcript in normal specimens of 
adult and fetallivers and kidneys. As illustrated, the level of the hepatic CYP27A transcript 
was found to be higher in specimens obtained from adult than in those obtained from fetal 
livers (p<0.05). CYP27A was detected in kidney ofboth adult and fetal specimens but no 
significant differences in the steady state levei of the gene transcript were observed between 
adult and fetai kidney specimens. The Ievei of the CYP27A gene transcript was found to be 
significantly higher in adult Iiver than in adult (p<0.0001) or fetai kidney (p<0.01). In fetai 
specimens, no significant difference was observed in the Ievel of CYP 27 A mRNA between 
Iiver and kidney specimens. 
ln situ hybridization of normal Iiver specimens illustrates that CYP27A is expressed 
in hepatocytes throughout the hepatic acinus (Fig. 3). However, an intensity gradient from 
the portal area to the perivenous region of the hepatic acinus is apparent suggesting an 
intrahepatic regionalisation of CYP 27 A in the human liver. 
The comparative steady state expression of CYP27A in normal specimens obtained 
from liver and kidney of men and women is presented in Figure 4. The levels of the CYP27A 
transcript were found to be slightly higher in specimens obtained from women than in those 
obtained from men (p<0.05) but no significant difference between men and women was 
observed in the level of the kidney transcript. As indicated in Table 1, circulating 250HD 
concentrations were found to be similar in men and women (40.8 ± 6.2 and 45.5 ± 7.2 
nmollL in men and women respectively). 
As illustrated in Figure 5, significant differences in the hepatic level of CYP27A 
mRNA (Fig. SA) and in the serum 250HD (Fig. 5B) concentrations were observed between 
specimens obtained in spring/summer and those obtained in fall/winter with significantly 
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higher values observed for both parameters in spring/summer than in fall/winter (p<O.05). 
A multiple correlation analysis indicated that the season of the year (p<O.OI) and the 
circulating 250HD concentrations (p<O.05) are the best predictors of the mRNA abundance 
for the gene encoding CYP27A in normal adult livers. As shown in Figure 5C, .this 
observation is illustrated by a significant linear correlation between the circulating 250HD 
concentrations and the hepatic level of CYP 27 A mRNA. No significant correlation was found 
between the hepatic level ofCYP27A mRNA levels and the circulating albumin (p=0.47) or 
1,25(OH)2D (p=O.66) concentrations. In kidney, no significant correlation was ohserved 
between serum 250HD or 1,25(OH)2D concentrations and the levels of CYP27A mRNA 
(data not shown). 
Figure 6 illustrates the hepatic CYP27A steady-state expression in normal and 
pathological specimens obtained from six men and women. A very large difference in the 
level of the CYP 27 A transcript was observed between the specimen obtained from the normal 
hepatic area and that obtained from an hepatic carcinoma area in one man. In that patient, the 
serum 250HD concentrations were found to be high considering the level of CYP27A 
mRNA in the normal hepatic areasuggesting that the neoplastic tissue contributed to the C-
25 hydroxylation of the vitamin. Evaluation ofCYP27A mRNA level in the hepatoceIlular 
. carcinoma ceIl line HepG2 and in the hepatoblastoma ceIl line Hep3B did not suggest, 
however, an increased expression when compared to that observed in primary culture of 
normal human hepatocytes (Fig. 6B). Specimens were also obtained from two patients 
suffering from focal hepatic hyperplasia. In one woman, the level of CYP27A mRNA was 
found to be twice as high in the pathological than in the normal area while in the other the 
steady-state expression of CYP27A was found to be similar in both areas. No difference in 
the level of the CYP27A transcript was observed between the specimens obtained form 
normal areas and those obtained form either an hepatic adenoma or from two intrahepatic 
colon metastases. 
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DISCUSSION 
The data obtained during the present studies c1early demonstrate that CYP27 A is 
expressed in the adult and fetalliver and kidney. In situ hybridization of normal adult livers 
illustrates that the gene encoding CYP 27 A is well expressed throughout the hepatic acinus 
but that its intensity increases in the perivenous area indicating that a predominant 
perivenous regionalisation of the gene is present in humans. In the rat (Wiese et al. 1992; 
Vlahcevic et al. 1996) but not the rabbit (Araya et al. 1995), CfP27 A is highly sensitive to 
the prevailing concentrations of bile acids with increases in enzyme activity, steady state 
mRNA level, and the rate of gene transcription following interruption of the enterohepatic 
circulation of bile acids (Vlahcevic et al. 1996; Twisk et al. 1995b). Moreover, a regio-
selective dynamic response of the liver CYP27 A following depletion of the bile acid pool 
has been reported in the rat with significant increases in the perivenous but not in the 
periportal area of the acinus (Twisk et al. 1995b). The volunteers who participated in the 
studies were not reported to present significant cholestasis suggesting that in the normal 
human liver the mitochondrial D3-25 hydroxylase seems to be predominantly located in the 
distal area of the hepatic acinus. 
Our study shows that the liver of 17 to 19 week old human fetuses express the 
CYP27 A gene transcript albeit at a much lower level than that observed in the adult liver. 
This observation is congruent with observations that 250HD is lower in cord than in 
maternai serum although, a significant relationship is observed between the two sites (Del vin 
et al. 1982). It is also congruent with data showing that premature infants have low 
circulating 250HD concentrations than infants born at term (Hillman et al. 1985; Salle et al. 
1983). 
Although, in rat hepatocytes, the CYP27A mRNA half-life has been reported to be 
between 18 and 24 hours suggesting a slow response to regulators (Stravitz et al. 1996), 
several hormones and endogenous products have already been shown to regulate the gene. 
They inc1ude, as reported above, bile acids but also growth hormone, glucocorticoids, insulin 
and the physiological state of the animal (Su et al. 1990; Mullick et al. 1995; Vlahcevic et 
al. 1996; Twisk et al. 1995a; Twisk et al. 1995b). To date, however, most regulation studies 
on CYP27A have been linked to cholesterol and/or bile acids metabolism and few studies 
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have addressed the effect of these hormones on the handling of vitamin D. The present study 
points to a possible regulation by the vitamin D status with higher level of CYP27A 
expression being observed when the circulating 250HD concentrations are high than when 
they are low, aIthough the present study does not allow to draw conclusions on a causal 
relationship between the two parameters. Interestingly, however, Lehmann et al. (Lehmann 
et al. 1997) have lately reported that in human keratinocytes, CYP 27 A is inducible by DJ or 
VVB irradiation suggesting the presence of a positive regulation of the vitamin (or of its 
products) on the mitochondrial D3-25 hydroxylase in these cells. 
The regulation of the human enzyme by sex hormones has not been studied. The 
mitochondrial enzyme has been shown in the rat to be several times more active in females 
than in males (Saarem & Pedersen, 1987; Addya et al. 1991). In addition, Saarem and 
Pedersen (Saarem & Pedersen, 1987) observed that enzyme activity increased when p-
estradiol was injected to male while testosterone decreased enzyme activity when injected 
to female rats. Addya et al. (Addya et al. 1991) aiso reported that the relative level of the DJ-
25 hydroxylase was reduced in castrated females while it was increased in castrated males. 
Our studies indicate that in the human liver, the steady-state level of CYP27A mRNA is 
higher in women than in men despite the subjects' age (average age in women 57 years 
indicating a post-menopausal status in most subjects). 
The sterol-27 hydroxylase has been claimed to be the only enzyme involved in the 
C-25 hydroxylation of DJ in humans. However, mutations affecting either CYP27A 
expression or its primary sequence (leading to cerebrotendinous xanthomathosis, an inherited 
disorder of sterol metabolism and storage characterized by atherosclerosis and progressive 
neurological dysfunction) does not seem to completely abolish the C-25 hydroxylation ofDJ 
(Kuriyamaet al. 1993; Leitersdorf et al. 1993; Berginer et al. 1993; Leitersdorf et al. 1994). 
This observation suggests the presence of alternative, but as yet, unidentified D3-25 
hydroxylase(s) in humans. In addition, the human celiline Hep3B has also been shown to 
efficiently activate the synthetic compound 1 a-hydroxyvitamin D3 at C-25 despite the 
absence of any detectable CYP 27 A gene transcript when evaluated by Northern analysis (Guo 
et al. 1991; Strugnell et al. 1995) although we presently report very low CfP 27 A level 
(Figure 6) in the Hep3B cellline available in our Iaboratory. Moreover, recent studies have 
shown that in the mouse nuU for the CfP27A gene (Rosen et al. 1998), normal 
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concentrations of250HD and l ,25(OH)2D3 are observed indicating that, in the mouse, as in 
other species, D3-25 hydroxylase(s) other than CYP27 A are most likely to be present in the 
basal state (Gascon-Barré, 1997; Postlind et al. 1997) but most particularly following 
treatment with drugs known to be inducers of cytochromes P450 such as drugs of the 
anticonvulsant family (Gascon-Barré et al. 1986; Mawer, 1979). In 1994 and 1995, two 
pediatric cases were reported where two sets of siblings were shown to have low circulating 
250HD concentrations despite normal vitamin D intake. In these two case-reports, 250HD 
concentrations were shown to increase upon treatment with pharmacological concentrations 
ofvitamin D or 250HD (Casella et al. 1994; Nützenadel et al. 1995). Unfortunately, in these 
two cases, the CYP 27 A genotype was not characterized, the serum cholesterol concentrations 
were not reported and the subjects were too young to exhibit the clinical manifestations of 
cerebrotendinous xantomathosis (Rowland, 1995) precluding any meaningful conclusion on 
the importance ofCYP27 A or of other as yet unidentified enzyme(s) in the hydroxylation of 
vitamin D at C-25 while the reported porcine microsomal CYP25 (Postlind et al. 1997; Gill 
et al. 2000) does not seem to be expressed in the human liver. 
In conclusion, our data show that CYP 27 A is present not only in the human adult liver 
but also in the adult kidney as well as in the fetalliver and kidney. They also illustrate that 
CYP 27 Amay be modulated by the vitamin D3 status as suggested by an increase in the level 
of its transcript during the summer months. Our observations also indicate that CYP27A 
expression can be significantly upregulated in certain pathological situations such as in 
hepatic carcinoma and that the neoplastic tissue could contribute to the circulating 250HD 
concentration. 
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TABLE 1 
CIRCULATING BIOCHEMICAL VALUES IN ADULT VOLUNTEERS 
WOMEN MEN P 
MEAN ± S.E.M. MEAN ± S.E.M. VALUE 
Total calcium 2.2±0.1 2.3±0.1 0.2 
(2.23-2.62 mmol/l) 
Phosphate 1.0±0.1 1.1±0.1 0.44 
(0.7-1.3 mmolll) 
Bilirubin 15.3±6.2 14.6±1.6 0.93 
(2.1-17.1 ~molll) 
AST 82.7±42.0 27.7±3.5 0.31 
(12-32 U/I) 
ALT 61.3±26.4 19.1±3.5 0.22 
(0-39 U/I) 
25(OH)D 45.5±7.2 40.8±6.2 0.82 
(35-150omol/l) 
1,25(OH)2D 99.0±14.6 119.0±15.6 0.34 
(33-133 pmol/l) 
Ionized calcium 1. 16±0.06 1. 16±0.04 0.99 
(1.19-1.34 mmollI) 
Albumin 33.2±2.4 34.3±2.5 0.75 
(34-51 glI) 
Alkaline phosphatase 68.9±5.6 122.2±35.6 0.09 
(25-97 U/I) 
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Data are presented as means ± S.E.M. Normal reference values are presented in 
parenthesis. Statistically significant differences between group means were evaluated by the 
Student' s "t" test. 
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LEGEND TO FIGURE 1 
Specimens were obtained from aduit and fetaIIivers and kidneys. In adults, the mean 
age was: in men 58.1 ± 2.9 years (37 to 73) and in women 57.1 ± 3.7 years (30 to 86). Fetal 
specimens were obtained between the 17th and 19th week of gestationai age. Experimental 
protocols were approved form the Institutionai Human Ethics Review Board and informed 
consent was obtained from all volunteers. 
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LEGEND TO FIGURE 2 
Steady state expression of the gene encoding hCYP27A in specimens of normal 
parenchyma obtained from adult • and fetaHI livers and kidneys. A. Representative 
Northem analysis of the hCYP2 7 A. B. Means and S.E.M. for the expression ofthe hCYP 27 A 
relative to the expression of the l8S ribosomal gene. Statistically significant differences 
between group means were evaiuated by the Student' s "t" test. Liver: adult, n = 27, fetai, n 
= 3. Kidney: adult, n = 14, fetal, n =3. 
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LEGEND TO FIGURE 3 
Photomicrographs of a human liver section obtained from a 30 years oid woman 
showing a perivenous area of the liver acinus. A. In situ hybridization was carried out using 
an hCYP27A anti-sens riboprobe following in situ RT-PCR (10 cycles). Note the 
accumulation of silver grains around the venous area. B. Adjacent RNase-treated liver 
section prior to RT-PCR and in situ hybridization. 
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LEGEND TO FIGURE 4 
Comparative steady state expression of the gene encoding hCYP27A in normal 
parenchyma of liver and kidney specimens in men. and women D. A. Representative 
Northem analysis of the hCYP 27 A. B. Means and S.E.M. for the expression of the hCYP 27 A 
relative to the expression of the 18S ribosomal gene. Statistically significant differences 
between group means were evaluated by the Student's "t" test. Liver: men, n = 9, women, 
n = 14; kidney: men, n = 7, women, n = 7. 
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LEGEND TO FIGURE 5 
Steady state expression of the gene encoding hCYP 27 A in specimens of normal adult 
livers and the circulating 250HD concentrations in spring/summer (April 15th to November 
14th) and in fall/winter (November 15th to April 14th). In aIl cases, hCYP27A and circulating 
250HD concentrations were measured in the same subject. A. Mean expression of the 
hCYP27A relative to the expression of the 18S ribosomal gene. B. Mean serum 250HD 
concentrations. C. Pearson correlation coefficient observed between the level of the 
hCYP27A and the circulating 250HD. R2 = 0.41, p<0.05. Statistically significantdifferences 
between group means were evaluated by the Student's "t" test. Summer, n = 15, winter, n 
=7. 
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LEGEND TO FIGURE 6 
Steady state expression of the gene encoding hCYP 27 A in A. Paired specimens 
obtained from normal~ and pathological. areas adult livers, and B. in the liver celllines 
Hep3B (hepatocellular carcinoma) and HepG2 (hepatoblastoma), and in normal isolated 
human hepatocytes. hCYP27 A was evaluated by Northern analysis and values are presented 
relative to the expression of the 18S ribosomal gene. 0 indicates the serum 250HD 
concentrations. 
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2.2.3 Additional Results 
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Figure 2.1: Effect of 1,25(OH)2D3 on CYP7cx (cholesterol 7cx-hydroxylase) rnRNA steady 
state levels. AnimaIs were implanted with osmotic mini-pumps releasing 28pmol/day of 
1,25(OH)2D3, and sacrificed following 1,3,5 and 7 days oftreatment. RNA was extracted 
from liver and rnRNA levels were assessed as described in Article 1. A cDNA CYP7cx probe 
was generated specifically for this study by RT-PCR using the primers described in the study 
by Twisk et al. (227). A. Representative Northern analyses of the CYP7cx gene transcript. 
B. Densitometric analyses. Data are presented as means ± S. E. M. Statistically significant 
differences between group means were analysed by ANDV A with individual contrasts 
evaluated by the Bonferonni test. Overall ANOV A p<0.02. Significantly different from D-
Ca-, *p<0.03, **p<O.OOOI; n=3 animaIs/group. 
Results: CYP7a rnRNA levels were decreased by 28% (NS) starting on the Ist day of 
1,25(OH)2D3 treatment. Levels further decreased by 38% (p<0.03) by day 3 and by 68% at 
the end of the 7 day treatment (p<O.OOI). 
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Figure 2.2: Effect of ketoconazole alone or in combination with vitamin D metabolites 
on CYP27A steady state levels. 
AnimaIs were injected with 1.75mg/kg i.p. ofketoconazole daily, 2 days before beginning 
supplementation for 3 days with 28pmol/d 25(OH)D3 or 1,25(OH)D3 by osmotic mini-pump 
at which time ketoconazole injections continued to be administered. A. Representative 
Northem analyses of the CYP27A gene transcript. B. Densitometric analyses. Data are 
presented as mean ± S. E. M. Statistically significant differences between group means were 
analysed by ANOY A with individual contrasts evaluated by the Bonferonni test. Main 
effect p<O.0005, * p<O.0002, n=3 animaIs/group. 
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Results: Ketoconazole administration alone, or administered together with 1,25(OH)2D3 
produced a slight stimulatory effect on CYP27A steady state levels compared to D-Ca- rats 
(10% and 25% respectively, NS). 25(OH)D3 treatment increased steady state levels by 8% 
(NS) whereas 1,25(OH)2D3 decreased levels by 29% (NS). Ketoconazole in conjunction 
with25(OH)D3 increased CYP27A mRNA levels 2 foid (p<0.0002) Circulating 25(OH)D3 
levels were in the order of less th an 10 nmol/L as reported in Article 3 among al! groups. 
Administration of ketoconazole did not pro duce significant changes in 1,25(OH)2D3 
concentrations, although a noteworthy elevation from 624±41 pmollL to Il 02± 125 pmollL 
in the group receiving 1 ,25(OH)zD3 and ketoconazole was observed compared to that with 
1 ,25(OH)2D3 alone . 
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2.3 CONCLUSIONS 
The data obtained in these studies indicate that hepatic CYP 27 A is affected by the D3 
status in both human and rat. The human gene levels were significantly correlated with 
circulating levels of 25(OH)D and were higher in the spring/summer compared to the 
faU/winter. Fetalliver also expressed the CYP27A gene transcript, albeit at a much lower 
level than that observed in the adult. In addition, expression levels were higher in females 
compared to males, and gene levels were also detectable in pathological states, where levels 
could be significantly upregulated. 
Rat CYP27A was affected by a chronic treatment of 1,25(OH)2D3, which proved to 
have a sharp abolishing effect on the transcription rate, whereas the half-life was unaffected. 
D3 and 25(OH)D3 were without anyeffect. In paraUe1, the rat CYP7cx mRNA levels were 
also sensitive to only 1,25(OH)2D3 repletion. Hepatocytes showed the highest level of 
expression in CYP27A rnRNA levels, although the gene was also detected in stellate, Kupffer 
and endothelial cells. As with the human CYP27A, rat CYP27A was significantly higher in 
female compared to male rats. The signal localization was found in both the PV and pp 
areas in the rat, whereas the human CYP27A gene transcript was mainly localized only in the 
PV region of the liver acinus. 
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CHAPTER 3: EXPERIMENTAL SECTION (STUDIES IN INTESTINE) 
3.1 EFFECT OF THE VITAMIN D3 HORMONAL AND NUTRITIONAL STATUS ON 
CYP27A, THE INTESTINAL VITAMIN D3 25-HYDROXYLASE 
3.1.1 Preliminary jindings 
In the intestine, 1,25(OHhD3 elicits both genomic, as exemplified by the synthesis 
of calbindins (229) and non-genomic responses, involving rapid increases in intracellular 
calcium concentration, cGMP levels and altered phospholipid synthe sis (230;231). Although 
the role of D3 in the intestine has been directly and mainly linked to the absorption of 
calcium and phosphorus, it has also been shown that D3 plays a role in intestinal membrane 
integrity and physiology (232). In addition, in the human fetai jejunum, 1,25(OH)zD3 acts 
as a hormonal agent by controlling cellular proliferation and differentiation (233). 
Of the hydroxylases involved in the activation and metabolic pathways of D3, aIl 
three major hydroxylation activities (C-25, C-24 and C-l Ci) have been reported and described 
in the intestine. 
The presence of CYP27 A, a cytochrome principally invoived in the metabolism of 
biliary acids, but also capable of hydroxylating D3 at C-25, has been reported in mouse 
intestine (234). 
1 Ci-hydroxylase activity has been described in CaCo-2 cells (235) which is the cell 
line best resembling morphologically the small intestinal absorptive cells (236;237). 
Recently, the gene has also been identified in fetal and adult rat intestine (238). 
The 24-hydroxylase system has been extensively studied in intestine, and shown to 
display an induction profile responsive to D3 supplementation in vivo (96;239). 
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3.1.2 Hypotheses 
The presence of the three hydroxylases in the intestine, suggests local 25(OH)D3, 
1,25(OH)2D3 and 24,25(OH)2D3 production and evokes the possibility ofthe intestine being 
an organ responding to D3 and/or its metabolites via an autocrine/paracrine mode of action. 
Moreover, the levels of 1,25(OH)2D3 are tightly regulated in the body, depending on calcium 
and phosphorus status. This regulation has been proposed to be at the level of the D3 
hydroxylases (240), and is thought to be mediated by the VDR. 
3.1.3 Objectives 
- Investigate the effect of the D3 hormonal and nutritional status on the rat intestinal 
CYP27A in our D-Ca- rat model. 
- Evaluate the presence ofCYP27A, CYP27B1, CYP24 and VDR along the human 
fetal intestine and colon and investigate the effect of 1,25(OH)2D3 on their 
expression levels. 
3.2 RESULTS 
3.2.1 Article 3: 1,25-Dihydroxyvitamin D3 downregulates the rat intestinal vitam in D3 
25-hydroxylase CYP27A. 
Article published in Am J Physiol Endocrinol Metab. 2001 Aug;281(2):E315-25. 
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ABSTRACT 
The vitamin D3-25 hydroxylase CYP27 A is predominantly located in liver but its 
expression is also detected in extrahepatic tissues. Our aim was to evaluate the regulation of 
CYP27A by vitamin D3 (D3) or its metabolites in rat duodena. D depleted rats were repleted 
with D), 250HD3, or 1,25(OH)2D), or acutely injected 1,25(OH)2D3 to investigate the 
mechanisms of action of the hormone. AIl D3 compounds led to a progressive decrease in 
CYP27A mRNA with levels after D3 representing 20% of that observed in D depletion. 
250HD3 decreasedCYP27A mRNA by 55%while 1,25(OH)2D3Ied to a40%decreasewhich 
was accompanied by a 31 % decrease in CYP27 A prote in levels and an 89% decrease in 
enzyme activity. Peak circulating 1 ,25(OH)203 concentrations were, however, the highest in 
D3-, followed by 250HD3- and 1 ,25(OH)203-repleted animaIs. 1 ,25(OH)2D3 resulted in both 
a decrease in CYP27A mRNA half-life and transcription rate. Our data illustrate that the 
intestine expresses the 0 3-25 hydroxylase and that the gene is highly regulated in vivo 
through a direct action of 1,25(OH)203 or through the local production ofD3 metabolites. 
Key words: Intestinal 0 3-25 hydroxylase, CYP27A, vitamin D3, 1,25(OH)2D3' 250HD3. 
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INTRODUCTION 
Vitamin D3 (D3) of endogenous origin or ingested vitamin D2 (D2) (collectively referred 
to as vitamin D (D)) are natural secosteroids that have, in their native forms, no biological 
activity. D exhibits a short circulating half-life and is efficiently captured by storage sites 
su ch as adipose tissues and muscles, and by the liver where the vitamin undergoes its first 
anabolic biotransformation through a C-25 hydroxylation reaction. The hepatic product 25-
hydroxyvitamin D (250HD) is rapidly exported to the systemic circulation where its half-life 
has been reported to be in the order of 2-3 weeks in humans. This long half-life associated 
with the efficient hepatic capture and hydroxylation of the parent compound makes 250HD 
the most reliable marker of the vitamin D nutritional status in humans and laboratory animaIs 
. At physiological concentrations, 25(OH)D is not, however, known to have any significant 
biological activity but must undergo regulated-hydroxylation steps at C-l ex or C-24 in the 
kidney to achieve full biological action through either its hormonal form 1 a,25-
dihydroxyvitamin D (1,25(OH)2D), or the now active bone and cartilage candidate 24,25-
dihydroxyvitamin D3 (24,25(OH)2D) (39). Other vitamin D compounds such as lex-
hydroxyvitamin D3 (1 exOHD3) and dihydrotachysterol must also undergo the necessary C-25 
hydroxylation step to acquire their full biological activity (11,26,41). 
To date, two independent mono-oxygenase systems active on the C-25 hydroxylation 
ofD3 or D2 family of compounds have been described. DeLuca's group (9) first reported the 
enzyme to be located in the hepatic microsomal fraction while a few years later, Bjorkhem 
and Holmberg (10) reported that the mitochondrial sterol-27 hydroxylase exhibited enzyme 
activities towards the C-25 hydroxylation ofD3' The molecular identity of the human or rat 
microsomal D-25 hydroxylase has not yet been reported while the mitochondrial enzyme has 
been cloned in several species and the gene encoding the enzyme termed CYP27A 
(3,14,26,49,54). 
Studies on the kinetics of the hepatic D3-25 hydroxylases have demonstrated that the 
affinity of the microsomal enzyme is much higher (as indicated by a significantly lower Km) 
than that of the mitochondrial enzyme, an observation which has led to the conclusion that 
the microsomal D3-25 hydroxylase is most likely physiologically more relevant than its 
mitochondrial counterpart (22). The intestine, however, is likely to be exposed to 
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significantly higher concentrations ofD compounds than the liver. lndeed, both the vitamin 
of dietary or pharmacological origin will be presented to the small intestine while only a 
fraction of the vitamin of either endogenous or exogenous origin will be captured by the liver 
(24,25). These observations strongly indicate that, in the small intestine, the physiological 
significance of the mitochondrial D-25 hydroxylase may be highly relevant. Interestingly, the 
small intestine has been reported to express CYP27A (3), and to also exhibit enzyme 
activities related to the hydroxylation ofD compounds at C-24 (5,36,47) while the Caco-2 
cellline (a line c10sely resembling the small intestine) (30) has been reported to be able to 
hydroxylate 250HDJ at C-lct (16) indicating that the small intestine, in addition to its 
response to the DJ endocrine system, may be fully able to regulate its own D metabolism and 
to respond to its local D-dependent needs through an auto- and/or intracrine process. 
To date, studies on the regulation of the CYP27A gene products have focussed solely on 
its significance and importance in relation to the biosynthesis of bile acids, and the molecular 
mechanisms by which CYP27A is regulated by DJ or its metabolites, most particularly in 
intestine, are presently unknown. The aims of the studies were, therefore, to deterrnine the 
effect of an in vivo exposure to vitamin DJ, 25(OH)D), or 1,25(OH)2D) on the level of the 
CYP27A gene transcript in rat duodena, and to evaluate the mechanisms by which 
1 ,25(OH)2DJ regulates its expression. 
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MATE RIALS AND METHODS 
EXPERIMENTAL DESIGN 
The influence of the vitamin D endocrine system on the steady-state expression of the 
duodenal CYP27A was studied in D depleted rats repleted with either calcium alone, D3, 
250HD3 or 1,25(OH)2D3' In order to investigate the mechanism of action by which 
1,25(OH)2D3 influenced the expression ofCYP27A, studies were conducted on the half-life 
as well as the transcription rate of the gene. The effect ofknown cytochrome P-450 inducers 
on the steady-state levels ofCYP27A mRNA was also evaluated. 
ANIMALS 
AlI animaIs used during the experiments were treated according to the standards of 
ethics for animal experimentation of the Canadian Council on Animal Care. An proto cols 
were approved by the local animal ethics committee. 
Studies on the characterization of the CYP 27 A fragment generated in our laboratory 
were done in normal male Sprague-Dawley rats (50). Hypocalcemic-vitamin D depleted male 
rats (D-Ca-) were obtained as previously described (21,27). AnimaIs were then submitted 
to experimental protocols aimed at achieving an in vivo repletion with dietary calcium alone 
or with physiological concentrations of DJ, 250HD3 or 1,25(OH)2DJ as described below. 
REPLETION WITH CALCIUM, D3, 25(OH)D3, OR 1,25(OH)2D3 
Expression of the CYP27 A duodenal gene transcript was first studied under steady-state 
conditions in D depleted animaIs and in animaIs repleted with calcium alone, or with DJ 
compounds. Repletion with calcium alone was achieved by an oral supplementation with a 
3% calcium gluconate solution as drinking water for a period of 7 days as previously 
described (21,27). Repletion \vith D3 compounds was achieved by the intraperitoneal 
implantation of mini-osmotic pumps (Alza Corporation, Palo Alto, CA, USA) containing 
either DJ at a dose of 6. 5 nmol/day, 25(OH)D3 at a dose of28 pmol/day, or 1 ,25(OH)2DJ also 
at a dose of28 pmol/day (21,27). AU compounds were administered in vehic1e containing 
95% ethanol:propylene glycol:0.9% saline, 3:13:4, v/v/v. At the time of mini-pump 
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implantation a Ioading dose of3.2 nmoi DJ, 14 pmoI25(OH)DJ, or 14 pmoi 1,25(OH)2DJ 
was administered i.p. in order to rapidly raise serum concentrations of DJ, 25(OH)DJ, or 
1,25(OH)2DJ and hence accelerate the establishment of steady state conditions. D depleted 
animaIs were implanted with mini-osmotic pumps containing vehic1e only. Repleted rats 
were given a 0.5% calcium gluconate solution as drinking water while D-depleted controls 
received demineralized water. AnimaIs repleted with DJ were killed after one week of 
repletion while animaIs repleted with 250HDJ or 1 ,25(OH)zDJ were killed 1, 3, 5 or 7 days 
following initiation of the repletion protocol. At the time of euthanasia the animaIs were 
between 7-8 weeks of age. 
TREATMENT WITH CVTOCHROME P-450 INDU CERS 
Studies on the induction of the gene encoding CYP 27 A were achieved using xenobiotics 
known to induce cytochrome P-450 izozymes. Normal male rats were exposed to 
dexamethasone (one single i.p. injection: 400mg/kg), 3-methylcholanthrene (one single i.p. 
injection: 30 mg/kg), (3-naphtoflavone (three daily i.p. injections: 80mg/kg), acetone (1 % v:v 
in drinking water for a period of 10 days), or phenobarbital (350 mg/ml in drinking water for 
a period of 10 days) (40). 
HALF-LIFE OF THE CYP27A GENE TRANSCRIPT 
Studies on the half-life of the CYP27A gene transcript were achieved in D depleted rats 
subjected to a single i.v. dose (0, 2.4, 12, 120, or 240 nmol/kg) 1,25(OH)2D3. 
Pharmacological hormonal concentrations were used in order to rapidly achieve the 
1,25(OH)2D3 effect on the CYP27A gene before the production of significant down stream 
metaboIites of the hormone. A single i.p. dose of O. 5 mg/kg actinomycin D dissolved in 95% 
ethanol:saline (1: 1 v:v) was administered 3 hours after exposure to 1 ,25 (OH)2DJ and animaIs 
were sacrificed prior to and 1, 3, or 6 ho urs after actinomycin D administration. CYP27A 
mRNA levels were evaluated as described below. 
TRANSCRIPTION RATE OF THE GENE ENCODING CYP27A 
The transcription rate of the gene encoding CYP27A was evaluated in duodenal nucIei 
obtained from either hypocalcemic DJ depleted rats or from rats exposed to a single i.v dose 
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of 120 nmol/kg 1 ,25(OH)2D3 6 hours before euthanasia. Nuclear run-on assays were done as 
indicated below. 
2S-HYDROXYLASE ACTIVlTY 
The mitochondria125-hydroxylase activity was measured in freshly isolated duodenal 
mitochondria obtained from D-depleted rats and from animaIs repleted by intraperitoneal 
mini-osmotic pumps containing 28 pmollday 1 ,25(OH)2D3 for a period of7 days as described 
above. 1 cx-hydroxyvitamin 0 3 (1 cxOH03) (Leo Pharma Inc., Ajax, Ontario, Canada) was used 
as substrate. 
Duodenal mucosal cells were gently scrapped off and mitochondria were isolated as 
described by Rosenberg and Kappas (42). The final mitochondrial pellet was resuspended 
in 0.25 M sucrose, 10 mM Tris, 10 mM KCI, 1 mM EDT A, heparin 3 U/ml, pH 7.4. Protein 
concentration was determined according to Bradford (13). The incubation reaction (0.4-0.6 
mg protein in 1.0 mL) contained 40 mM potassium phosphate, 0.25 M sucrose, 200 )lM 
EDTA, 20 mM MgCI2, 0.2 mg BSA, 2 !-tg N,N' diphenylphenylelenediamine (Aldrich Chem. 
Co., Milwaukee, WI), 10 mM isocitric acid (Sigma Chemical Co., St. Louis, MO), pH 7.4. 
The reaction was started with 20 nmol 1 cxOHD3 and al10wed to continue for 40 min at 37°C 
under gentle shaking. Blank reactions were carried out with boiled mitochondria. The 
. reaction was terminated with 3.75 mL chloroform:methanol (1:2 v:v), and 6000 cpm 
eH] 1 ,25(OH)2D3 was added to correct for recovery during the extraction and 
chromatographic procedures. Reaction mixtures were extracted twice as described by Bligh 
and Dyer (12). After extraction and evaporation, the residue was dissolved in 150 JlL hexane 
and injected into a Beckman model160 HPLC (Beckman Instruments, Palo Alto, CA) fitted . 
with aZorbax-Sil colurnn (4.6 x 250 mm) (Dupont Instruments, Wilmington, DE) and eluted 
in hexane:isopropanol (9: 1 v:v) at a flow rate of2mLlmin. Metabolites were detected at 254 
nm. The fractions corresponded to crystalline l ,25(OH)203 (retenti on time 15 min. without 
overlapfrom 1aOHD3) were collected and counted (Beta LS1801 spectrometer, Beckman 
Instrument, Palo Alto, CA). The identity of the product formed was confirmed by a second 
HPLC on a C-18 column eluted with hexane:isopropanol (8:2 v:v). 
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EXPERIMENT AL PROCEDURES 
Determination of Circulatillg IOllized Calcium alld Vitamin D Metabolites 
Serum Ca2+ concentrations were measured with an lCA2 ionized calcium analyser 
(Radiometer, Copenhagen, Denmark). Serum 25(OH)D3 and 1,25(OH)2D3 concentrations 
were measured using the lncstar 25(OH)D and 1,25(OH)2D RIA assay kits (Incstar 
Corporation, Stillwater, Minnesota, USA) according to the manufacturer's instructions. 
Molecular Biology Procedures 
At the time of euthanasia, the duodena and livers were isolated and immediately frozen 
in liquid nitrogen and stored at -80°C until RNA extraction. 
Total intestinal RNA was extracted, blotted onto nylon membranes (Qiagen, 
Mississauga, Ontario, Canada) and processed for Northem analyses as previously described 
(35). The radiolabeled CYP 27 A probe was a cDNA fragment generated specifically for the 
present studies by RT -PCR. The 404 bases corresponded to base pairs 399 to 803 within the 
N-terminal co ding region of the rat gene based on the published sequence of Su et al. (49), 
(Genbank accession #M38566). The primers 5'TCTCTGGCTCT AAACTCTTGGC3' and 5' 
CTCGTGAAGTGCAGCACATA 3' used were custom synthesised by the Sheldon 
Biotechonology Centre (McGill University, Montreal, Quebec, Canada). The following PCR 
pro gram was used for 30 cycles: 30s at 65°C, lOs at 72°C and 30s at 95°C. The fragment 
obtained was cloned into the vector PCRIl (In Vitrogen, Carlbad, CA, USA) and sequenced 
in order to confirm identity. The functional specificity of the CYP 27 A fragment generated 
revealed higher mRNA expression in female than in male liver and a significant hepatic 
induction of the gene transcript by dexamethasone (50) as expected from previous studies 
(1,2,4,48). 
The CYP24 probe was a 247 base rat renal cDNA insert from the KpnI site of the 
pUC19 vector (38), and the 18Sribosomal RNA was a 1.5 kb human cDNA insert from the 
EcoRI site of pBluescript SK vector (A TCC #77242). Probe labelling, blot hybridization, 
washing, exposure and photodensitometric evaluation were performed as previously 
described (18,35). 
Nuclear run-on transcriptional assay 
Nuclei were isolated from duodena of D-Ca- or of 1 ,25(OH)2D3 repleted rats by the 
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method of Widnell and Tata (56) using successive sucrose gradient centrifugations. The 
nuclei obtained were resuspended in storage buffer (40% glycerol, 5 mM MgC12, 10 mM Tris 
pH 7.4, 1 mM DTT and 1 mM EDTA) and stored.at -80°e. The rate of CYP27A gene 
transcription was measured using a previously described nuc1ear run-on transcriptional assay 
(43) with the following modifications. Nuc1ei were pelleted by centrifugation and 
resuspended in 50/lL of nuc1ear run-off reaction mixture (50 mM Tris pH 7.5, 50 mM MgCI2, 
2 mM DTT, 2 mM spermidine, 25U Rnase inhibitor, 1 mM ATP, 1 mM CTP, 1 mM GTP, 
and 50 /lCi e2p] UTP (3000Ci/mmol, Amersham Pharmacia Biotech, Baie D'Urfé, Quebec, 
Canada) and incubated at 30°C for 60 min. The labelled RNA was hybridized to nylon 
membranes on which 300 ng of the 404 bp D3-25-hydroxylase cDNA fragment with 150 ng 
of 18S ribosomal RNA cDNA fragment ( positive control), and 100 ng of pBS (negative 
control) had been dotted and hybridized in 5% SDS, 400 mM N aPO 4 pH 7.2, 1 mM EDT A, 
1 mg/ml BSA, 50% formamide and 240 /lg/ml of salmon sperm DNA. The membranes were 
prehybridized for 4 hours at 52°C in hybridization solution without labelled RNA then 
hybridization was perfonned at 52°C for 72 hours. The membranes were washed and exposed 
to x-ray films for 14 days and densitometry was performed as previously described (18,35). 
Western analyses of tlle CYP2 7 A protein 
The relative levels of CYP27A protein was determined by Western blot analyses. 
Membranes from intestinal samples were disrupted by sonication and homogenized in 100 
mM TRIS pH 7.6, 3mM PMSF, 300 mM KCl and 1 % BSA, centrifuged at 100 OOOg, and the 
supernatant was precipitated with 40% ammonium sulfate ovemight. 30 /lg of proteins were 
loaded onto a SDS-P AGE 5-15% gradient acrylamide gel and transblotted on PVDF 
membranes. The membranes were first incubated for 1h with a rabbit polyclonal antibody 
raised against human CYP27A 1:1000 (gift from Dr. David Russel, University of Texas 
Southwestern Medical Center, Dallas,TX), followed by an incubation with an anti-rabbit IgG 
streptavidin-biotinylated species specific antibody 1: 1 000 (Amersham Pharmacia Biotech, 
Baie D'Urfé, Quebec, Canada), and finally incubated with a streptavidin-biotinylated 
horseradish-peroxidase complex 1:1000 (Amersham Pharmacia Biotech, Baie D'Urfé, 
Quebec, Canada). The antigen-antibodycomplex was visualized with 3,3'-diaminobenzidine 
(Sigma Chemical Co., Mississauga, Ontario, Canada). Quantification was achieved by 
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densitometric scanning. 
STATISTICAL ANALYSES 
Data are presented as means ± SEM. StatisticaUy significant differences between group 
means wereevaluated by ANOVA, orthe Student's "t"test as indicated in the figure legends. 
lndividual between-group contrasts were evaluated using the Bonferroni test. 
140 
RESULTS 
RELATIVE INTESTINAL CYP27A LEVELAND DRUG INDUCIBILITY 
Figure 1 A and B presents the relative level of CYP 27 A expression in normal male rat 
liver and duodenum. As illustrated, the steady-state level of CYP 27 A mRNA was found to 
be 3 fold higher in liver than in duodenum (p<0.0001). A survey of other parts of the 
intestine indicates values relative to those found in duodenum of 85%, 69% and 77% in 
jejunum, ileum and colon respectively. 
In order to investigate the modulation of the duodenal CYP27A transcript by known 
pharmacological agents, animaIs were treated with acetone, phenobarbital, p-naphtoflavone, 
3-methylcholanthrene, and dexamethasone. As illustrated in Figure 2A and B, only 
dexamethasone was found to significantly increase (5 fold induction) CYP27A mRNA 
expression in intestine (p<O.OOOI). Finally, the effect of the calcium and vitamin D status on 
the relative abundance of the CYP27 A gene transcript was investigated. As illustrated in 
Figure 2C and D, CYP27A was found to be 2 fold higher in vitamin D depleted than in 
normal rat duodenum (p<0.02) and this irrespective of the calcium status of the animaIs. 
Indeed, no significant difference was observed in CYP27A gene expression in duodena 
obtained from hypocalcemic (D-Ca-) compared to that obtained from normocalcemic (D-
Ca+) D depleted rats. 
EFFECT OF D3, 25(OH)D3, OR 1,25(OH)2D3 REPLETION ON CYP27A mRNA LEVEL 
The influence of the D status on intestinal CYP27A mRNA abundance, prompted 
investigation on the CYP27A gene response to a one week repletion with either the parent 
compound DJ, or with its hepatic (250HDJ), or kidney (1 ,25(OH)2DJ) metabolites. 
Repletion witlz D j 
DJ was found to significantly influence CYP27A mRNA levels with, as illustrated in 
Figure 3, an 80% decrease in the abundance of the CYP27A gene transcript observed after 
one week of repletion (p<0.0001). The dose of DJ used achieved normalization of the 
circulating ionized calcium, 250HDJ and 1,25(OH)2D3 after one week of repletion as 
previously reported (17,21,27). The 1 ,25(OH)2DJ concentrations achieved were found to be 
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1760 ±152 pmollL at day one of the repletion period and to decrease to 1115 ±128 pmollL 
at the time of euthanasia. 
Repletion with 25(OH)D3 
The serum ionized calcium concentrations increased steadily from a mean value of 0.82 
± 0.01 mmollL in D-Ca- to 1.13 ± 0.04 after one week 250HD3 administration. Serum 
25(OH)D3 concentrations remained, however, low during the period studied with a mean 
concentration of 6.5 nmollL after one week of repletion, whereas seruml,25(OH)2D3 
concentrations increased from an average of 95 ± 15 pmoIlL in D depleted animaIs to an 
average of 1143 ±11O pmol/L after one week of 250HD3 repletion. 
As illustrated in Figure 4, the intestinal CYP27A gene transcript exhibited a 
progressive decrease in its level ofexpression with a non-significant 10% decrease at day one 
but with a significant 33% decrease after 72 hours of 25(OH)D3 administration (p<0.03). 
After one week of250HD3 repletion, the mean level ofthe CYP27A transcript was found to 
be decreased by 55% when compared to the level observed in animaIs not exposed to 
250HD3 (p<0.008). Moreover, the decrease in CYP27A mRNA abundance was shown to 
be linear over the one week-period studied (r= 0.787, p<O.OOl). 
Repletion with 1,25(OH)P3 
The serum ionized calcium concentrations increased steadily from a mean value ofO. 73 
± 0.03 to 1.21 ± 0.09 mmoI/L throughout the one week of I,25(OH)2D3 repletion. Serum 
25(OH)D3 remained unchanged during the course of 1,25(OH)2D3 administration while 
1,25(OH)2D3 concentrations which averaged 95 ± 15 pmol/L at day zero remained at a 
plateau during the course of 1 ,25 (OH)2D3 repietion averaging 603 ± 90 pmoIIL after one day 
ofrepietion and 503 ± 123 pmollL after one week of 1,25(OH)2D3 administration. 
As illustrated in Figure SA and B, 1,2S(OH)2D3 administration resulted in ahighly 
significant 30% decrease in C YP 27 A mRN A levels as soon as 24 hours after the beginning 
of 1,25(OH)2D3 administration (p<0.0008). CYP27 A mRNA levels remained thereafter 
unchanged with an observed 40% decrease (p< 0.0008) in CYP27A mRNA abundance after 
one week of 1,25(OH)2D3 exposure compared to the level observed in rat duodena not 
exposed to the hormone. Moreover, Western analyses (Figure S C and D) revealed a 
concomitant 31 % decrease in CYP27 A prote in level after one week of 1,25(OH)2D3 
administration (p<0.003). 
25-hydroxylase aetivity 
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Figure 6 illustrates the effect of one-week exposure to 28 pmol/day 1 ,25(OH)2D3 on the 
25-hydroxylase activity is isolated duodenai mitochondria. 1,25(OH)2D3 repletion had a 
significant influence on CYP27A activity with an average 89% decrease in la,25(OH)2D3 
production following incubation with 1 aOHD3 (p<0.0 1). 
MECHANISMS OF 1,25(OH)2D3 ACTION 
The observation thatthe decrease in CYP27A mRNA were highly and rapidly sensitive 
to 1,25(OH)2D3 prompted studies on the mechanisms by which the hormone influences the 
abundance of the CYP27A gene transcript. These studies were conducted using an acute 
mode! of 1 ,25 (OH)2D3 exposure. 
Effeet of aeute 1,25 (OH)]D3 administration Oll the level of the CYP27A gene 
transcript 
Serum ionized calcium concentrations increased only slightly from 0.78 ±O.O 1 to a range 
varying from 0.90 ± 0.01 (2.4 nmollkg dose) to 1.01 ± 0.03 (240 nmol/kg dose) 6 hour after 
the i.v. injection of 1,25(OH)2D3' The 1,25(OH)2D3 concentrations reached, at the time of 
euthanasia, were 9277 ± 551 pmol/L in rats injected with the 2.4 nmoI/kg dose to over 30 
000 pmollL in animaIs injected with the 12, 120 and 240 nmol/kg doses of 1,25(OH)2D3 
(p<0.001). 
As is illustrated in Figures 7 A and B, as soon as 6h after 1,25(OH)2D3 exposure, 
duodenal CYP 27 A mRNA Ievels were found to progressively decrease with increasing doses 
of the hormone (2.4 to 240nmollkg) whereas CYP24 mRNA Ieve!s, which were used as 
controis for the 1,25(OH)2D3 response, were found to be concomitantly and highly 
significantly upregulated (Figures 7e and D). 
CYP2 7 A mRNA half-life 
As is illustrated in Figure 8, treatment of Ca-D- rats with 0.5mg/kg actinomycin D did 
not significantly influence CYP27A mRNA levels in untreated rats over the 6 hour period 
studied aithough a slight, but not significant, increase over basal values was observed at the 
6 hour-time period. A dose of 5mglkg actinomycin D which was also used in order to verify 
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whether the dose of actinomycin D used in the original experiment was sufficient to hait 
CYP 27 A gene transcription reveaied that CYP 27 A mRNA Ievels were not influenced for up 
to six ho urs following actinomycin D injection when compared to untreated D-Ca- controis. 
AH further studies were, therefore, done using the 0.5 mg/kg dose of actinomycin D. The 
effectiveness ofthe dose ofactinomycin D used in inhibiting the process of transcription was 
aiso verified by examining its effect on the mRNA Ievels of the gene encoding CYP24. A 
O.5mg/kg dose given one hour before 1,25 (OH)2D3 injection was found to effectively 
prevent the upregulation of the CYP24 gene transcript (results not shown). Following the i.v. 
injection of 1,25(OH)2D3' a 24% decrease in the levei of the CYP27A gene transcript was 
observed one hour after actinomycin D administration when compared to the level observed 
in D-Ca- animaIs. Moreover, the levels of the transcript steadily decreased to 36% of the 
Ievel observed in· animaIs not subjected to actinomycin D administration, 6 hours after 
actinomycin D administration (p<O.03). When compared to their actinomycin D-paired D 
depleted control s, the relative abundance of the CYP27A gene transcript was found to be 
decreased by 77% at the 6 hour-time point (p<0.002). 
CYP2 7 A gene transcription rate 
Nuc1ear transcription mn-on assays were performed on nUc1ei isolated from duodena of 
hypocalcemic D depleted rats as weIl as on nuc1ei obtained from duodena of D-Ca- animaIs 
exposed to a single 120 nmollkg i.v. dose of 1,25(OH)2D3 (Figure 9). The 18S ribosomai 
gene was used as a control gene for both the untreated and treated groups. Quantification for 
the nuc1ear mn-on assays demonstrated that within 6 ho urs of 1,25(OH)2D3 exposure, the 
transcription rate of the gene encoding CYP27A decreased by 32% when compared to the 
level of expression observed in control duodena. Non-specifie hybridization, estimated by 
hybridization to pBS plasmid DNA, did not account for the observed CYP27A decrease in 
transcription. 
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DISCUSSION 
Although several studies have reported that the mitochondrial cytochrome P-450 27 A 
is present in multiple sites (14,31,33,37), no study has addressed the regulation of the enzyme 
in intestine, and the effect of the vitamin D3 status on the expression of the gene encoding 
CYP27A in small intestine is also unknown. Indeed, most studies to date have focussed on 
the hepatic regulation of the gene which has, up to now, been reported to be sensitive to bile 
acids, glucocorticoids, growth hormone and insulin (37,46,48,52,53,55). Axén et al. (7), on 
the other hand, have reported that CYP27A located in kidney and liver was affected by 
1 ,25(OH)2D3 administration stressing that the kidney CYP 27 A mRNA levels were decreased 
to a greater extent than those of the liver, an observation which we have confirmed in our 
laboratory (51). The significance ofthese observations on the C-25 hydroxylation ofD3 have 
not yet been investigated although earlier studies have raised the hypothesis that 1,25(OH)2D3 
might inhibit the production of 250HD3 in hum an subjects (8). Later studies in the rat 
indicated, however, that the decrease in serum 250HD3 concentrations could mainly be 
explained by an acceleration in its metabolic clearance rate (15,27,28) although species 
differences in the C-25 hydroxylation ofD3 have not been ruled out, the microsomal D3-25 
hydroxylase being the predominant enzyme in the rat while, in humans, the mitochondrial 
CYP27 A has been claimed to be the sole D3-25 hydroxylase (44,45). Our studies show that 
duo den al CYP27A mRNA levels are significantly lower than those observed in liver but, as 
in liver (55), the duodenal transcript was shown to be significantly upregulated by 
dexamethasone while common cytochrome P-450 inducers were shown to be without effect. 
Data also indicate that when compared to duodena obtained from normal D replete animaIs, 
CYP27A mRNA levels are significantly higher in duodena obtained from D depleted and 
that, independently of the circulating ionized calcium, clearly indicating that the intestinal 
CYP27A is highly sensitive to the vitamin D status. 
Our studies on the effect ofD3, 250HD3 and 1 ,25(OH)2D3 indicate that each compound 
significantIy lowered the abundance of the CYP27A gene transcript. A time-course of the 
decrease in CYP27A mRNA levels following continuous i.p. administration indicates that 
the decline in mRNA abundance is graduaI with significant decreases observed after 72 hours 
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of 250HD3 repletion and as soon as 24 hours following the initiation of 1,25(OH)2D3 
repletion. CYP27 A protein levels and 25-hydroxylase enzyme activity were also shown to 
be sensitive to 1,25(OH)2D3" Furthermore, the studies with the i.v. injection of 1,25(OH)2D3 
as weIl as those on the half-life of CYP 27 A mRNA indicate that the gene transcript is rapidly 
and dose-dependently down-regulated within hours of exposure to the hormone. These data 
demonstrate that in rat duodena the gene encoding CYP 27 A is highly sensitive to the in vivo 
exposure to the vitamin D3 hormone. Whether 1,25(OH)2D3 is the sole mediator of the 
observed down regulation of the CYP27A gene transcript is not known. Attempts at 
evaluating the specifie role of 1,25(OH)2D3 versus that of 250HD3 in the regulation of 
CYP27A gene expression were done using ketoconazole to inhibit the C-la hydroxylase 
when 250HD3 was administered. Unfortunately, these attempts were unsuccessful for the 
foIlowing reasons: i) ketoeonazole proved to be a non-specifie monooxygenase inhibitor, 
inhibiting not only the C-la (29) but also the C-24 hydroxylase (32,57) which resulted in 
unexpeeted changes in eireulating 1,25(OH)2D3' ii) the effect of 1,25(OH)2D3 on the 
CYP27A gene transeript proved to be too sensitive to evaluate subtle changes in the 
1,25(OH)2D3 circulating concentrations induced by ketoeonazole, and iii) 1,25(OH)2D3 
exhibited a rapid effect (significant inhibition observed within 6 hours after i.v. 1,25(OH)2D) 
exposure) to discriminate its role versus that of 250HD3 although the time-course of 
inhibition suggests that the latter is most likely not responsible for the inhibition observed 
during the present studies. Although the data obtained during our studies suggest a highly 
significant effect of 1 ,25 (OH)2D3 on the down-regulation ofthe duodenal CYP27 A transcript, 
they do not entirely mIe out the participation of other metabolites sueh as 24,25(OH)2D3' 
and/or of down stream products of the hormone. 
The differenees observed in the sensitivity of CYP 27 A between animaIs repleted with 
D3, 250HD3, or 1,25(OH)2D3 warrants comments. Interestingly, an earlier study carried out 
in our laboratory has indicated that the kinetics of the serum 250HDJ and 1,25(OH)2DJ 
achieved as well as that of the involution of the associated secondary hyperparathyroidism 
was quite different when animaIs were repleted with DJ, or with 1,25(OH)2D3 alone (23). 
Indeed, the serum 1,25(OH)2D) concentrations achieved with D) repletion are much higher 
(in the 1500 to 2000 pmol/L range, most likely due to the high 1 a-hydroxylase activity 
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induced by D depletion) than those achieved when the hormone is applied by i.p. mini-
osmotic pump which, in the present study, proved to be quite constant averaging 500 to 600 
pmollL between day 1 and day 7 of 1,25(OH)2D3 repletion. These differences could explain 
the greater effect of the parent compound (after 7 days of repletion) on the steady-state 
expression of the gene encoding CYP 27 A when compared to that observed foUowing 
1 ,25 (OH)2D3 administration. However, the in vivo effect of 1 ,25 (OH)2D3 on CYP27 A mRNA 
levels is clearly illustrated by the clear dose-response curve achieved foUowing i.v. 
administration. A clear effect of 1,25(OH)2D3 on CYP27A mRNA half-life, and on the 
transcription rate of the gene also supports an action mediated by the hormone, or by 
immediate and rapidly formed down-stream metabolite(s). 
The data illustrating that the duodenum (as well as the jejunum, ileum and colon) clearly 
expresses CYP27A as weU as the D3-25 hydroxylase protein lead us to put forward the 
hypothesis that a local production of 250HD3 can be achieved in the smaU intestine. In 
addition, the already reported presence of 250HD3-1 ex hydroxylase and 250HD3-24 
hydroxylase activities in intestinal ceIls as weIl as in the Caco-2 cell line (5,16,36,47) 
suggests that D of dietary origin could be 10caUy processed and transformed into 250HD, 
1,25(OH)2D, or 24,25(OH)2D/1,24,25(OH)3D. Moreover, Axén et al. (6) have reported that 
the C-27 hydroxylase purified from pig and rabbit livers as well as recombinant human 
CYP27A was also able to catalyse the lex-hydroxylation of250HD3 albeit at a much lower 
rate than that observed for the conversion of D3 into 250HD3 (7). Furthermore, CYP27 A 
has also been shown to be active on other D compounds such as D2, and 1 exOHD3 as 
illustrated in the present studies (19,20,26). Collectively these observations illustrate that 
a large spectrum of compounds of the D family can be locally activated by intestinal cells 
into active metabolites when taken orally. 
The critical elements involved in the 1,25(OH)2D3-mediated down regulation of the 
CYP27A gene transcript have not been investigated. Our data indicate that the mechanisms 
responsible for the regulation of the gene involve a decrease in mRNA half-life and a 
decrease in transcriptional rate. The effect of calcitriol on the gene, however, is present even 
in the absence of normalization of the circulating Ca2+ concentrations as illustrated following 
the i.v. injection of 1 ,25(OH)2D3 suggesting that Ca2+ is not a cri tic al element in the response 
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to the hormone. In addition, repletion with calcium alone (which normalizes the serum Ca2+ 
concentration without affecting the D nutritional or hormonal status) do es not affect CYP27 A 
steady state mRNA levels. CYP 27 A and CYP 7 ex are genes involved in bile acid biosynthesis. 
CYP7 ex is known to be regulated by some of the orphan receptors mediating the response to 
fatty acid and cholesterol such as PXR (a nuclear receptor closely related to VDR) (34), FXR 
or PP AR which aIl have RXR as partner for DNA binding. It is not yet known, however, 
whether CYP27A is also regulated by these nuclear receptors and/or what is the role of 
1,25(OH)2D3 in these interactions most particularly in relation with its binding to the VDR 
and the subsequent involvement of RXR for DNA binding and activation. 
The data obtained during our studies clearly show that the rat duodenum expresses the 
mitochondrial D3-25 hydroxylase CYP27A. They also show an effect of the D3 nutritional 
status (D3 and 250HD3) as well as of the D3 hormonal status (1,25(OH)2D3) on the gene 
mRNA half-life and transcription rate. Thus, in addition to exhibiting high amounts ofVDR, 
the intestine seems to possess the major DJ hydroxylases, indicating that aside from being 
able to respond to the classic endocrine actions mediated by 1 ,25(OH)2D3' the small intestine 
may exhibit the presence of a fine intra/paracrine, or autocrine regulation of D3-related 
pathways. 
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LEGEND TO FIGURE 1 
N orthem analysis representing the relative abundance of the CYP 27 A gene transcript in 
male liver and duodenum (A). Means ± S. E. M. CYP27A mRNA levels observed in 4 
animaIs/group. Statistically significant differences between group means were analysed by 
the Student' s "t" test. 
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LEGEND TO FIGURE 2 
Influence of cytochrome P-450 inducers on the duodenal expression of the gene 
encoding CYP27A. A and C. Representative Northern analyses of the CYP27A gene 
transcript. B. Evaluation ofCYP27A mRNA levels in normal control male rat duodena and 
after administration of cytochrome P-450 inducers. n = 3 animaIs/group. D. Evaluation of 
the relative level of the CYP 27 A gene transcript in normal, and in hypocalcemic (serum Ca2+: 
O.78±0.02) and in normocalcemic (serum Ca2+: 1.26±0.02) vitamin D depleted male rat 
duodena. Data are presented as means ± S. E. M. 
n = Il for control, n = 15 for D-Ca- and n = 3 for D-Ca+. Statistically significant differences 
between group means were analysed by ANOV A (cytochrome P-450 induction studies), and 
by the Student's "t" test (normal and D-Ca- or D-Ca+ studies). 
te 
CY?27 AI l8S (Arbitrary Units) 
control ~ 
1 acetone ~ 
phenobarbital • 
"0 
1\ 
0 
0 j3-naphtoflavone _ 0 0 
methylcholanthrene 
dexamethasone 
~ 
CYl!27A1l8S (Arbitrary Units) 
~-
control 
D-Ca-
(J 
~ 
........ N ~ ~ 
1",1-
N N 
N w 
::0;- ::-;" 
0"' 0"' 
\) 
~ 
........ N ~ ~ 
Ii~illl % ,&il:! 
N 
N 
~ 
N 
W 
::-;" 
0"' 
> 
('j 
.-. 
0'1 
.-. 
162 
LEGEND TO FIGURE 3 
Influence ofD3 repletion on the duodenal expression of the gene encoding CYP27A. A. 
Representative Northem analysis of the CYP27A gene transcript in D-Ca-, and after 7 days 
of 0 3 repletion by mini-osmotic pump (i.p.) at a dose of 6.5 nmol/day. B. Steady-state levels 
ofCYP27A mRNA in D-Ca-, and in D3 repleted rat duodena. Data are presented as means 
± S. E. M. n = 5 animaIs/group. Statistically significant differences between group means 
were analysed by the Student' s "t" test. 
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LEGEND TO FIGURE 4 
Influence of 250HD3 repletion on the duodenal expression of the' gene encoding 
CYP27A. A. Representative Northem analysis of the CYP27A gene transcript in D-Ca-, and 
following 1, 3, 5 or 7 days of250HD3 repletion by mini-osmotic pump (i.p.) at a dose of28 
pmollday. B. Steady-state levels of CYP27A mRNA in D-Ca-, and in 250HD3 repleted rat 
duodena. Data are presented as means ± S. E. M. n = 3 animals/group. Statistically 
significant differences between group means were analysed by ANOV A with individual 
contrasts eval uated by the Bonferonni test. Main effect, p<O. 001, significantly different from 
D-Ca-, * p<0.003, ** p<0.002, *** p<0.0008. 
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LEGEND TO FIGURE 5 
Influence of 1,25(OH)2D3 repletion on the duodenal expression of the gene encoding 
CYP27A, and on the level of the CYP27A prote in. A. Representative Northern analysis of 
the CYP27A gene transcript in D-Ca-, and following 1, 3, 5 or 7 days of 1,25(OH)2D3 
repletion by mini-osmotic pump (i.p.) at a dose of 28 pmol/day. B. Steady-state level of 
CYP27A mRNA in D-Ca-, and in 1,25(OH)2D3 repleted rat duodena. C. Representative 
Western analysis of the CYP27 A protein in D-Ca-, and 7 days after 1 ,25(OH)2D3 repletion. 
D. Steady-state level ofCYP27 A prote in in D-Ca-, and in 1 ,25(OH)2D3 repleted rat duodena. 
Data are presented as means ± S. E. M. n = 3 animaIs/group. Statistically significant 
differences between group means were analysed by ANOV A with individual contrasts 
evaluated by the Bonferonni test. Main effect, p<O.0002, significantly different from D-Ca-, 
* * *p<O.0008. 
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LEGEND TO FIGURE 6 
Mitochondrial 25-hydroxylase activity from freshly isolated duodenal mucosal cells 
obtained from hypocalcemic vitamin D depleted (D-Ca-) (n=2) or 1 ,25 (OH)2D3 repleted rats 
(n=3). Statistically significant differences between group means were analyzed by the 
Student' s "1" test. 
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LEGEND TO FIGURE 7 
Influence of acute 1 ,25(OH)2D3 administration on the expression ofthe genes encoding 
CYP27A and CYP24. AH animais received a single i.v. dose of 0, 2.4, 12, 120, or 240 
nmollkg and killed 6 hours later. A. Representative Northem analysis of the CYP27A gene 
transcript in D-Ca-, and in animaIs exposed to 1,25(OH)2D3' B. Steady-state levels of 
CYP27A rnRNA in duodena of D-Ca- and of animaIs injected with 1,25(OH)2D3' C. 
Representative Northem analysis of the CYP24 gene transcript in D-Ca-, and in animaIs 
exposed to 1,25(OH)2D3' D. Steady-state levels of CYP 24 mRNA in duodena ofD-Ca- and 
of animais injected with 1 ,25(OH)2D3' n:=:3 animaIs/group. StatisticaHy significant differences 
between group rneans were analysed by ANOV A with individual contrasts evaluated by the 
Bonferroni test. CYP27A mRNA Ievels: Maineffect: p<0.003. StatisticallydifferentfrornD-
Ca-, * p<0.03, ** p<0.0008; CYP24 mRNA levels: Main effect: p<O.OOOl. StatisticaUy 
different from D-Ca-, *** p<0.0008. 
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LEGEND TO FIGURE 8 
In vivo half-life ofCYP27A mRNA induodenaofD-Ca- and 1,25(OH)2D3 injeetedrats. 
AnimaIs received a single i.v. dose (120nmol/kg) of either 1,25(OH)2D3 or vehicle,3 hours 
before the actinomycin D (O.5mg/kg) administration. AnimaIs were killed 1,3, or 6 hours 
after actinomycin D administration .• CYP27A mRNA levels in D-Ca- rat duodena, • 
CYP27A mRNA levels in 1,25(OH)2D3 injected rat duodena. Data are presented as means 
± S. E. M. n = 2 animaIs/group. Statistieally significant differences between group means 
were analysed by ANOV A, with individual contrasts evaluated by the Bonferonni test. Main 
effeet, p<O.04, Significantly different from D-Ca-, * p<O.03. 
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LEGEND TO FIGURE 9 
Rate of transcription of the CYP27A gene transcript in duodena of D-Ca- and 
1,25(OH)2D3 injectedrats. Animalsreceived a single i.v. dose (120nmol/kg) ofl,25(OH)2D3 
6 ho urs before euthanasia. A. Representative nuclear nm-on transcriptional assays. B. 
Quantitative evaluation of the transcriptional mn-on assays was achieved by scanning 
densitometry. Transcriptional activitywas measured in three different experiments using 2-3 
rats per experiment for each group. Data are presented as means ± S. E. M. Statistically 
significant differences between group means were analysed by the Student's "t" test. 
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3.2.2 Article 4: Calcitriol regulates the expression of the gene encoding al! three vitam in 
D3 hydroxylases and the drug metabolizing enzyme CYP3A4 in the human jetaI 
intestine. 
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ABSTRACT 
The human fetal jejunum has been shown to harbour the vitamin D3 (D3) nuclear 
receptor (VDRn) and to be responsive to calcitriolll,25-dihydroxyvitamin D3 
(1,25(OH)2D3) through modulation of proliferation and differentiation processes. The aim 
of the study was to evaluate the presence as well as the effect of 1,25(OH)2D3 exposure 
on the expression levels of the three key D3-hydroxylase gene transcripts (25-
hydroxylase, CYP27A; 24-hydroxylase, CYP24; lcx-hydroxylase, CYP27Bl) as weIl as 
that of the 1,25(OH)zD3-responsive endobiotic/xenobiotic metabolizing enzyme CYP3A4 
(which is also considered a major detoxifiying enzyme) in the human proximal and distal 
intestine. Specimens from normal fetuses ranging from 15 to 20 weeks of gestation were 
obtained foIlowing elective termination of normal pregnancies. Intestinal explants were 
cultured for a period of24h or 48h with 10-7M 1,25(OH)2D3. AlI data were compared to 
paired-control cultures without 1,25(OH)2D3. Total RNA was extracted and cDNA 
synthesized by RT-PCR. The cDNA obtained was amplified by radioactive PCR, the 
signal intensity evaluated by densitometric analyses and expressed in relation to the 
levels ofGAPDH. Data indicate that VDRn, the three D3-hydroxylases as weIl as CYP3A4 
are expressed in aIl segments of the human fetal smaIl intestine and in the colon. Basal 
expression levels of VDRn, CYP27A, CYP24 and CYP3A4 were found to be similar in the 
proximal, median and distal jejunum as weIl an in the proximal and distal colon. In 
contrast, basal lcx-hydroxylase CYP27Bl expression levels were found to be 65% higher 
in the colon than in the sm aIl intestine (p<0.02). The lcx-hydroxylase was also found to 
be sensitive to 1,25(OH)2D3 with a 31 % decrease in its expression levels within 24h of 
1,25(OH)2D3 exposure to reach a 55% decrease after 48h of incubation in the presence of 
179 
the hormone (p<0.05). Furthermore, the levels of the 25-hydroxylase gene transcript were 
also decreased by 10% within the first 24h and by 29% after 48h of incubation in the 
presence of 1,25(OHhD3 (p<0.003). VDRn expression levels were also found to be 
reduced following incubation in the presence of 1,25(OH)2D3. In contrast, exposure to 
1,25(OH)2D3 contributed to a 4.8 fold increase in the expression of the 24-hydroxylase 
gene transcript within the first 24h of exposure (p<0.03), and to a highly significant 
induction (24, 22 and 1.5 fold over basal values) of the CYP3A4 gene transcript in 3 of 
the 4 specimens studies. Collectively, the data illustrate that at mid-gestation 
1,25(OH)2D3 is fully active in the modulation of aIl D3-hydroxylases in the human 
developing intestine. They also show that the detoxifying enzyme CYP3A4 is not only 
present along the intestinal tract but is also sensitive to 1,25(OH)2D3 indicating that the 
hormone may be a key element in intestinal development and in the maintenance of the 
intestinal mucosa integrity in the basal state and in response to damage-inducing agents. 
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INTRODUCTION 
Pregnancy leads to several changes in maternaI calcium homeostasis inc1uding 
significant increases in the circulating concentrations of the vitamin D (D/D3) binding 
protein (DBP) (Haddad, Jr. & Walgate 1976; Abbas et al., 1987) as weIl as in the total 
and free serum concentrations of the main D3 metabolites 25-hydroxyvitamin D3 
(250HD3) and 1,25-dihydroxyvitamin D3 (calcitriol, 1,25(OH)2D3) (Kumar et al., 1979; 
Bouillon et al., 1981; Bikle et al., 1984; Weiss et al., 1998). These adjustments contribute 
to adequately me et the large calcium and phosphate requirements of the growing fetus 
and to preserve the maternaI skeleton by increasing intestinal calcium and phosphate 
absorption in the mother (Christakos & Norman 1980; Halloran & DeLuca 1980; Care, 
1997). 
In the last three decades, several groups have reported the presence of a positive 
relationship between the maternaI and the fetal or venous umbilical cord blood 250HD3 
as weIl as between the maternaI and fetal 1,25(OH)2D3 concentrations in humans (Bishop 
& Salle, 1997; Rummens et al., 2000). In addition, in all species studied, D3 metabolites 
have been shown to be transferred across the placenta (Haddad, Jr. et al., 1971; Hillman 
& Haddad, 1974; Bouillon et al., 1981; Goff et al., 1982; Ron et al., 1984). However, 
despite positive correlations between the mother and the fetus, circulating D3 metabolites 
have consistently been reported to be lower in the fetus than in the mother (Weisman et 
al., 1978; Gertner et al., 1980; Paulson et al., 1987). These observations have led to the 
hypothesis that the fetus is dependent on the mother to satisfy its needs in 250HD3 and in 
1,25(OHhD3 (Bishop & Salle, 1997; Salle et al., 2000). This is further illustrated by the 
presence of rickets in infants born of mothers presenting signs of D deficiency (Ford et 
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al., 1973; Park et al., 1987). 
Despite the reported dependence of the fetus on the mother's D supply, the 
presence of enzymes involved in D metabolism have been reported in severai fetai 
organs. Indeed, the mitochondrial D3 25-hydroxylase gene transcript has been shown to 
be expressed in the liver and kidney of 17 to 19 week-old human fetuses (Gascon-Barré 
et al., 2001) while expression of the lcx-hydroxylase has been reported in the kidney, 
intestine and bone of mouse fetuses (Ishida et al., 1988; Panda et al., 2001) indicating 
that the enzyme is not only present in the kidney but also in "non-classical" tissues and 
organs as is the case in human adult subjects (Zehnder et al., 2001). Moreover, Wieland 
et al. (Wieland et al., 1980) have proposed, based on higher 1,25(OH)2D3 concentrations 
in fetal arterial blood compared to those observed in umbilical vein, that the human fetal 
kidney was able of synthesizing 1,25(OH)2D3. In support of the latter hypothesis, Moore 
et al. (Moore et al., 1985) have shown that fetal circulating 1,25(OH)2D3 concentrations, 
although decreased, were still detectable when pregnant sheep were bilaterally 
nephrectomized thus clearly indicating that the fetus is able to synthesize the D3 hormone 
(Moore et al., 1985). 
The aim of the present studies was to i) investigate the presence of the genes 
encoding the three key D3 metabolizing enzymes, the mitochondrial 25- (CYP27A), 24-
(CYP24), and lcx-(CYP27BI) hydroxylases, the nuclear D3 receptor (VDRn) as well as a 
recently identified 1,25(OH)zD3-responsive gene, cytochrome P450 3A4 (CYP3A4) in 
human fetal jejunum and colon, and ii) study the effect of 1,25(OH)2D3 exposure in vitro 
on their transcript levels in the proximal intestine. 
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MATERIALS AND METHODS 
CHEMICALS 
Garamycin and serum-free Leibovitz L-15 medium were obtained from Gibco 
BRL (BurIington, ON, Canada), One-Step RT-PCR from Qiagen (Mississauga, ON, 
Canada), [ex_32p] dCTP from ICN Biomedicals Inc. (Mississauga, ON, Canada), Kodak 
NBT-2, D19 developer and fixer from Interscience (Mississauga, ON, Canada). 
1,25(OHhD3 was a gift from Hoffmann-LaRoche Ltd. (Mississauga, ON, Canada). 
SPECIMENS 
Small intestine (proximal, median and distal jejunum), colon (proximal, distal) as 
well as liver and kidney specimens from normal fetuses 15-20 weeks of postfertilization 
age (4-5 subjects for each condition studied) were obtained following voluntary 
termination of normal pregnancy. No tissue was collected from cases associated with 
known fetal abnormality or fetal death. AU intestinal segments were isolated according to 
anatomical location. The specimens were immersed in Leibovitz L-15 medium (room 
temperature) containing Garamycin (40mg/ml) and brought to room temperature within 
30min. The tissues were frozen in liquid nitrogen and· kept at -80°C until further 
processing for PCR analyses. 
Normal liver and kidney speCImens were also obtained from adult subjects 
recruited among patients referred for hepatic or renal surgery at St-Luc Hospital, 
Montreal, Canada (4 men and one woman, mean age 63 ± 2.8). 
Protocols were approved by the Institutional Ethics Review Board and informed 
consents were obtained from all women before voluntary termination of pregnancy as 
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well as from all adult volunteers. 
ORGAN CULTURE 
The small intestine of each fetus was cleansed of mesentery, split longitudinally, 
washed in culture medium and eut into several explants (3X7mm). Explants were 
randomly transferred onto lens paper in each organ culture dish (Falcon Plastics, Los 
Angeles, CA) and cultured in serum-free Leibovitz L-15 medium according to the 
technique described earlier (Ménard et al., 1988). After a 3-hour stabilization period, 
1,25(OHhD3 in ethanol was added to the culture medium at a final concentration of 10-
7M, while control specimens were exposed to the vehicle only. Proximal intestinal 
explants were cultured for periods of 24h and 48h. The tissues were removed from the 
culture medium and immediately snap frozen in liquid nitrogen and kept at -80°C until 
ready for PCR analyses. 
SAMPLE EXTRACTION AND RT-PCR ANALYSES 
Total intestinal RNA was extracted as previously described (Lemay et al., 1995). 
After Dnase treatment, 1 Ilg of total RNA was converted in cDNA (First-Strand cDNA 
synthesis Kit) using pd(N)6 as primer; 2,0 ilL of RT reaction was amplified for either 25 
(CYP27A), 35 (CYP27Bl), 30 (CYP24), 27 (VDR), 30 (CYP3A4) and 20 cycles (GAPDH) 
using specifie primers and Taq PCR Master Mix and 0,1 ilL of [cx}2p] dCTP (3 000 
Ci/mol) in a Touchdown Thermal Cycling system (Hybaid, Teddington, U.K.). Design of 
primers to generate CYP27A, CYP27Bl, CYP24, VDR and GAPDH cDNA fragments was 
made with the Primers Software of Williamstone Enterprises 
(http://www.williamstone.com) from the sequences of Cali et al. (Cali et al., 1991), 
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(CYP27A) Fu et al. (Fu et al., 1997) (CYP27Bl), Chen et al. (Chen et al., 1993) 
(CYP24), Baker et al. (Baker et al., 1988) (VDR) and Tso et al. (Tso et al., 1985) 
(GAPDH). CYP3A4 primers were identical to those used by Schmiedlin-Ren P et al. 
(Schmiedlin-Ren et al., 2001) (Table 1). cDNA PCR products were loaded and separated 
onto a non-denaturing 8% polyacrylamide TBE gel. The gel was dried and exposed to 
Kodak X-Omat AR film at -80°C in the presence of an intensifying screen for 4 to 16 
hours. Densitometry was performed as described previously (Lemay et al., 1995; Demers 
et al., 1997). AU values are reported in relation to the level of expression of the 
housekeeping gene GAPDH for each sample analyzed. The number of PCR cycles for 
each gene was in the linear portion of the cDNA amplicons generated as indicated in the 
figure legends. 
STATISTICAL ANALYSIS 
Several RT-PCR replicates were obtained for each specimen and the mean value 
obtained. For each condition, the group mean ± SEM was then obtained using the mean 
replicate value of each condition. Data obtained foUowing 1,25(OH)2D3 exposure are 
presented as mean ± SEM % values obtained in comparison to paired-control specimens 
incubated in the absence of 1,25(OH)2D3. The mean levels of expression in the fetal 
jejunum and in the colon were calculated from the levels of expression observed in aU 
jejunum or colon segments of aU individual specimens studied. Statistical significant 
differences between group means were determined by the Student' s "t" test for paired 
and unpaired variates as indicated in the figure legends. 
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RESULTS 
The D3 25-hydroxylase CYP27A 
The representative expression profile of the CYP27A gene transcript III the 
proximal, median and distal jejunum as weIl as in the proximal and distal colon of 
specimens obtained from fetuses of 15-20 weeks gestation is presented in Figure lA. As 
illustrated, CYP27A is clearly present in aIl segments of the fetai intestine and although 
higher in the colon than in the jejunum, no significant differences were found in the mean 
steady state expression Ieveis of the CYP27A gene transcript between the small and the 
large intestine (Fig. lA and B). However, when compared to the fetal or adult liver (Fig. 
le and D) (the main expression site of the CYP27A gene transcript), the fetal jejunum 
expression levels of the CYP 27 A gene were found to be two fold lower than those found 
in fetalliver (p<0.0004), and 5.9 fold lower than those found in adult livers (p<0.0001). 
The differences observed between the fetai or adult liver and the fetal colon were 1.5 fold 
(N.S.) and 4.5 foid (p<O.OOOl) lower in the colon than in the fetal or adult liver 
respectively. 
The effect of 1,25(OH)2D3 exposure in vitro on CYP27A expression levels is 
presented in Figure 2. As indicated, incubation in the presence of 1,25(OH)2D3 for a 
period of24h led to a 10% decrease in CYP27A mRNA levels (N.S.) while a further 19% 
decrease was observed after 48h of 1,25(OH)2D3 exposure to reach a level of expression 
of71 % compared to specimens not exposed to 1,25(OH)2D3 (p<0.003). 
The D3 lcx-hydroxylase CYP27Bl 
Figure 3A presents a representative expression profile of the CYP27Bl gene 
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transcript in the fetal proximal, median and distal jejunum as weIl as in the fetal proximal 
and distal colon. As iIlustrated, CYP27Bl was found to be present in aIl segments of the 
fetal intestine. Moreover, calculation of the mean level of expression of the gene in the 
fetal jejunum and in the colon (Fig. 3B) revealed a 65% higher CYP27Bl mRNA levels 
in the colon than in the jejunum (p<0.02). Comparisons between the intestinal and renal 
CYP27Bl mean expression levels (the main expression site of the gene encoding 
CYP27Bl (Fig. 3C and D) indicate that the fetal small intestine CYP27Bl mRNA levels 
were 20% lower than those found in fetal kidney (N.S.) and 32 fold lower than those 
found in the adult kidney (p<0.0001). Comparisons between the mean CYP27Bl mRNA 
levels found in the fetal colon and those found in the kidney indicate that the fetal colon 
CYP27Bl levels were similar to those found in the fetal kidney but 19.5 fold lower than 
those found in the adult kidney (p<0.0001). 
Figure 4 presents the effect of 1,25(OH)2D3 exposure on the expression of the 
CYP27Bl gene transcript. As indicated, after 24h exposure to 1,25(OH)2D3 (Fig. 4), 
CYP27Bl mRNA levels were found to decreased by 31 % (N.S.) compared to the levels 
found in specimens not exposed to the hormone. After 48h incubation in the presence of 
the hormone, the mean level of expression of the CYP27Bl gene was found to represent 
only 45% ofthose observed in control specimens (p<0.05). 
The D3 24-hydroxylase CYP24 and drug-metabolizing enzyme CYP3A4 
Figure 5A illustrates the representative expression profile of the CYP24 gene 
transcript in the various segment of the jejunum and the colon. As illustrated (Fig. 5A and 
B), similar expression levels of the CYP24 gene transcript were found along the intestinal 
tract with no significant differences observed in mean CYP24 levels between the jejunum 
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and the colon. 
CYP 3A 4 expression levels were investigated in four small intestinal and colon 
specimens. Basal expression of the CYP3A4 gene transcript was clearly found in all 
specimens studied as illustrated in Figure 5C and D with no observed differences in 
mRNA levels between the jejunum and the colon. 
Studies on the effect of 1,25(OH)2D3 on the mean CYP24 mRNA levels (Fig. 6A) 
revealed that the gene expression levels were significantly upregulated within the first 
24h of incubation in the presence of the hormone with an observed mean 4.8-fold 
increase compared to the values observed in çontrol specimens (p<0.03). A 2-fold 
increase was also observed after 48h of incubation in the presence of 1,25(OH)2D3 as 
illustrated in Figure 6A (p<0.07). 
Similarly, exposure to 1,25(OH)2D3, led to a 1.5-, 22- and 24-fold induction 
respectively in CYP3A4 mRNA levels in three of the specimens studied (Fig. 6B) while 
in one specimen CYP3A4 mRNA levels decreased by 90% compared to its paired control 
not exposed to 1,25(OHhD3. Calculation of the Pearson's correlation coefficient between 
CYP24 and CYP3A4 mRNA levels following exposure (Fig. 6C) illustrates a positive 
relationship between these two VDRn-regulated genes (p<0.03). 
The nuclear D receptor VDR II 
Figure 7 A and B presents the steady state expression levels of the gene encoding 
VDRn. As illustrated, VDRn mRNA was found in aIl segments of the small and large 
intestine. No significant differences were found between the mean VDR II mRNA steady 
state expression levels in the jejunum and the colon. When compared with the fetal or 
adult kidney (Fig. 7C), the fetal jejunum and colon were found to exhibit lower mRNA 
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levels than both the fetal or adult kidney respectively (N.S.). 
As illustrated in Figure 7D, VDRn mRNA levels were significantly downregulated 
within 24h of incubation in the presence of 1,25(OHhD3 (p<0.005). Values remained 
within the same expression levels after 48h of incubation in the presence of the hormone 
(p<0.03). 
DISCUSSION 
Our studies clearly illustrate, for the first time, the presence of the genes encoding 
aIl three key D3 hydroxylases (25-hydroxylase CYP27A, 1ex-hydroxylase CYP27Bl, and 
24-hydroxylase CYP24) as weIl as CYP3A4 in both the small and large intestine of 
human fetuses aged 15-20 weeks. Moreover, in accordance with previous studies by 
Delvin and Ménard (Ménard et al., 1995; Delvin et al., 1996), the VDRn was also clearly 
found in both the jejunum and the colon. To date, however, little is known about the 
regulation of the human fetal intestinal endobiotic/xenobiotic metabolizing enzymes, 
although metabolic activities and the expression of several cytochrome P-450s have been 
reported in both animal and human fetal intestine where biotransformation activities are 
generally found to be greater in the proximal intestine than in the ileum and colon (Traber 
et al., 1988; Flinois et al., 1992; Toda et al., 1994; Dai et al., 2001). Comparison of the 
D3 metabolizing enzymes along the intestinal tract revealed that only the 1ex-hydroxylase 
exhibited a higher expression level in the colon than in the small intestine. In addition, 
the steady-state 1ex-hydroxylase mRNA levels observed in the fetal jejunum and colon 
were similar to those found in the fetal kidney, the main expression site of the enzyme 
after birth. These observations indicate a very early acquisition of the D3 1 ex-hydroxylase 
gene in the intestine where 1,25(OH)2D3 has been shown to be an essential hormonal 
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factor for the complex regulation of hum an gut development (Arsenault & Ménard, 1987; 
Ménard et al., 1995). These observations suggest that, during fetal life, the auto/paracrine 
action of the hormone may be more important than its endocrine action which involves 
the classical Ca2+-PTH-kidney loop with the hormone mainly acting at distal sites. 
Our studies also illustrate that all genes studied were influenced by 1,25(OH)2D3. 
Indeed, the hormone clearly upregulated expression of the D3 24-hydroxylase gene (a 
prototype gene for its response to 1,25(OH)2D3) by close to five-fold at the 24h time-
point following incubation in the presence of the hormone while a two-fold induction was 
still present at the 48h time-point. The decrease in the induction profile at the 48h time-
point compared to that observed earlier may be due to a decreased sensitivity of the 
1,25(OH)2D3-mediated response after prolonged exposure to the hormone. Interestingly, 
CYP3A4, which has recently been shown to be a 1,25(OH)2D3-responsive gene 
(Thummel et al., 2001) and a VDRn-mediated lithocholic acid sensor (Makishima et al., 
2002), was not only clearly identified in the small intestine but also in the colon with no 
observed differences between the two sites. This observation is interesting since in the 
adult intestine, the expression of the gene has been reported to be higher in the small 
intestine than in the colon (De Waziers et al., 1989; Paine et al., 1997). Our data, thus, 
indicate that in the developing human intestine, both intestinal segments seem to 
constitutionally express similar levels of the CYP3A4 gene transcript. 
Most interestingly, our studies are the first to report a 1,25(OH)2D3-mediated 
regulation of the gene encoding CYP 3A 4 in the human intestine. Indeed, CYP 3A 4 was 
shown to be highly inducible by 1,25(OH)2D3 (over 2000% over basal values in two of 
the specimens studied) while a more modest, but nevertheless important induction (150% 
over basal value) was observed in a third specimen. No induction was observed in the 
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forth specimen studied. The large heterogeneity in the induction of the CYP3A4 gene 
transcript may be due to the known genetically determined inter-individual variability in 
the constitutive expression of the gene (Guengerich, 1999; Ozdemir et al., 2000), as weIl 
as in variability in several factors known to be involved in its induction. Indeed, several 
endogenous and exogenous ligands acting through the pregnane X receptor/steroid and 
xenobiotic receptor (PXRlSXR) are known to induce CYP3A4 (Honkakoski & Negishi, 
2000) while the induction of CYP3A4 by 1,25(OH)2D3 has been shown to be mediated 
by both VDRE and PXRE (Makishima et al., 2002; Thurnrnel et al., 2001). Our data on 
the two 1,25(OHhD3-responsive genes, the D3 24-hydroxylase and CYP3A4, also show 
as a positive correlation in the induction profile of the two genes. This observation, 
therefore, suggest that the response of the two genes to calcitriol harbours common 
elements and that the non-responsive specimen may have exhibited an intrinsic signaling 
defect to 1,25(OH)2D3 despite apptopriate VDRn mRNA abundance. Moreover, the 
specimen was also shown, contrary to others, to exhibit no down-regulation in the 10:-
hydroxylase mRNA but an up-regulation foIlowing exposure to 1,25(OH)2D3. The reason 
for these differences in response to 1,25(OH)2D3 in this specimen in not clear. A genetic 
defect in VDRn responsiveness, the mother's nutritional status (including the D3 and 
calcium status), or her exposure to specific nutrients or drugs may be evoked. Indeed, 
women have been reported to consume an average of 10.3 different drugs during 
pregnancy and several of these xenobiotics are detectable in the infant's serum at birth 
(Cresteil, 2001). Moreover, there is a weIl documented inter-individual variability in 
cytochrome P-450 responses which may be attributed to genetic factors (polymorphysim, 
mutations), environrnental factors, drug exposure, nutritional status, age, etc. In fact, 90% 
of the inter-individual variability in CYP3A4 activity are presumed to be genetically 
191 
determined (Ozdemir et al., 2000). 
A response to 1,25(OH)zD3 was also observed for both the 25-hydroxylase and 
the lex-hydroxylase with a 1,25(OH)2D3-mediated decrease in the level of expression of 
both genes. Indeed, the 1 ex-hydroxylase was shown to rapidly decrease with an observed 
significant down-regulation at the 24h time-point while a more progressive decrease was 
observed in the 25-hydroxylase mRNA levels to reach a significant down-regulation at 
the 48h time-point. The latter observation is in agreement with a previous study showing 
that in rat intestine both the 25-hydroxylase mRNA and protein levels are decreased by 
1,25(OH)2D3 to a level similar to that observed for the D3 25-hydroxylase mRNA 
observed in the present study (Theodoropoulos et al., 2001). In the rat intestine, the 
mechanisms involve both a decrease in mRNA half-life and in the 25-hydroxylase 
transcription rate which translated in a significant decrease in the activity of the enzyme 
(Theodoropoulos et al., 2001). Our data thus suggest that in the hum an intestine, 
regulation of CYP27A is similar to that observed in the young adult rat and that exposure 
to the D3 hormone contributes to decrease the abundance of the D3 25-hydroxylase gene 
transcript. The down-regulation of the human 1 ex-hydroxyase gene by 1,25(OH)2D3 is 
also concordant with observations showing that in murine kidney, the transcription rate of 
CYP27Bl is significantly decreased by 1,25(OH)2D3 (Murayama et al., 1999). 
Our studies also clearly show the presence of: the three key D3 hydroxylase gene 
transcripts in freshly harvested fetal intestines as weIl as in fetal intestines under 
organotypic culture conditions known to promote differentiation of the organ to exhibit 
characteristics similar to the normal post-natal intestine (Ménard, 1989). The presence of 
the three hydroxylase transcripts in the hum an intestine suggests that the latter is most 
likely able to pro duce aIl the main D3 metabolites (25(OH)D3, 1,25(OH)2D3, 
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24,25(OH)2D3, 1,24,25(OH)3D3) for auto/paracrine purposes to promote either intestinal 
cell proliferation or differentiation as already shown by Ménard et al. (Arsenault & 
Ménard, 1987; Ménard et al., 1995). Our studies thus clearly illustrate that the hum an 
intestine has the potential to fully respond, in a VDRn-responsive manner, to endogenous 
or exogenous stimuli as observed with the clear induction of CYP24 and CYP3A4, two 
major detoxifying cytochrome P-450s. The . local association of 1,25(OH)2D3 and the 
VDRn in the human intestine also points out that the latter would also be able to respond 
to intestinal toxins such as lithocholic acid (a suspected intestinal carcinogen) which has 
recently been shown to induce cytochrome P-450 3A in a VDRn-dependent manner in an 
experimental murine model (Makishima et al., 2002). These observations offer a 
plausible mechanism of action to already known associations, as illustrated by 
epidemiological and experimental studies, between the incidence of colon cancer or the 
susceptibility to intestinal DNA damage and vitamin D intake/ultraviolet exposure or the 
VDRn genotype (Pence & Buddingh, 1988; Martinez et al 1996; Garland et al., 1999; 
Kallay et al., 2001). Our data, thus, clearly illustrate the potential importance of the D3 
auto/paracrine system as a key element in the maintenance of the intestinal mucosa 
integrity in both the basal state and in response to damage-inducing agents. 
\ 
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TABLE 1 
Description of sequence primers: 
Primers Sequences Base N umbers 
lcx-Ohase 5' ACGCTGTTGACCATGGC3' 706-722 
5'GTGACACAGAGTGACCAGCATAT3' 1248-1226 
24-0hase 5'GATTCCTTTATGGCATTAGGG3' 2542-2562 
5'AAACTTTGAAACATGCCCTG3' 2752-2733 
25-0hase 5'CAACGGAGCTTAGAGGAGATTC3' 181-202 
5'CCTCATTGAAAGCATCCGTATA3' 571-550 
VDR 5'CAGCGGCCAGCACCTCCCTGC3' 99-117 
5'CTGTCCTTCAAGGCCTCTTCC3' 442-426 
CYP3A4 5'CCTACATATACACACCCTTTGGAGT3' 1392-1412 
5'AGCTCAATGCATGTACAGAATCCCCGGTTA3' 1770-1741 
GAPDH 5'CCCTTCA TTGACCTCAACT ACA TGGT3' 208-233 
5 'GAGGGGCCATCCACAGTCTTCTG3 , 677-655 
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LEGEND TO FIGURE 1 
Steady state expression of the gene encoding the D3 25-hydroxylase CYP27A in 
the human fetal intestine. A. Representative CYP27A expression profile in the proximal, 
median and distal jejunum, and proximal and distal colon of fetuses 15 to 20 weeks of 
gestational age. B. Mean CYP27A mRNA levels observed in the fetal jejunum (averaged 
values of proximal, median and distal) and fetal colon (averaged values of proximal and 
distal) (n = 5 subjects). C. Representative CYP27A expression profile in fetal and adult 
liver. D. Mean CYP27A levels observed in thefetal and adult liver. Data in Band D are 
presented as mean ± S.E.M. 25 PCR cycles were used and found to be in the linear 
portion of the CYP27A cDNA amplicon generated (20, 25, and 30 PCR cycles, n = 3, r2 = 
0.96, p<O.OOl). 20 PCR cycles were used and found to be in the linear portion of the 
GADPH cDNA amplicon generated (15, 20, and 25 PCR cycles, n = 3, r2 = 0.97, 
p<O.OOOl). StatisticaIly significant differences between the group mean CYP27A mRNA 
levels observed in fetal jejunum and fetal colon as weIl as between the fetal jejunum or 
the fetal colon and the fetal or adult liver were analyzed by the Student's "t" test; a 
represents the level of significance of the differences between the fetal jejunum and the 
fetalliver p<0.0004, or the adult liver, p<O.OOOl; b represents the difference between the 
fetal colon and the fetalliver, N.S., or the adult liver, p<O.OOOl. 
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LEGEND TO FIGURE 2 
Effect of 1,25(OH)2D3 exposure on the expression of the gene encoding the D3 
25-hydroxylase CYP27A in the human fetal jejunum. Specimens were incubated in the 
. presence of 1O-7M 1,25(OH)2D3 for a period of 24h (n = 5 subjects) or 48h (n = 4 
subjects). Data are presented as % (mean ± S.E.M.) differences over the value obtained in 
paired fetal intestinal specimens obtained from the same subject incubated in the absence 
of 1,25(OH)2D3. Statistically significant differences between the group mean mRNA 
levels observed in the presence or absence of 1,25(OH)2D3 were analyzed by the paired 
Student's "t" test, *p<0.003. 
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LEGEND TO FIGURE 3 
Steady state expression of the gene encoding the D3 1Ci-hydroxylase CYP27Bl in 
the human fetal intestine. A. Representative CYP27Bl expression profile in the proximal, 
median and distal jejunum, and proximal and distal colon of fetuses 15 to 20 weeks of 
gestationa1 age. B. Mean CYP27Bl mRNA levels observed in the fetal jejunum (averaged 
values of proximal, median and distal) and fetal colon (averaged values of proximal and 
distal) (n = 5 subjects) and fetal colon (averaged values of proximal and distal) (n = 4 
subjects). C. Representative CYP27Bl expression profile in the fetal and adult kidney. 
D. Mean CYP27Bl levels observed in the fetal and adult kidney. Data in B and D are 
presented as mean ± S.E.M. 30 PCR cycles were used and found to be in the linear 
portion of the CYP27Bl cDNA amplicon generated (25, 30, and 35 PCR cycles, n = 3, r2 
= 0.67, p<0.004). StatisticaIly significant differences between the group mean CYP27Bl 
mRNA levels observed in fetal jejunum and fetal colon as weIl as between the fetal or the 
fetal colon and the fetal or adult kidney were analyzed by the Student's "t" test; a 
represents the level of significance of the differences between the fetal jejunum and the 
fetal kidney, N.S., or the adult kidney, p<O.OOOI; b represents the difference between the 
fetal colon and the fetal kidney, N.S., or the adult kidney, p<O.OOOl. 
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LEGEND TO FIGURE 4 
Effect of 1,25(OH)2D3 exposure on the expression of the gene encoding the D3 
lcx-hydroxylase CYP27Bl in the human fetal jejunum. Specimens were incubated in the 
presence of 1O-7M 1,25(OH)2D3 for a period of 24h (n = 5) or 48h (n = 4). Data are 
presented as % (mean ± S.E.M.) differences over the value obtained in paired fetal 
intestinal specimens obtained from the same subject incubated in the absence of 
1,25(OH)2D3. Statistically significant differences between the group mean mRNA levels 
observed in the presence or absence of 1,25(OHhD3 were analyzed by the paired 
Student's "t" test, *p<0.05. 
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LEGEND TO FIGURE 5 
Steady state expression of the genes encoding the D3 24-hydroxylase CYP24 and 
CYP3A4 in the human fetal intestine. A. Representative CYP24 expression profile in the 
fetal proximal, median and distal jejunum, and fetal proximal and distal colon. B. Mean ± 
S.E.M. CYP24 mRNA levels observed in the fetal jejunum (averaged values of proximal, 
median and distal) (n = 5 specimens) and fetal colon (averaged values of proximal and 
distal) (n = 4 specimens). 30 PCR cycles were used and found to be in the linear portion 
of the CYP24 cDNA amplicon generated (25, 30, and 35 PCR cycles, n = 3, r2 = 0.83, 
p<O.OOI). C. Representative CYP3A4 expression profile in the proximal, median and 
distal jejunum and the proximal and distal colon. D. Mean ± S.E.M. CYP3A4 mRNA 
levels observed in the fetal jejunum (n = 5 specimens) and fetal colon (proximal and 
distal) (n = 2 specimens). 30 PCR cycles were used and found to be in the linear portion 
of the CYP3A4 cDNA arnplicon generated (25, 30, and 35 PCR cycles, n = 3, r2 = 0.80, 
p<0.0007). Statistically significant differences between the group rnean rnRNA levels 
were analyzed by the Student' s "t" test. 
A 
CYP24 
GAPDH 
B~ 
....... 
..... 
S::::150 ~ 
C;> 
ro 
1-< 
....... 
..... 
..n ~100 
'-' 
0 
..... 
&j p:: 
~ 50 
èS ~ 
~ 
~ 0 
U 
Figure 5 
proximal median distal proximal distal 
JEJUNUM COLON 
N.S. 
Jejunum colon 
FETAL INTESTINE 
c 
~ 
....... 
'El 
~ 
~ 
1-< 
....... 
..... 
..n 
~ 
'-' 
0 
..... 
&j p:: 
~ Q 
Q., 
èS ~ 
~ 
~ 
U 
CYP3A4 
GAPDH 
ISO 
100 
50 
0 
proximal median distal proximal distal 
JEJUNUM COLON 
N.S. 
Jejunum colon 
FET AL INTESTINE 
214 
LEGEND TO FIGURE 6 
Effect of 1,25(OH)2D3 exposure on the expression of the genes encoding the D3 
24-hydroxylase CYP24 (A) and CYP3A4 (B) in the human fetaljejunum. Specimens were 
incubated in the presence of 1O·7M 1,25(OH)2D3 for a period of 24h or 48h. Data for are 
presented as % differences over the value obtained in paired fetal intestinal specimens 
obtained from the same subject incubated in the absence 1,25(OH)2D3. Statistically 
significant differences between group CYP24 mean mRNA levels observed in the 
presence or absence of 1,25(OH)2D3 were analyzed by the paired Student's "t" test, 
CYP24: n = 6 at the 24h time-point and (n = 4) at the 48h time point, *p<0.03. CYP3A4: 
n = 4. C. Pearson's correlation coefficient between CYP24 and CYP3A4 mRNA levels 
following 24h 1,25(OH)2D3 exposure. n = 4, r2 = 0.80, p<0.03. 
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LEGEND TO FIGURE 7 
Steady state expression of the gene encoding the nuclear vitamin D receptor VDRn 
in the human fetal intestine. A. Representative VDRn expression profile in the proximal, 
median and distal jejunum, and proximal and distal colon of fetuses 15 to 20 weeks of 
gestational age. B. Mean ± S.E.M. VDR mRNA levels observed in the fetal jejunum 
(averaged values of proximal, median and distal) (n = 5 subjects) and fetal colon 
(averaged values of proximal and distal) (n = 3 subjects). Statistically significant 
differences between the group mean mRNA levels were analyzed by the Student's "t" 
test. C. Representative VDRn expression profile in fetal and adult kidney. D. Mean VDR n 
levels observed in the fetal and adult kidney. E. Effect of 1,25(OH)2D3 exposure on the 
expression of the genes encoding VDRn in the human fetal jejunum. Specimens were 
incubated in the presence of 1O-7M 1,25(OH)2D3 for a period of 24h (n = 4) or 48h (n = 
4). Data are presented as % (mean ± S.E.M.) differences over the value obtained in paired 
fetal intestinal specimens obtained from the same subject incubated in the absence of 
1,25(OH)2D3. 27 PCR cycles were used and found to be in the linear portion of the VDRn 
cDNA amplicon generated (22, 27 and 32 PCR cycles, n = 3, r2 = 0.91, p<O.OOOI). 
Statistically significant differences between the group mean mRNA levels observed in 
the presence or absence of 1,25(OH)2D3 were analyzed by the paired Student's "t"; * 
p<0.005, ** p<0.03. 
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3.2.3 Additional Results 
A 
CYP27BI 398 bp 
cyclophilin 670bp 
B 
,-.. 
ZJ 
'2 1.2 
=:> 
è 1.0 (\j 
b 
:E 
..... 0.8 
:$ 
;:: 
~ 0.6 
~ 0.4 <.> 
""' -2 
....., 0.2 
r::: 
'" ~ 0.0 
\.) ~ 0; 
\.) Ê Cl 0 0:: 
Figure 3.1: Expression of CYP27Bl in normal and D-Ca- rats. CYP27Bl mRNAs were 
reversely transcribed into cDNAs and amplified by PCR (25 cycles for CYP27Bl and 20 
cycles for cyclophilin, control gene), using specifie probes (see method details in Article 4). 
cDNA formed was loaded on a 1.2% agarose gel and transferred onto a Southem blot which 
was then hybridized with the appropriate probe. Band intensity was then analysed by 
densitometric analysis. A. Representative southem blot of amplified CYP27Bl cDNA. B. 
Relative intensity of CYP27Bl in normal and D-Ca- rats. Results are presented as mean ± 
S.E.M. Statistically significant differences were evaluated by the Student's t test, *p<0.05; 
normal, n=6; D-Ca-, n=ll. 
Results: CYP27Bl mRNA levels were 4-fold less abundant in rats fed a normal diet 
compared to those subjected to a D-depleted di et (p<0.05). 
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3.3 CONCLUSIONS 
These experiments show that the intestine harbours alI three D3 hydroxylases. 
Intestinal CYP27A mRNA steady state levels were three times less abundantly expressed than 
in liver and was downregulated by aIl major D3 metabolites, D3, 25(OH)D3 and 1,25(OH)2D3, 
byan effect on the transcription rate. The strong CYP24 induction following 1,25(OHhD3, 
administration, underlies the importance of this cytochrome in D3 metabolite catabolism. 
Furthermore, CYP27Bl proved to be sensitive to the D status. 
AlI hydroxylases, CYP3A4 as weIl as the VDR were expressed along the human fetal 
intestine and colon. However, only CYP27Bl levels were significantly upregulated in the 
latter part. The sensitivity of the hydroxylases, CYP3A4 and the VDR to 1,25(OH)2D3 
administration establish the intestine as an organ capable of autoregulatory control through 
hydroxylase modulation by an autocrine/ paracrine mechanism of regulation. 
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CHAPTER 4: OVERALL DISCUSSION AND CONCLUSIONS 
In the present work, we have examined hepatic and intestinal CYP27A expression in 
relation to D homeostasis in both the rat and the human. The first part illustrates the effect 
of the D hormonal and nutritional status on hepatic CYP27A in the liver, the primary and 
major organ in D3 hydroxylation (164). Intestinal CYP27A regulation was then evaluated in 
relation to the other hydroxylases present in this organ, CYP27BI, CYP24 and CYP3A4. Our 
findings illustrate for the first time the sensitivity of CYP27A, to D homeostasis, and 
therefore open further opportunities for investigation and debate into the role and regulation 
of this cytochrome in relation to D metabolism. 
Little is known regarding the regulation of 2S(OH)D production. Indeed, the 
apparent non regulation in D mitochondrial 2S-hydroxylation (21 ;22) is contradictory to the 
tight regulatory control mechanisms reported for its hydroxylase counterparts CYP27B 1 and 
CYP24. 
The liver and intestine being c10sely linked by the enterohepatic circulation, which 
prolongs the presence of D metabolites and increases their exposure to CYP27 A, making 
these tissues highly relevant in their regulation. 
Previous in vivo studies, based primarily on enzymatic activities, have been inconc1usive 
with respect to the effects of the D status on hepatic 2S-hydroxylation and have solely 
focused on this tissue. Our results c1early show the sensitivity of hepatic CYP27 A gene to 
only 1,2S(OH)2D3 administration in rats, and a correlation between circulating 2S(OH)D 
concentrations and CYP27A mRNA steady state levels in humans. This correlation implies 
a link between the nutritional status and the gene levels (r2=0.41, p<O.OS) . 
Interestingly, rat hepatic CYP27A mRNA levels proved to be sensitive only to the i.v. 
administration of hormonal form of the vitamin, 1,2S(OH)2D3, and not to D3 or 2S(OH)D3. 
Thus, although a CYP27A interspecies similarity in sex regulated mechanisms is observed, 
the role of the D status is not as c1ear-cut. As may be encountered in other studies, the 
regulatory pattern and mechanisms of a rat specific gene cannot be fully extrapolated into its 
human counterpart, consequently supporting that studies must be fully and thoroughly 
undertaken to obtain a complete and c1ear understanding of human gene regulation. 
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Our findings suggest that different metabolites and/or mechanisms are affecting 
CYP27A gene levels between these two species. It appears that the human CYP27A is 
sensitive to the 25(OH)D concentrations whereas in the rat it is sensitive to only 
1,25(OH)2D3 i.p. administration. 
We are lead to hypothesise that in the D-Ca- ràt model under investigation, sorne 
other metabolite(s) produced downstream of 1,25(OH)2D3 may be responsible for CYP27A 
downregulation by a marked effect on the transcription rate, whereas the half-life remains 
unaffected. Our studies using ketoconazole further support this hypothesis. Ketoconazole 
administration together with 1,25(OH)2D3 inhibited the CYP27A downregulation observed 
with 1,25(OH)2D3 alone, suggesting further P450 modification is required for an effect on 
CYP27A. Indeed, Harant et al. (241) have demonstrated that along the D catabolic pathway, 
biologic activity of sorne natural metabolites is retained despite an apparently lower affinity 
for VDR, that normally regulates VDR responsive genes. However, we cannot confirm that 
a D3 metabolite is in fact affecting gene levels. Moreover, the question arises as to the 
mechanism oftranscriptional inhibition and of the presence and functionality of a VDR in 
the liver. To date, this receptor in the liver has been characterised by certain investigators 
(190;191), inc1uding our group who has identified the VDR by RT-PCR in the 
nonparenchymal cells and to a lesser extent in the hepatocyte (242). We may also speculate 
that another type ofreceptor, abundantly present in the liver, may be involved. No studies 
have addressed binding of 1,25(OH)2D3 to other types of receptors. 
Unfortunate1y, the lack of information about the precise sequences upstream of the 
transcriptional initiation sites remain unpublished by the two groups of investigators who 
have published regulatory studies (52;53). Their hopeful identification in the near future will 
answer the questions pertaining to potential receptor (i.e. VDR) and transcription factor 
binding sites. 
Altematively, a bile acid metabolite may be responsible for the CYP27A gene 
regulation observed since 1,25(OH)2D3 undergoes glucuronidation and excretion into bile. 
This would not be surprising, since CYP27 A is indeed an enzyme downregulated by bile 
acids via a transcriptional mechanism (227). The enzyme also exhibits a higher degree of 
hydroxylation towards cholesterol than D3 (227). Interestingly, CYP7cx, the enzyme involved 
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in the neutral pathway of bile aeid synthesis, was also downregulated by 1,25(OH)2D3 
supplementation, further strengthening this hypothesis. D3 and 25(OH)D3 proved to have 
no effeet (results not shown). Therefore, as reported in previous studies on the effeet of bile 
aeids in rat livers, CYP7cx and CYP27A mRNA levels were observed to change in the same 
direction (227;243;244). 
Recently, lithocholic aeid (LCA) and its major metabolites 3'keto-LCA, glyco-LCA 
and 6'keto-LCA have been reported to aetivate VDR and the expression of CYP3A (17). The 
concentration at whieh these bile acids aetivate VDR is below the pharmacologie range that 
aetivates the other bile aeid reeeptors sueh as farnesoid X receptor (FXR) and pregnane X 
receptor (PXR), thus strengthening the physiological signifieance of the VDR binding (17). 
These data suggest that VDR is a more sensitive receptor for bile acids than are FXR and 
PXR, and particularly for LCA and its major metabolite 3'keto-LCA (17). 
The conclusions regarding the biologie relevance and importance of the CYP27 A and 
other potential 25-hydroxylases require additional researeh. Although mitoehondria were 
previously believed to be the only organelle possessing 25-hydroxylase aetivity in humans 
(27;43), a recent paper indicates microsomes also possess this activity (28), eonfirming an 
older study (245). Our studies raise the question of the physiologie significanee and role of 
CYP27 A in D3 homeostasis. It has been previously reported that rats fed D defieient diets 
and supplemented with physiologie amounts of D2 have 25(OH)D2 as their predominant 
monohydroxylated D2 metabolite in plasma (62), suggesting that CYP27 A is not the 
physiologie enzyme responsible for 25-hydroxylation of D, sinee CYP27 A is unable to 
hydroxylate D2 (47). The question thus arises as to the physiologieal signifieance of 
CYP27 A in terms of D homeostasis, since it is primarily considered to be an enzyme 
involved in bile aeid biosynthesis. The laek of development of CTX abnormalities in the 
CYP27A -/- mouse, presumably due to the role of the mierosomaI25-hydroxylase(s) (246), 
exemplifies the redundaney in 25-hydroxylase aetivity. Implieating CYP27 A in D3 
metabolism is the fact that sorne patients suffering from CTX have been reported to exhibit 
abnormal bone metabolism as weIl as early osteoporosis (69). However mutations affeeting 
CYP27A do not seem to completely abolish the C-25 hydroxylation ofD3 (67;69;71). This 
observation suggests the presence of an alternative, but as of yet, unidentified D3 25-
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hydroxylase(s) in humans, possibly an equivalent to the pig microsomal D3 25-hydroxylase 
(32). The molecular identity is still not known. Vpon c10ning and identification ofthis/these 
hydroxylase(s), it will be of great interest to examine their response in relation to D 
homeostasis. 
Furthermore, our observations indicate that CYP27A expression can be significantly 
upregulated in certain pathological situations such as in hepatic carcinoma and in intrahepatic 
metastasis of the colon and that the neoplastic tissue could contribute to the circulating 
25(OH)D concentration. It is c1ear that CYP27 A also plays a role in disease. Beyond its 
involvement in CTX, it is involved in the metabolism of oxysterols such as 7-
ketocholesterol, which is potentially pro-atherogenic, and is a quantitatively important 
oxysterol in both atherosc1erotic les ions and macrophage foam cells (247). Studies with 
CYP27 A-I- mice have shown increases in triacylglycerol and hepatic synthesis of fatty acids, 
which is associated with hypertriglyceridemia and hepatomegaly (248). These findings 
confirm the importance of CYP27 A in bile acid synthesis and reveal a function of the 
enzyme in triacylglycerol metabolism. The presence of CYP27 A in a wide variety of tissues, 
contrary to CYP7cx, which is confined exc1usively to the liver, suggests a global importance 
of CYP27 A in the maintenance of cellular integrity. It will be of interest to determine 
(knowing levels may be upregulated in certain pathologies) whether the hepatic signal 
distribution may vary in the state of malignancy since in the normal state it is confined to the 
PV region, as evidenced by in situ hybridization in humans. To our knowledge, this is the 
first time CYP27A upregulation is linked to non-atherogenic type pathologies (hepatic 
carcinoma and intrahepatic colon metastasis), indicating a potentially more widespread 
involvement in other disease states, and the possible involvement of D homeostasis. 
Although, CYP27 A is most abundantly expressed in the li ver, it is also present in 
many other tissues inc1uding kidney, adrenals, testes and the intestine (234). In the intestine, 
its mRNA steady state expression is three times less than in the liver. Our study examines 
for the first time the regulation of this gene in the intestine. 
In addition to the presence and regulation ofboth CYP24 and CYP27A by the D3 
status, we were able to characterise the presence of CYP27Bl in the rat intestine. 
Expression levels in the D-Ca- rat proved to be significantly higher than those observed in 
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the nonnal intestine. The increase in gene expression levels may be necessary in the D-Ca-
rat in order to maximize and potentialize the production of the 1,25(OH)2D3 for local and/or 
systemic actions. This hypothesis remains to be investigated. 
The intestine has long been regarded as a c1assic D response tissue. D is well known 
to have profound effects upon the small intestine through upregulation of calbindin 9K, the 
cytosolic calcium binding protein (249), as well as calcium pumps situated on the basolateral 
membrane of small intestinal epithelial cells (250). The cellular effects are believed to 
greatly enhance the transport of calcium from the lumen of the small intestine and colon into 
the bloodstream (251 ;252). Furthermore, until recently, it has been believed that virtually 
aU circulating 1,25(OH)2D3 is formed in the kidney from 25(OH)D3, based upon the 
observation that nephrectomy almost completely depletes circulating 1,25(OH)2D3(253). The 
present work thus changes the status of this organ from a simple D3 target organ, to one 
potentially autoregulatory in its own actions through hydroxylase modulation. Recent 
findings in the field of colon carcinogenesis suggest the possibility of a local effect of 
1 ,25(OHhD3 through the conversion of 25(OH)D3 to 1 ,25(OH)2D3 (17). 
Contrary to intestinal CYP27A and CYP27BI, regulatory control ofCYP24 has been 
weU documented. As opposed to the on/off switch observed with the CYP24 intestinal 
regulation, CYP27A levels in both the intestine and in the liver were not completely 
decreased despite the high pharmacological doses of 1,25(OH)2D3 administered. These 
findings suggest the potential need of basal expression levels, evoking a more widespread 
role than solely in D metabolism, and most probably in bile acid metabolism. CYP27A has 
even been proposed as a potential renal D3 1 cx-hydroxylase (254). 
Thus, the proven regulatory control foUowing D supplementation of D-Ca- rats, with 
aU three hydroxylases affected, suggests that the intestine is a tissue capable of 
autoregulatory control in terms of D3 homeostasis. It remains to be investigated whether 
hydroxylase changes are related to the control of calcium and/or phosphorus homeostasis 
and/or local hormonal effects on the tissue itself. lndeed, 1,25(OH)2D3 affects intestinal 
physiology. Furthennore, the presence and regulatory control by D3 may also open the door 
to potential treatment in gastrointestinal disease, through the use of D3 metabolites. Low 
levels of circulating D3 have been proposed as a risk factor for distal colorectal adenomas 
/ 
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(255). The use of D3 metabolites as therapeutic agents is already the subject of many studies 
and has provided sorne promising results in therapy (256;257). The development of nontoxic 
analogs and the understanding of their molecular mechanism of action will be of significant 
importance in the prevention and treatment of cancer by D3. 
Furthermore, we studied the effect of 1,25(OH)2D3 hormonal action on D3 
hydroxylase regulation. The effect of 1,25(OH)2D3 was investigated in an organotypic 
human intestinal culture model where 1,25(OH)2D3 functions as a hormonal agent with 
respect to cellular proliferation and differentiation (233). The intestinal fetal model under 
investigation, although eorresponding to the mid-gestational period in development, is fully 
developed and is similar to that of the adult human intestine (205). 
Basal expression levels of the D3 hydroxylases CYP 27 A and CYP 24 did not vary 
along the intestine and colon, unlike CYP27Bl which was significantly higher in the colon. 
Overall, it is believed cytochrome P450 activity tends to decrease along the intestine (258), 
however an exception (2-aminofluorene acetylase activity) has been reported (259). The 
expression pattern of specifie P450s has not been previously addressed. The levels obtained 
in our study may however be specifically characteristic of the fetal stage. 
Our results show that aIl three D3 hydroxylases are regulated by 1,25(OH)2D3 in the 
hum an intestinal expIant cultures in our study. CYP27A and CYP27Bl were significantly 
downregulated after 48h of culture, whereas CYP24 was upregulated after 24h. An 
interindividual variability in response was observed between the samples in the case of 
CYP24, with sorne responding much more than others, and one sample not responding at aIl. 
Interestingly, such a type ofP450 variability has also been observed in cultured lung explants 
(260). These data may be explained by polymorphisms in VDR as weIl as in the specific 
hydroxylases, and illustrate the non-uniform response that may be obtained when studying 
human samples. Unfortunately, due to ethical reasons, we were unable to obtain information 
on the D3 status and overall health of the mother. The access to such data would have 
permitted a more analytical understanding and strengthened the study. 
Furthermore, 1,25(OH)2D3 highly induced CYP3A4, a P450 involved in xenobiotic 
metabolism. Several endogenous and exogenous ligands acting through the PXR and SXR 
induce CYP3A4. CYP3A4 is also inducible by a non-classical mechanism involving binding 
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of the heterodimer VDRlRXR, not to a VDRE, but to PXRE in PXR independent fashion 
(261). These findings suggest a more widespread role of D3 in the regulation of cytochromes 
also involved in detoxification processes, in addition to the hydroxylases directly involved 
in its own anabolism and catabolism. 
Overall, our findings directly demonstrate the sensitivity of hepatic CYP27A 
expression levels to D3 deficiency, pathologies and repletion with 1,25(OH)2D3. Intestinal 
CYP27Bl was also observed to be sensitive to the D3 deficient state and to D3, 25(OH) D3 
and 1,25(OHhD3 repletion. The homeostatic changes related to the D status that occur 
following an alteration in the D3 endocrine status affects the cytochromes involved not only 
in the vitamin's own anabolismlcatabolism, but also others such as CYP3A4. These findings 
are important, keeping in mind also that the D3 hydroxylases may be involved in other 
regulatory mechanisms, as is the case in bile acid regulation for CYP27 A. Alterations in the 
D3 endocrine system remain an ever-present concern in today's society, with the high 
prevalence ofD3 depletion in the elderly, and the increased risk of developing D3 deficiency 
in healthy individuals. Our studies detail how CYP27A, but also other cytochromes involved 
in drug metabolism may be affected. 
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